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Congenital adrenal hyperplasia 
about causes and consequences 
 
1. Ook bijnier steroïd precursors hebben glucocorticoïde werking 
en kunnen daarmee gedeeltelijk compenseren voor 
cortisoldeficiëntie aanwezig in patiënten met adrenogenitaal 
syndroom. (dit proefschrift) 
 
2. De definitie van cortisoldeficiëntie moet opnieuw ter discussie 
gesteld worden. (dit proefschrift) 
 
3. Testiculaire bijnier resttumoren zijn een veel voorkomende 
langetermijncomplicatie en de belangrijkste oorzaak voor een 
verminderde gonadale functie in mannen met adrenogenitaal 
syndroom. (dit proefschrift)   
 
4. Testiculaire bijnier resttumoren hebben zowel bijnier als 
testiculaire eigenschappen en ontstaan uit een pluripotente cel 
door stimulatie met ACTH. (dit proefschrift) 
 
5. Op basis van kwaliteit van leven gaat het erg goed met mannen 
met adrenogenitaal syndroom. (dit proefschrift) 
 
6. Ik heb er wèl de ballen verstand van. 
 
Manon Engels 
Nijmegen, 18 december 2018 
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The adrenal gland 
The human body contains two adrenal glands, located superior to the kidneys. Each 
gland has a cortex and a medulla (Fig. 1.1A). Embryologically, the medulla originates 
from neural crest tissue, while the adrenal cortex arises from the coelomic mesoderm 
of the urogenital ridge of which also the kidneys and gonads are formed. The adrenal 
glands have important endocrine functions. Chromaffin cells in the medulla are able to 
produce epinephrine and norepinephrine (also called (nor)adrenalin(e)), while the 
cortex produces steroid hormones. The adrenal cortex is divided into three zones with 
different steroid synthesis characteristics: the zona glomerulosa, the zona fasciculata 
and the zona reticularis (Fig. 1.1A). Adrenal steroidogenesis converts cholesterol via 
several enzymatic steps to three types of steroid hormones: mineralocorticoids, 
glucocorticoids and androgens (Fig. 1.1B). Expression of adrenocortical enzymes differs 
between the zones, but all zones express cholesterol side-chain cleavage enzyme and 
3β-hydroxysteroid dehydrogenase/Δ5-4 isomerase (3β-hydroxysteroid dehydrogenase), 
two common enzymes of all steroidogenic cells. Furthermore, the zona glomerulosa 
expresses 21-hydroxylase, cytochrome P450 11B1 (11-hydroxylase) and cytochrome 
P450 11B2, but not 17α-hydroxylase/17,20lyase (17-hydroxylase), resulting in the 
production of mineralocorticoids. Mineralocorticoids, such as aldosterone, are 
responsible for the regulation of blood pressure and electrolyte balance and its 
secretion is regulated by the renin-angiotensin-aldosterone system. The zona 
fasciculata expresses 17-hydroxylase, 21-hydroxylase, and 11-hydroxylase resulting in 
the production of glucocorticoids. Glucocorticoids, such as cortisol, regulate glucose 
metabolism and immune response. The production of cortisol is regulated by the 
hypothalamus-pituitary-adrenal (HPA) axis. The hypothalamus produces corticotrophin-
releasing hormone (CRH), which stimulates the pituitary gland to produce 
adrenocorticotropic hormone (ACTH), which in turn stimulates the adrenal gland to 
produce cortisol. Cortisol functions in a negative feedback loop as it inhibits CRH and 
ACTH synthesis. In contrast to the other zones, the zona reticularis does not express 
21-hydroxylase and 11-hydroxylase, but does express 17-hydroxylase resulting in 
production of adrenal androgens, such as dehydroepiandrosterone (DHEA) and 
androstenedione. Sulfation of DHEA leads to the inactive steroid DHEA-S.  
1 
10 | Chapter 1 
 
 
 
Fig. 1.1: The adrenal gland and adrenal steroidogenesis. A) Schematic representation of the adrenal gland 
consisting of a medulla and a cortex with 3 zones: zona glomerulosa, zona fasciculata, and zona reticularis.  
B) Adrenal steroidogenesis converting cholesterol to cortisol, aldosterone and adrenal androgens via several 
enzymatic steps in the adrenal cortex. Brown indicates enzymatic steps that are performed in all adrenal 
cortex zones, while green indicates enzymatic steps specific for the zona fasciculata and zona reticularis. The 
purple box indicates specific enzymatic steps for the zona glomerulosa, while within the yellow box 
enzymatic steps specific for the zona fasciculata are shown. In white, enzymatic steps converting adrenal 
androgens to sex steroids in peripheral tissues (mainly in the gonads) are presented. Abbreviations and 
synonyms: 17β-HSD, testosterone or estradiol 17β-dehydrogenase 3; 3β-HSD, 3β-hydroxysteroid 
dehydrogenase/Δ5-4 isomerase; 5α-reductase, 3-oxo-5α-steroid 4-dehydrogenase 1; DHEA, 
dehydroepiandrosterone; DHT, dihydrotestosterone. 
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Congenital adrenal hyperplasia 
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders of the 
adrenal cortex caused by a defect of one of the enzymes involved in the adrenal 
steroidogenesis. The most common enzyme deficiency (>90%) causing CAH is 21-
hydroxylase deficiency (CYP21A2 mutation) with an incidence of 1:12 000 (1, 2). About 
5% is caused by 11-hydroxylase deficiency (CYP11B1 mutation). In this thesis we focus 
on patients with 21-hydroxylase deficiency.  
Patients with CAH caused by 21-hydroxylase deficiency (Fig. 1.2A) suffer from impaired 
cortisol production and consequently elevated ACTH concentrations due to the lack of 
the negative feedback on the pituitary gland. The increased ACTH concentrations 
eventually lead to hyperplasia of the adrenal cortex and accumulation of steroid 
precursors before the enzymatic block (mostly 17-hydroxyprogesterone). These 
steroids are subsequently shunted to the unaffected androgen pathway and alternative 
pathways producing elevated concentrations of 21-deoxycortisol, 11-hydroxy-
progesterone, 16-hydroxyprogesterone, 11-oxygenated androgens, and dihydro-
testosterone. The severity of the disease depends on the residual 21-hydroxylase 
activity. The most severe patients have <1% residual enzyme activity with cortisol and 
aldosterone deficiency and are classified as group null, A, or classic salt-wasting type. 
Patients with 1-5% residual enzyme activity have cortisol deficiency, but sufficient 
mineralocorticoids and are classified as group B or classic simple virilizing type (1-3). 
Patients with a very mild mutation in the CYP21A2 gene have a residual enzyme activity 
of 20-50% and are classified as non-classic CAH. Non-classic CAH patients have 
generally no cortisol and aldosterone deficiency, but about two-third of the patients 
have suboptimal response to ACTH (4). Patients with non-classic CAH also have slightly 
elevated androgen concentrations, eventually resulting in clinical complaints related to 
hyperandrogenism mostly in girls, such as precocious puberty, irregular menses, acne, 
and hirsutism (5). 
 
Other forms of CAH 
The second most common enzyme deficiency (about 5%) causing CAH is caused by 
mutations in the CYP11B1 gene, resulting in 11-hydroxylase deficiency (Fig. 1.2B). 
These patients also have impaired cortisol production and high ACTH and androgen 
concentrations. Patients with 11-hydroxylase deficiency suffer from hypertension, as 
increased concentrations of the adrenal steroid precursor 11-deoxycorticosterone, 
which has mineralocorticoid potency, are present (6). 
1 
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Fig. 1.2: The most common enzyme deficiencies of the adrenal cortex resulting in congenital adrenal 
hyperplasia. A) 21-hydroxylase deficiency causes impaired production of cortisol and aldosterone (indicated 
in gray), while adrenal steroid precursors (mostly 17-hydroxyprogesterone) before the enzymatic block 
accumulate. These steroid precursors are converted via several alternative enzymatic steps indicated in 
purple. B) 11-hydroxylase deficiency causes impaired cortisol (indicated in gray) and elevated adrenal 
androgen concentrations. Adrenal steroid precursors 11-deoxycorticosterone and 11-deoxycortisol 
accumulate. Abbreviations and synonyms: 11β-HSD, corticosteroid 11β-dehydrogenase; 17β-HSD, 
testosterone or estradiol 17β-dehydrogenase 3; 3β-HSD, 3β-hydroxysteroid dehydrogenase/Δ5-4 isomerase;  
5α-reductase, 3-oxo-5α-steroid 4-dehydrogenase 1; DHEA, dehydroepiandrosterone; DHT, 
dihydrotestosterone. 
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Mutations in HSD3B2, CYP17A1, POR, StAR, and CYP11A1 are rare, but can also cause 
CAH (2, 7). All have in common the impaired production of cortisol leading to increased 
ACTH concentrations, but with different deficiencies or accumulation of steroid 
precursors based on the type of defect. For example, patients with 17-hydroxylase 
deficiency also have low peripheral aldosterone and androgen concentrations, but 
exhibit high concentrations of 11-deoxycorticosterone and corticosterone, which cause 
hypertension (8). 3β-hydroxysteroid dehydrogenase deficiency also results in low 
aldosterone and androstenedione concentrations, but increased concentrations of the 
precursor steroid DHEA (9).  
 
Diagnosis of CAH 
In CAH patients, adrenal steroid precursors before the enzymatic block will accumulate. 
One of the hallmarks of patients with 21-hydroxylase is therefore an increased 
concentration of the adrenal steroid precursor 17-hydroxyprogesterone, and diagnosis 
of 21-hydroxylase is therefore based on increased concentrations of this steroid. 
Measurement of 17-hydroxyprogesterone in dried blood spots is included in the Dutch 
neonatal screening program. Confirmatory testing using liquid chromatography-
tandem mass spectrometry (LC-MS/MS) is indicated, especially when primary 
measurement was performed with immunoassays (1). Nowadays, measurement of 21-
deoxycortisol is also suggested to diagnose 21-hydroxylase deficiency, as steroid 
production of 21-deoxycortisol is negligible in healthy persons (10). Preferably, 
mutation analysis should also be performed to confirm the diagnosis of CAH. Diagnosis 
of 11-hydroxylase deficiency is mainly based on increased 11-deoxycorticosterone 
concentrations in blood. 
 
Treatment 
Classic CAH patients require lifelong substitution therapy to replace missing 
glucocorticoids and mineralocorticoids, and consequently lower ACTH and adrenal 
androgen concentrations. However, in practice mostly supraphysiological dosages of 
glucocorticoids are needed to normalize adrenal androgen concentrations, increasing 
the risk on adverse effects due to the high dosages of glucocorticoids (1, 11).  
 
 
1 
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Consequences of CAH 
Cortisol deficiency can lead to severe complaints, such as weakness, fatigue, weight 
loss, and can also lead to life-threatening adrenal crises especially in situations of 
increased demands of cortisol (12, 13). CAH patients might also suffer from several 
long-term consequences due to cortisol and aldosterone deficiency, excess 
concentrations of androstenedione, or treatment with supraphysiological dosages of 
glucocorticoids, or aldosterone excess due to mineralocorticoid overtreatment. 
Common long-term complications are premature pubarche (14), reduced final height 
(15-17), impaired gonadal function (14, 17-20), decreased bone mineral density (14, 
17), and an increased risk on obesity (14, 15, 17, 21), and cardiovascular morbidity (14, 
17, 21).  
Impairment of gonadal function in CAH males 
Fertility and gonadal function can be impaired due to abnormal semen quality, Sertoli 
cell dysfunction, low testosterone and high gonadotropin concentrations 
(hypergonadotropic hypogonadism), or low testosterone and low gonadotropin 
concentrations (hypogonadotropic hypogonadism). Low gonadotropin concentrations 
are a result of negative feedback on the hypothalamus-pituitary-gonadal (HPG) axis, 
caused by the aromatization of increased adrenal androgens to estrogens. Gonadal 
function can also be impaired due to the development of testicular adrenal rest tumors 
(TARTs). TARTs are a common complication in CAH males and can cause gonadal 
dysfunction and infertility by obstruction of the seminiferous tubules or due to 
paracrine effects of hormones produced by TART (14, 17-20). An extensive introduction 
on TART will be given in our review described in chapter 4 of this thesis.  
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Aim of the thesis 
Many processes in the body are regulated by strict hormonal balance. CAH patients 
suffer from the consequences of increased adrenal androgens, and decreased cortisol 
and aldosterone concentrations. Due to the rarity of the disease, mechanisms and 
related consequences of CAH are still not completely understood. The aim of this thesis 
is therefore to gain further insights into the disturbed adrenal steroidogenesis and its 
consequences in patients with CAH. 
The first chapters of this thesis focus on adrenal steroidogenesis and the role of steroid 
precursors in CAH patients. Cortisol deficiency can lead to the development of life-
threatening adrenal crises, especially during severe stress moments, as the stress 
response is impaired. However, not all untreated CAH patients present with the typical 
features of a cortisol deficiency, such as neonatal hypoglycemia or conjugated 
jaundice. Adrenal steroid precursors are synthesized from cholesterol and closely 
resemble the molecular structure of cholesterol and one another. Therefore, 
glucocorticoids and mineralocorticoids can bind to the glucocorticoid and 
mineralocorticoid receptor (GR and MR). We investigated in chapter 2 whether adrenal 
steroid precursors 21-deoxycortisol, 17-hydroxyprogesterone, progesterone, and 
androstenedione are able to activate the GR and thereby may compensate for the 
cortisol deficiency. In chapter 3 we continued this research by studying the potency of 
glucocorticoid and mineralocorticoid precursors on the GR in vitro. Furthermore, we 
described a unique cohort of Indonesian CAH patients that survived without any 
glucocorticoid treatment. We studied their steroid profile biochemically and linked 
steroid concentrations to their potency to activate the GR. 
In the following chapters we focus on long-term consequences in male CAH patients. In 
chapter 4 we present a review on a common complication that occurs in male CAH 
patients: TART. TARTs are benign nodules with both testicular and adrenal 
characteristics and probably originate from the adrenogonadal primordium. GATA 
transcription factors, involved in the adrenogonadal development, were recently linked 
to TART development in mice. We investigated in chapter 5 the expression of GATA 
transcription factors in human TART and compared expression patterns to Leydig cell 
tumors to come up with a marker that discriminates these tumor types to prevent 
incorrect treatment due to a misdiagnosis. Furthermore, in chapter 6 we present an 
unusual case of TART in a patient with Cushing's syndrome. In chapter 7 we studied 
gonadal function, including the presence of TART, in a multicenter European cohort of 
the dsd-LIFE study. The same cohort of patients was used to investigate the quality of 
life in male patients with CAH in chapter 8. The thesis concludes with a summary and 
general discussion presented in chapter 9. 
1 
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transactivation of the glucocorticoid receptor
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Abstract 
Patients with congenital adrenal hyperplasia (CAH) are often clinically less severely 
affected by cortisol deficiency than anticipated from their enzymatic defect. We 
hypothesize that adrenal steroid hormone precursors that accumulate in untreated or 
poorly controlled CAH have glucocorticoid activity and partially compensate for cortisol 
deficiency. We studied the in vitro effects of 17-hydroxyprogesterone, progesterone, 
21-deoxycortisol, and androstenedione on the human glucocorticoid receptor (GR). 
Competitive binding assays were performed in HeLa cells. Nuclear translocation of the 
GR was studied by transfection of COS-7 cells with a GFP-tagged GR and fluorescence 
microscopy. Transactivation assays were performed in COS-7 cells and in HEK293 cells 
after cotransfection with GR and luciferase reporter vectors using a dual luciferase 
assay. 17-hydroxyprogesterone, progesterone, and 21-deoxycortisol are able to bind to 
the GR with binding affinities of 24-43% compared with cortisol. Androstenedione has 
a low binding affinity. Incubation with 21-deoxycortisol led to complete nuclear 
translocation of the GR, whereas treatment with 17-hydroxyprogesterone or 
progesterone resulted in partial nuclear translocation. 21-deoxycortisol transactivated 
the GR with an EC50 approximately 6 times the EC50 of cortisol.  
17-hydroxyprogesterone and progesterone transactivated the GR with EC50 values of 
more than 100 times the EC50 of cortisol. No GR transactivation was detected after 
incubation with androstenedione. 21-deoxycortisol, 17-hydroxyprogesterone, and 
progesterone are able to bind, translocate, and transactivate the GR in vitro and thus 
may have glucocorticoid activity. 21-deoxycortisol might have a clinically relevant 
agonistic effect on the GR and could potentially partially compensate the cortisol 
deficiency in CAH patients. 
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Introduction 
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder caused by a 
deficiency of one of the enzymes involved in adrenal steroid synthesis. Ninety-five 
percent of cases are caused by 21-hydroxylase deficiency. This results in impaired 
synthesis of cortisol. In 75% of cases patients also suffer from clinically relevant 
aldosterone deficiency (1). Due to the reduced negative feedback to the hypothalamus 
and pituitary gland, cortisol deficiency leads to increased pituitary secretion of 
adrenocorticotropic hormone (ACTH). Consequently, the steroid hormone precursors 
prior to the enzymatic block accumulate and are shunted into the androgen-synthesis 
pathway. The presence of increased concentrations of adrenal steroid hormone 
precursors is a hallmark feature of patients with CAH and these precursors can be used 
as diagnostic markers (2). CAH caused by 21-hydroxylase deficiency represents a 
spectrum of disease depending on the severity of the enzymatic defect. The most 
severe, classic CAH, is subdivided in a salt-wasting form and a simple virilizing form 
without aldosterone deficiency. Non-classic CAH is less severe with generally only mild 
symptoms of hyperandrogenism (1). The treatment of classic CAH consists of lifelong 
replacement of glucocorticoids and if necessary also of mineralocorticoids. The goal of 
treatment is to prevent adrenal and salt-wasting crises and to suppress abnormal 
secretion of adrenal androgens by suppression of the pituitary gland. Treatment of 
non-classic CAH is only indicated when there are severe symptoms of androgen excess 
and/or glucocorticoid deficiency (2). 
Patients with CAH are clinically often less severely affected by cortisol deficiency than 
anticipated from their enzymatic defect. For example, patients with salt-wasting CAH 
have a severe cortisol and aldosterone deficiency due to a residual enzymatic activity 
of less than 1% (1). They develop salt-wasting crises neonatally, but only a minority 
present with hypoglycemia or conjugated jaundice, a classic symptom of infantile 
glucocorticoid deficiency (3). Patients with simple virilizing CAH have a residual 
enzymatic activity of 1-2% and a suboptimal increase of cortisol after stimulation with 
ACTH. In areas where neonatal screening is not implemented, male patients with 
simple virilizing CAH often present with signs of androgen excess in (early) childhood, 
without a history of Addisonian crises during illness or surgery prior to their diagnosis 
(1). Furthermore, many adult patients with classic CAH who are lost to endocrine 
follow-up and are not adherent to treatment with glucocorticoids do not develop 
adrenal crises for long periods of time (4). Finally, between 30 and 40% of patients with 
non-classic CAH diagnosed in adolescence or adulthood show a suboptimal cortisol 
response to ACTH stimulation, suggesting a potential risk of adrenal insufficiency 
during illness or surgery (5-7). However, these patients usually do not report a history 
2 
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of signs or symptoms consistent with adrenal insufficiency during surgery or illness (5, 
7).  
These observations could hypothetically be explained by the presence of adrenal 
steroid hormone precursors that accumulate in patients with untreated and poorly 
controlled CAH. These precursors, such as 17-hydroxyprogesterone, progesterone, 21-
deoxycortisol, and androstenedione (2), have structural similarities to cortisol (8). We 
hypothesize that they may have clinically significant glucocorticoid activity and partially 
substitute for cortisol. To analyze their glucocorticoid properties, we studied their 
effects on binding, nuclear translocation, and transactivation of the human 
glucocorticoid receptor (GR). 
 
Materials and Methods 
In vitro receptor binding assays 
Competitive binding assays for the GR were performed as described previously (9). 
HeLa cells were cultured in DMEM high glucose (4.5 g/L) with L-glutamine 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (all PAA 
Laboratories, GmbH). Whole cells (0.2-1.0 106) were incubated in serum and phenol-
red-free RPMI medium (final volume, 150 µL) for 1.5-2 hours at 37°C in a series of 0.5 
mL microcentrifuge tubes containing 30 nM 3H-cortisol (PerkinElmer, Inc.) and an 
increasing amount of unlabeled competitor: cortisol, 17-hydroxyprogesterone, 21-
deoxycortisol, androstenedione (all Steraloids), or progesterone (Sigma-Aldrich). Non-
specific binding was assessed by means of 500-fold excess of dexamethasone 
(Steraloids). Radioactivity was counted in a J3 counter. Specific binding was expressed 
as the percentage of specific binding over binding of radioligand only, corrected for 
non-specific binding. 
In vitro nuclear translocation assays 
For the intracellular localization assays, GR DNA (pRShGRα) was PCR amplified using 
primers with BamHI and EcoRV restriction sites (Sigma-Aldrich). It was cloned into a 
pcDNA6-V5/HisB-EGFP vector (Invitrogen Corp.). The correct insertion of the GR 
construct as well as the integrity of the cDNA was checked by direct DNA sequencing. 
The assays were carried out in COS-7 cells, which is a cell line that does not contain 
endogenous GR. The COS-7 cells were cultured in DMEM high glucose (4.5 g/L) with  
L-Glutamine supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin. COS-7 cells (n=1.5 105) were grown in six-well plates on glass 
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coverslips. After 24 hours the cells were transiently transfected with 2 µg of GFP-GR 
using the TransIT-LT1 DNA transfection reagent (Mirus Bio). Forty-eight hours after 
transfection the cells were treated for 60 minutes with one of the steroids (cortisol, 17-
hydroxyprogesterone, progesterone, 21-deoxycortisol, androstenedione) in a 
concentration of 10-6M. Afterward the cells were fixated on coverslips in 100% 
methanol at -20°C for 15 minutes and mounted with Vectashield with DAPI (Vector 
Laboratories) on microscope slides. The cells were studied under the Zeiss Apotome 
Fluorescence microscope with Zeiss AxioVision imaging software (version 4.7.2) at a 
magnification of 200X for the localization of the GR. Representative images were taken. 
The experiment was performed in duplicate. 
In vitro transactivation assays 
For the transactivation assays, the GR DNA was cloned into a pcDNA6-V5/HisB vector 
(Invitrogen Corp.) using the same restriction enzymes as described above. The 
luciferase reporter vectors used for the transactivation assays were MMTV-luc and 
pRL-TK (Promega). MMTV-luc is a firefly luciferase reporter construct. Transcription is 
controlled by glucocorticoid response elements immediately upstream from the 
luciferase sequence. pRL-TK contains a renilla luciferase. It serves as an internal 
standard to normalize firefly luciferase light emission measurements with regard to 
transfection efficiency and the number of cells in each well. 
The COS-7 cells were cultured in DMEM high glucose (4.5 g/L) with L-glutamine 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin and seeded 
in 24-well plates in a density of 2 104 cells per well. Twenty-four hours after seeding, 
the COS-7 cells were transiently cotransfected using the TransIT-LT1 DNA transfection 
reagent with 0.2 µg pcDNA6- V5/HisB-GR, 0.3 µg MMTV-luc, and 0.01 µg pRL-TK per 
well. Two days after transfection the cells were treated with one of the steroids 
(cortisol, 17-hydroxyprogesterone, progesterone, 21-deoxycortisol, androstenedione). 
Steroid solutions in ethanol were made in concentrations of 200X the final desired 
concentration (10-9 to 10-4M) and diluted 1:200 with DMEM prior to adding them to 
the transfected cells. Twenty-four hours after adding the steroid, firefly and renilla 
luciferase activity were measured using the Dual-Luciferase Reporter Assay System 
(Promega) on a Fluoroskan FL luminometer (Thermo Scientific). Firefly luciferase/renilla 
luciferase ratios were calculated to normalize for transfection efficiency. Each 
experiment was performed in triplicate. 
To ensure that the COS-7 cell line did not contain relevant amounts of endogenous 
steroid receptors, the transactivation activities of the different steroids were also 
measured in COS-7 cells that had not been transfected with steroid receptor 
expression vectors. Likewise, the system was tested for the presence of endogenous 
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steroids by measuring the transactivation activity after transfection with the GR vectors 
but without addition of steroids. In neither approach relevant transactivation was 
measured. 
The transactivation assay was repeated in HEK293 cells using the methods described 
above. These experiments were performed in duplicate. 
Statistical analysis 
Analyses were performed using GraphPad Prism software version 5.0 for Windows. 
Steroid concentrations were expressed on a log scale and dose-response curves were 
calculated using nonlinear regression. For the receptor binding assays, the 
concentration of unlabeled steroid that reduces binding of the radioligand by half (IC50) 
was determined. The relative binding affinity of the study steroids compared with 
cortisol was calculated by IC50:cortisol/IC50:test steroid   100%. For the transactivation assays, 
the estimated concentration for 50% transactivation (EC50) was determined. For 
calculation of the relative functional sensitivity of the GR to the different steroids, the 
transactivation potential of cortisol was set at 100%. The sensitivity of the GR to the 
other test compounds was calculated as EC50:cortisol/EC50:test steroid   100%. 
 
Results 
Receptor-binding assay 
The receptor-binding curves for the studied steroids are shown in Fig. 2.1. The IC50 and 
the relative binding affinity of cortisol, 17-hydroxyprogesterone, progesterone,  
21-deoxycortisol, and androstenedione were calculated (Table 2.1). The results 
demonstrate that 17-hydroxyprogesterone, progesterone, and 21-deoxycortisol bind to 
the GR with relative binding affinities of 27, 43, and 24%, respectively. The binding 
affinity for androstenedione is dramatically less (0.4%) than that of cortisol. 
Nuclear translocation assay  
Incubation with cortisol in a concentration of 10-6M resulted in complete nuclear 
translocation of the GR within 60 minutes (Fig. 2.2B). Adding 17-hydroxyprogesterone, 
progesterone, and 21-deoxycortisol to the transfected cells in a concentration of 10-6M 
resulted in respectively almost complete, partial, and complete transport to the 
nucleus (Fig. 2.2C-E). After treatment of the cells with androstenedione, the location of 
the GR was still predominantly cytoplasmic (Fig. 2.2F). 
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Fig. 2.1: Binding assay. Competition of various steroids for binding of 3H cortisol to the glucocorticoid receptor 
in HeLa cells. Binding data are expressed as the percentage of specific binding (Bs) remaining after adding 
increasing amounts of competitor. 
 
 
 
Table 2.1: Binding and transactivation capacity of cortisol, 17-hydroxyprogesterone,  
progesterone, 21-deoxycortisol, and androstenedione to the glucocorticoid receptor. 
Adrenal  
Steroid  
Metabolite 
Binding Assay Transactivation Assay  
in COS-7 cells 
Transactivation Assay  
in HEK293 cells 
IC50  
(95% CI) 
Relative  
binding  
affinity 
EC50  
(95% CI) 
Relative  
sensi- 
tivity 
EC50  
(95% CI) 
Relative  
sensi-
tivity 
cortisol 2.2 10-8  
(1.3 10-8 - 3.8 10-8) 
100% 1.7 10-8  
(1.0 10-8 - 2.8 10-8) 
100% 3.5 10-9  
(1.8 10-9 - 6.9 10-9) 
100% 
17-hydroxy-
progesterone 
8.2 10-8  
(3.8 10-8 - 1.6 10-7) 
27% 2.2 10-6  
(1.5 10-6 - 3.2 10-6) 
0.8% 1.2 10-6  
(7.6 10-7 - 1.9 10-6) 
0.3% 
progesterone 5.1 10-8  
(3.1 10-8 - 7.8 10-8) 
43% 3.0 10-6  
(1.5 10-6 - 5.9 10-6) 
0.6% 2.3 10-6  
(1.2 10-6 - 4.8 10-6) 
0.2% 
21-deoxy-
cortisol 
9.1 10-8  
(6.2 10-8 - 1.3 10-7) 
24% 1.0 10-7  
(5.2 10-8 - 2.0 10-7) 
17% 4.1 10-8  
(2.1 10-8 - 8.2 10-8) 
8.5% 
androstene-
dione 
5.9 10-6  
(2.0 10-6 - 2.2 10-5) 
0.4% - - - - 
 
IC50: estimated concentration that reduces binding of the radioligand by 50%, in mol/L. 
Relative binding affinity: the binding affinity of cortisol is set at 100%. The binding of the other steroids to the 
GR is calculated as IC50:cortisol/ IC50:test steroid   100%. EC50: Estimated concentration for 50% transactivation, in 
mol/L. Relative sensitivity: the transactivation potential of cortisol is set at 100%. The sensitivity of the GR to 
the other test compounds is calculated as EC50:cortisol/EC50:test steroid   100%. 
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Fig. 2.2: Localization of the GR in COS-7 cells transfected with the GR, without steroids (A) and after incubation 
with various steroids in a concentration of 10-6M (B–F). The nucleus is stained blue and the GR is tagged with a 
green fluorescent protein. B, cortisol. C, 17-hydroxyprogesterone. D, progesterone. E, 21-deoxycortisol. 
F, androstenedione. 
 
GR transactivation assay in COS-7 cells 
Cortisol activated the GR with an EC50 of 1.7 10
-8M (Fig. 2.3; Table 2.1). Exposure of the 
GR to increasing concentrations of 17-hydroxyprogesterone, progesterone, and 21-
deoxycortisol resulted in increasing GR transactivation, up to a maximum. A dose-
response curve was fitted (Fig. 2.3) and the EC50 values for these steroids were 
calculated. The EC50 value was 2.2 10
-6M for 17-hydroxyprogesterone, 3.0 10-6M for 
progesterone, and 1.0 10-7M for 21-deoxycortisol (Table 2.1). Androstenedione did not 
transactivate the GR at the concentrations tested (Fig. 2.3).  
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Fig. 2.3: Transactivation of the glucocorticoid receptor (GR) in COS-7 cells by 17-hydroxyprogesterone, 
progesterone, 21-deoxycortisol, and androstenedione in comparison with the transactivation of the GR by 
cortisol (indicated in gray). 
 
GR transactivation assay in HEK293 cells 
The results for the transactivation assay in HEK293 cells are shown in Fig. 2.4 and Table 
2.1. In these experiments, the EC50 for cortisol was 3.5 10
-9M. 17-
hydroxyprogesterone, progesterone, and 21-deoxycortisol activated the GR with EC50 
values of 1.2 10-6M, 2.3 10-6M, and 4.1 10-8M, respectively. 
 
Discussion 
We describe here the binding of 17-hydroxyprogesterone, progesterone, 21-
deoxycortisol, and androstenedione to the GR and their effects on the nuclear 
translocation and transactivation of the GR, in comparison with the effects of cortisol.   
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Fig. 2.4: Transactivation of the human glucocorticoid receptor (GR) in HEK293 cells by 17-hydroxyprogesterone, 
21-deoxycortisol and androstenedione in comparison with the transactivation of the GR by cortisol (indicated 
in gray). 
 
We found that 21-deoxycortisol and to a lesser extent 17-hydroxyprogesterone and 
progesterone can transactivate the GR. This is consistent with the receptor-binding and 
nuclear translocation of the GR we found after incubation with these steroids. It has 
previously been described that 17-hydroxyprogesterone and progesterone bind to the 
GR (10-12), but to the best of our knowledge this has not been shown for 21-
deoxycortisol previously. These agonistic properties on the GR might explain the clinical 
observation that CAH patients are often less severely affected by cortisol deficiency 
than anticipated from their enzymatic defect. 
Steroid hormone cross reactivity to receptors is a well-known phenomenon. For 
example, cortisol is known to have an agonistic effect on the mineralocorticoid 
receptor (13). In addition, in a previous study of our group we have demonstrated that 
17-hydroxyprogesterone and progesterone can influence the transactivation of the 
human mineralocorticoid receptor: both have anti-mineralocorticoid effects in vitro 
(14). The occurrence of cross reactivity of these steroids at both the GR and the human 
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mineralocorticoid receptor can be explained by the high degree of homology at the 
DNA- binding domains of these receptors (15). 
The EC50 of cortisol in our model is comparable to the EC50 previously described (16), 
demonstrating the reliability of our in vitro model. Under the experimental conditions 
21-deoxycortisol, 17-hydroxyprogesterone, and progesterone have the capacity to 
transactivate the GR. With the concentrations used in our experiments we were able to 
reconstruct complete dose-response curves, up to the point where maximum 
transactivation was reached. In the two cell lines studied, a comparable profile was 
found: 21-deoxycortisol has the greatest transactivation capacity, 17-
hydroxyprogesterone and progesterone are also able to transactivate the GR but only 
at much higher concentrations. Androstenedione does not transactivate the GR at the 
concentrations tested. Given that there was no transactivation detectable for 
androstenedione even in concentrations at least 100 times higher than the 
concentrations found in untreated CAH, we do not expect that relevant transactivation 
will occur with higher concentrations (17). The fact that androstenedione has no 
agonistic effect on the GR might be explained by the greater structural dissimilarity 
between androstenedione and cortisol compared with that of the other test 
compounds and cortisol (8). 
As illustrated by the EC50 values more than 100 times higher than the EC50 of cortisol, 
17-hydroxyprogesterone and progesterone are less potent agonists of the GR than 
cortisol. In healthy volunteers the 17-hydroxyprogesterone concentration is 
substantially lower than that of cortisol: reference values for serum 17-
hydroxyprogesterone are 2.0-10.8 nmol/L for males and 0.45-12.7 nmol/L for females, 
0900-h reference values for serum cortisol are 190-550 nmol/L. In this situation cross-
reactivity on the GR will be negligible. However, in patients with classic CAH 17-
hydroxyprogesterone concentrations can increase to very high concentrations of more 
than 1500 nmol/L (18, 19). Based on the dose-response curve we constructed, these 
concentrations might be high enough to result in relevant GR transactivation. 
Interestingly, the EC50 of 21-deoxycortisol is much closer to the EC50 of cortisol 
(approximately 6-fold in the transactivation assays in COS-7 cells, approximately 12-fold 
in the HEK293 cells). The serum concentrations of 21-deoxycortisol in untreated or 
poorly controlled patients with classic CAH can exceed 400 nmol/L (18, 19). Based on 
our results we hypothesize that these concentrations may lead to a clinically relevant 
transactivation of the GR. Less transactivation can be expected in non-classic CAH 
patients, given that in these patients the 21-deoxycortisol concentrations are lower 
and reach up to approximately 40 nmol/L (6). We suggest that high serum 21-
deoxycortisol concentrations in untreated or poorly controlled CAH patients may 
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partially compensate for their cortisol deficiency. In contrast, overtreatment with 
complete suppression of adrenal precursors including 17-hydroxyprogesterone and 21-
deoxycortisol might lead to an increased risk of adrenal crises and hypoglycemia. 
Therefore, adequate stress dosing is crucial once glucocorticoid treatment is initiated 
in patients with CAH. 
Considering that we have studied several elements of the GR transactivation cascade 
with consistent results, we are confident that our results represent actual 
glucocorticoid properties of 21-deoxycortisol, 17-hydroxyprogesterone, and 
progesterone. However, given that this is an in vitro model, our findings must be 
confirmed in additional studies. We have studied the transactivation properties of 
several steroids and not the other mechanisms by which the glucocorticoid receptor 
exerts its actions: transrepression and nongenomic effects (13, 20, 21). It might also be 
relevant to study other steroid precursors. Despite these limitations, we consider our 
results promising and potentially relevant for a significant group of patients with CAH. 
In conclusion, 21-deoxycortisol and to a lesser extent 17-hydroxyprogesterone and 
progesterone are able to transactivate the GR in vitro and thus may have glucocorticoid 
activity. 21-deoxycortisol, which can be strongly elevated in patients with untreated or 
poorly controlled CAH, has the strongest agonistic effect on the GR and may partially 
compensate for the cortisol deficiency in patients with CAH. 
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Abstract 
Objective: Cortisol deficiency can cause adrenal crises, which can be life-threatening. 
Cortisol production is impaired in patients with congenital adrenal hyperplasia (CAH). 
Here, we describe a unique population of severely affected untreated CAH patients, 
with proven cortisol deficiency but without clinical signs of cortisol deficiency even in 
severe stress-situations. The lack of clinical signs of cortisol deficiency in untreated CAH 
patients might be explained by the glucocorticoid activity of increased concentrations 
of adrenal steroid precursors.  
Design: Translational research. 
Methods: Adrenal steroid precursor concentrations before and 60 minutes after 
adrenocorticotropic hormone (ACTH) administration of 22 untreated Indonesian CAH 
patients (3-46 years) with proven cortisol deficiency (<500 nmol/L post-ACTH) 
measured by liquid chromatography tandem-mass spectrometry (LC-MS/MS) were 
compared to 6 control patients (Mann-Whitney U test). Glucocorticoid activity was 
determined by dual-luciferase assays in human embryonic kidney cells transfected with 
the glucocorticoid receptor and exposed to increasing amounts of adrenal steroid 
precursors for 24 hours.   
Results: Blood concentrations of the steroid precursors 11-deoxycortisol (457 nmol/L, 
p=0.003), 11-deoxycorticosterone (55 nmol/L, p=0.003), 17-hydroxyprogesterone (610 
nmol/L, p<0.001), progesterone (29 nmol/L, p<0.001), and 21-deoxycortisol (73 
nmol/L) were strongly elevated compared to controls. The GR was activated with 
comparable potency to cortisol by corticosterone and 21-deoxycortisol or with 4-100x 
lower potency by 11-hydroxyprogesterone, 11-deoxycortisol, aldosterone, 11-
deoxycorticosterone, progesterone, and 17-hydroxyprogesterone.  
Conclusions: We identified strongly elevated adrenal steroid precursor concentrations 
in blood from untreated CAH patients and demonstrated glucocorticoid activity of 
these adrenal precursors in vitro – implicating these precursors are able to compensate 
for cortisol deficiency in untreated CAH patients, thereby protecting against life-
threatening adrenal crises.  
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Introduction 
Adrenal crisis due to cortisol deficiency, also known as Addisonian crisis, is a life-
threatening condition when not properly treated with glucocorticoids. It is often 
described by its main symptoms: vomiting, diarrhea, and abdominal pain. Whereas the 
main cause of an adrenal crisis is cortisol deficiency, additional aldosterone deficiency 
can lead to the development of a salt-wasting crisis, which is treated by 
supplementation of mineralocorticoids and sodium chloride.  
Cortisol deficiency is one of the main findings in patients with congenital adrenal 
hyperplasia (CAH). CAH is an autosomal recessive disorder with impaired 
steroidogenesis in the adrenal cortex. Adrenal steroidogenesis involves the synthesis of 
cortisol, aldosterone, and androgens from the common precursor cholesterol via 
several enzymatic steps. More than 90% of CAH cases are caused by a mutation in the 
CYP21A2 gene resulting in 21-hydroxylase deficiency (21OHD). In 21OHD, conversion of 
the steroid precursors 17-hydroxyprogesterone and progesterone to 11-deoxycortisol 
and 11-deoxycorticosterone, respectively is impaired (Fig. 3.1). Consequently, cortisol 
production is inadequate, leading to elevated adrenocorticotropic hormone (ACTH) 
concentrations due to a lack of negative feedback to the hypothalamus and pituitary 
gland. Increased ACTH concentrations will stimulate the adrenal gland, eventually 
causing hyperplasia. Furthermore, adrenal steroid precursors before the enzymatic 
defect accumulate and are shunted into the androgen synthesis pathway (1). Increased 
concentrations of adrenal steroid precursors 17-hydroxyprogesterone and 21-
deoxycortisol are currently used as diagnostic markers for CAH (1-3). The severity of 
the disease depends on the residual enzymatic activity with a strong phenotype-
genotype relationship: Mutations that are classified as group null (0) or A are usually 
associated with <1% residual enzyme activity with additional aldosterone deficiency 
(classic salt-wasting type), group B with 1-5% residual enzyme activity without 
aldosterone deficiency (classic simple virilizing type), and group C with a residual 
enzymatic activity of 20-50% and a less severe phenotype with usually normal cortisol 
and aldosterone levels (non-classic type) (4).  
Approximately 5% of CAH cases are caused by mutations in the CYP11B1 gene resulting 
in 11-hydroxylase deficiency (11OHD). 11OHD results in accumulation of the precursors 
11-deoxycorticosterone and 11-deoxycortisol (Fig. 3.1). As in 21OHD, cortisol 
production is deficient and adrenal androgen concentrations are increased. However, 
in contrast to 21OHD, signs of mineralocorticoid excess occur with hypertension and 
hypokalemia due to the mineralocorticoid potency of 11-deoxycorticosterone (5).  
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Fig. 3.1: Adrenal steroidogenesis. Cholesterol is converted to aldosterone, cortisol, and androgens in the 
adrenal cortex via several enzymatic steps. Abbreviations: 11OHD, 11-hydroxylase deficiency; 21OHD, 21-
hydroxylase deficiency; HSD, hydroxysteroid dehydrogenase. 
 
Patients with cortisol deficiency are generally treated with glucocorticoids to substitute 
for cortisol deficiency in order to prevent life-threatening adrenal crises and to 
suppress the elevated androgens. In our clinical experience however, there are cases of 
untreated or noncompliant severely affected CAH patients known to have less clinical 
signs of cortisol deficiency than expected based on their enzyme deficiency and 
compared to patients with other forms of adrenal insufficiency. For example, only a 
minority of neonates with the most severe form of 21OHD present with typical 
features of cortisol deficiency (hypoglycemia or conjugated jaundice) (6). We have 
previously described a patient with salt-wasting CAH, who was only treated with 
sodium chloride for the first two years of life, without apparent complications from 
cortisol deficiency (7). Moreover, in countries without neonatal screening programs for 
CAH, CAH patients from group B (simple virilizing) usually only present with signs of 
androgen excess during childhood, without reporting a history of adrenal crises.  
The aim of our study was to determine if this lack of signs of cortisol deficiency might 
be explained by the glucocorticoid activity of increased concentrations of adrenal 
steroid precursors that accumulate before the enzymatic defect. Here, we describe the 
clinical phenotype and the biochemical profile of adrenal steroid precursors in a unique 
cohort of untreated 21OHD and 11OHD CAH patients, before and after ACTH 
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administration using liquid chromatography tandem-mass spectrometry (LC-MS/MS). 
The glucocorticoid activity of these precursor steroids was assessed by in vitro 
glucocorticoid receptor (GR) transactivation studies. 
 
Subjects and Methods 
Study design 
Within this translational study we had the objective to describe the phenotype and 
steroid profile of a cohort of untreated Indonesian CAH patients. No sample size 
calculation was performed in this descriptive study. We added 6 control patients and 2 
untreated CAH patients from the Netherlands in comparative biochemical analyses. 
Our inclusion criteria were untreated patients with a severe type of genetically 
confirmed CAH in which an ACTH stimulation test was performed. To understand the 
potential of different steroid hormones, we also performed cell culture experiments. 
We determined the potency to activate the GR for each steroid, in which each 
concentration was measured in triplicate. No rules for stopping data collections were 
defined. We reported all data and did not find outliers in our data. Main outcomes in 
our study were defined as the number of stress-full events, biochemical evaluation of 
the ACTH stimulations tests by LC-MS/MS and activation of GR.  
Patients  
Untreated CAH patients (n=22) were recruited from the local CAH database and 
included as a part of a cohort study on hormonal analysis and compliance in the Center 
for Biomedical Research, Faculty of Medicine Diponegoro University, Semarang, 
Indonesia (in compliance with relevant laws, institutional guidelines and the 
declaration of Helsinki). The study was approved by the local ethical committee of the 
Diponegoro University. Oral and written informed consent was obtained after full 
explanation of the purpose and nature of all procedures. Data were collected on the 
type of CAH, karyotype, gender, mutation analysis, signs of salt-wasting, and episodes 
of severe stress in their medical history (critical illness, trauma, surgery) by the local 
pediatric endocrinologist (AU). For all 21OHD patients, the severity of CAH was 
classified based on their mutation analysis into genotype groups 0, A, B, or C (4).  
In addition, the biochemical results of patients in whom an ACTH test was performed at 
Radboud university medical center in Nijmegen, the Netherlands in 2017 were included 
(n=8). Oral informed consent was obtained by the treating physician as additional 
measurements were performed on coded stored blood samples in accordance with the 
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Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands 
(http://www.federa.org/codes-conduct). Two patients had a CAH diagnosis, the other 6 
were non-CAH patients, falsely suspected of an adrenal disorder, and were used as 
control group. Three of these patients were females with polycystic ovarian syndrome. 
One male patient presented with an abnormal result in the neonatal screening 
program for CAH, which turned out to be false positive, and the 2 other patients were 
46XY neonates with ambiguous genitalia. In one of them, no final diagnosis could be 
made. In the other patient, a mutation with unknown pathogenicity was found in the 
NR5A1 gene. Additionally, 1 healthy adult female underwent an ACTH stimulation test 
in the Center for Biomedical Research, Faculty of Medicine Diponegoro University, 
Semarang, Indonesia to serve as a control patient.  
Biochemical analysis 
The standard ACTH stimulation test was performed in all patients to determine adrenal 
functioning by measuring steroid concentrations before and after ACTH administration. 
Synacthen (0.25 mg; Sigma Tau BV) was injected intravenously, with blood draws for 
steroid analysis before and 60 minutes after the injection. In the Indonesian patients all 
tests were performed before 9.00 am. Dutch patients had their ACTH stimulation test 
during their clinical appointment, which mostly took place in the morning. None of the 
patients did receive glucocorticoids at the time of biochemical analysis. Serum before 
and after ACTH administration were analyzed with LC-MS/MS to determine cortisol, 
corticosterone, 11-deoxycortisol, 11-deoxycorticosterone, 17-hydroxyprogesterone, 
progesterone, and 21-deoxycortisol concentrations. The LC-MS/MS protocol has been 
provided in the Supplemental Material.  
In vitro transactivation study 
Cell culture 
Human embryonic kidney cells (HEK293) were grown as a monolayer culture in DMEM 
with 4.5 g/L glucose with L-glutamine (Lonza; Leusden, the Netherlands) supplemented 
with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific; Landsmeer, the 
Netherlands) and 1% antibiotics (penicillin-streptomycin 10 000 U/mL; Gibco). Cells 
were cultured at 37°C in a humidified 95% air / 5% CO2 atmosphere and passaged 
when confluent.  
In vitro dual luciferase transactivation assays 
Human GR transactivation was measured using dual-luciferase transactivation assays 
(Promega; Leiden, the Netherlands) in which pcDNA6-V5/HisB-hGR, MMTV-luc, and 
pRL-TK vectors were used as described earlier (8). 
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HEK293 cells were seeded at 40 000 cells/well in 24-well plates. Transient transfection 
was performed after 24 hours, using 0.2 µg pcDNA6-V5/HisB-hGR, 0.3 µg MMTV-luc, 
and 0.01 µg pRL-TK per well and 1 µL TransIT-LT1 transfection reagent (Mirus; Ochten, 
the Netherlands) according to manufacturer's protocol. Cells were treated for 24 hours 
with one of the steroids (progesterone, 17-hydroxypregnenolone, pregnenolone 
(Sigma-Aldrich, Zwijndrecht, the Netherlands) or cortisol, aldosterone, corticosterone, 
11-deoxycortisol, 11-deoxycorticosterone, 17-hydroxyprogesterone, 11β-
hydroxyprogesterone, 16-hydroxyprogesterone, 21-deoxycortisol, (Steraloids, 
Newport, USA)) 2 days after transfection. Steroid solutions were prepared in ethanol 
(200X concentrated) and diluted 1:200 in culture medium prior to treatment. 
Thereafter, firefly and renilla luciferase activity was measured on a Fluoroskan FL 
luminometer (Thermo Scientific) according to manufacturer's protocol (Promega) and 
firefly/renilla ratios were calculated. Each concentration was measured in triplicate. 
As controls, HEK293 cells were transfected with the MMTV-luc and pRL-TK vector but 
not the GR and treated with 10-4M cortisol. Secondly, HEK293 cells were transfected 
with all the vectors but not treated with any steroid (medium with 0.5% ethanol). 
Neither of these approached resulted in transactivation activity.  
Statistical analyses 
GraphPad Prism software version 5.0 for Windows and SPSS Statistics 22 (SPSS Inc., 
Chicago, IL, USA) were used to analyze adrenal steroid concentrations. Normality was 
assessed and median steroid concentrations and interquartile ranges (IQR: Q1-Q3) 
were calculated. 21OHD and 11OHD patients were compared to the control group and 
distributions were compared using the Mann-Whitney U (MWU) test. P<0.05 was 
considered significant. GraphPad Prism was also used to calculate dose-response 
curves using nonlinear regression. The estimated concentration that causes 50% of the 
maximum transactivation (EC50) and its 95% confidence interval (95%CI) were also 
determined. Relative functional sensitivity of the GR to the different steroids was 
calculated as EC50 cortisol / EC50 test steroid x 100% in which cortisol was set as 100%.  
 
Results 
Clinical characteristics of untreated CAH patients 
Clinical characteristics of the included CAH patients are shown in Table 3.1. Twenty-two 
(long-time) untreated CAH patients were identified in the Indonesian CAH database, 
age 3-46 years, of which 17 had 21OHD and 5 had 11OHD. Most patients (n=15) were 
3 
40 | Chapter 3  
 
Table 3.1: Clinical characteristics of untreated CAH patients.  
# age CAH 
type 
Karyo-
type 
Gen-
der 
Mutations Geno-
type^ 
Treatment with 
GCs 
History 
of SW 
History of 
severe stress 
while 
untreated 
cortisol 
before 
ACTH 
cortisol 
after 
ACTH 
I1 28 11OHD 46XX F c.799G>A 
c.799G>A 
NA never no genital 
surgery 
164 163 
I2 19 11OHD 46XX F c.799G>A 
c.799G>A 
NA never no no 218 225 
I3 5 11OHD 46XX M c.799G>A 
c.799G>A 
NA never no no 150 155 
I4 13 11OHD 46XX M c.799G>A 
c.799G>A 
NA never no no 179 180 
I5 3 11OHD 46XX U c.799G>A 
c.799G>A 
NA never no no 202 202 
I6 19 21OHD 46XX F p.Ile172Asn 
p.Ile172Asn 
B treated at  
age 8-16yr 
stopped >3yrs 
no no 110 125 
I7 23 21OHD 46XX F p.Ile172Asn 
p.Ile172Asn 
B treated at  
age 13-20yr 
stopped >3yrs 
no no 233 238 
I8 21 21OHD 46XX F p.Arg356Trp 
p.Arg356Trp 
0 treated at  
age 10-19yr 
stopped >2yrs 
yes genital 
surgery 
68 66 
I9 9 21OHD 46XX F intron splice 
p.Arg356Trp 
A treated at  
age 5-7yr 
stopped >2yrs 
yes hospital 
admissions  
(SW crises) 
82 73 
I10 4 21OHD 46XX F intron splice 
p.Arg356Trp 
A treated at  
age 0-2yr 
stopped >2yrs 
yes hospital 
admissions  
(SW crises) 
35 33 
I11 13 21OHD 46XX F p.Arg356Trp 
p.Arg356Trp 
0 treated in 
childhood 
stopped >4yrs 
no genital 
surgery 
115 119 
I12 46 21OHD 46XX M p.Trp20* 
p.Ile172Asn 
B never no 2x severe 
gastritis  
typhoid fever 
159 159 
I13 15 21OHD 46XX M intron splice 
intron splice 
A never no no 89 79 
I14 32 21OHD 46XX M intron splice 
intron splice 
A never no genital 
surgery 
61 65 
I15 13 21OHD 46XX F p.Arg356Trp 
p.Arg356Trp 
0 treated at  
age 5yr 
stopped >8yrs 
no genital 
surgery 
tonsillectomy 
dengue 
typhoid fever 
75 68 
I16 15 21OHD 46XX M p.Arg356Trp 
deletion of 
exon 1-3 
0 never yes hospital 
admissions 
for vomiting 
and seizures 
57 58 
I17 14 21OHD 46XX M p.Ile386del 
p.Arg356Trp 
0 never yes hospital 
admissions 
for seizures 
53 50 
I18 14 21OHD 46XX F p.Pro30Leu 
p.Pro30Leu 
B treated at  
age 4-10yr 
stopped >4yrs 
 
no genital 
surgery 
210 187 
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I19 10 21OHD 46XX M p.Gln196* 
p.Arg356Trp 
0 never yes dengue 
hospital 
admission 
for vomiting 
61 60 
I20 19 21OHD 46XX F p.Ile172Asn 
deletion of 
exon 1-6 
B never no no 139 129 
I21 3 21OHD 46XX F p.Ile172Asn 
p.Arg356Trp 
B never no no 101 64 
I22 21 21OHD 46XX F deletion of 
exon 1-6 
NSM# 
NC never no tonsillectomy 
dengue 
146 149 
D1 0 21OHD 46XY M deletion of 
exon 1-3 
p.Ile172Asn 
B started after 
ACTHstimulation 
test 
 NA 30 70 
D2 0 21OHD 46XY M deletion of 
exon 1-7 
p.Pro30Leu 
B started after 
ACTHstimulation 
test 
 NA 30 90 
 
^Genotype classification is based on mutation analysis. Mutations in genotype group 0 and A have usually 
<1% residual enzyme activity, genotype B has 1-5% residual enzyme activity, while genotype C has a residual 
enzyme activity of 20-50% (4). We classified the p.Pro30Leu mutation in genotype group B. Cortisol 
concentrations are reported in nmol/L. *This patient also had a cluster of mutations in the CYP21A2 
promoter region in one allele, possibly resulting in a more severe phenotype. #This patient had very high 17-
hydroxyprogesterone levels (>400 nmol/L), and although no second mutations has been found it is very likely 
that this patient belongs to the same genotype group (B) as her sister (#I20). Abbreviations: 11OHD, 11-
hydroxylase deficiency; 21OHD, 21-hydroxylase deficiency; dengue, dengue hemorrhagic fever; F, female; 
GCs, glucocorticoids; M, male; NA, not applicable; NC, not classifiable; NSM, no second mutation reported; 
SW, salt-wasting; U, undefined; yr, year; yrs, years. 
 
never treated with glucocorticoids, and 7 patients were treated in the past but had 
been off treatment for at least 2 years at the time of biochemical analysis and were 
therefore considered as untreated. Additionally, we included the biochemical results of 
2 Dutch male CAH neonates, who were identified from the national CAH neonatal 
screening program and started glucocorticoid treatment only after the biochemical 
analysis of the ACTH stimulation test. All patients were diagnosed with a severe type of 
CAH based on mutation analysis. Episodes of severe stress in their medical history has 
been reported in 13/22 patients. In none of these episodes patients were treated with 
stress dosages of glucocorticoids. In the 11OHD group, 1 patient underwent genital 
surgery. In the 21OHD group, 5 patients underwent genital surgery (genotype group 0 
(n=3), A (n=1), B (n=1)) and 2 patients underwent tonsillectomy (genotype group 0 
(n=1), unclassifiable (n=1)). There were 5 reports of dengue hemorrhagic fever 
(genotype group 0 (n=2), unclassifiable (n=1)) or typhoid fever (genotype group 0 
(n=1), B (n=1). Also, 5 patients reported hospital admissions because of salt-wasting 
crisis (genotype group A (n=2)) or because of episodes of vomiting and/or seizures 
(genotype group 0 (n=3)).  
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Biochemical evaluation of serum adrenal steroid precursors 
In control patients, the cortisol concentration increased adequately after ACTH 
administration (>500 nmol/L (9-11)) and all other measured steroids remained low with 
a 2-5 fold increase. In contrast, in our study population cortisol concentrations 
remained low after ACTH administration with a median concentration of 73 (IQR 64-
129) nmol/L in the 21OHD patients and 180 (IQR 159-214) nmol/L in the 11OHD 
patients, confirming severe cortisol deficiency in our cohort (Table 3.1, Fig. 3.2). 
Adrenal precursor steroid concentrations were also measured in serum from CAH 
patients before and after ACTH administration (Fig. 3.2). As we did not find differences 
in steroid concentrations before and after ACTH administration, we further only report 
on the steroid concentrations in serum after ACTH administration. Corticosterone 
concentrations were significantly lower in untreated CAH patients (median 21OHD: 7.1 
IQR 5.9-8.2) nmol/L, MWU p<0.001; median 11OHD: 4.3 (IQR 3.7-8.4) nmol/L, MWU 
 
Fig. 3.2: Steroid concentrations in untreated CAH patients. Blood adrenal steroid concentrations were 
determined before and 60 minutes after ACTH administration. Gray indicates 21-hydroxylase deficient 
patients, purple indicates 11-hydroxylase deficient patients, and green indicates control. 
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(p=0.003) compared to controls (median 72 (IQR 55-78) nmol/L). Blood 11-
deoxycortisol and 11-deoxycorticosterone concentrations were significantly elevated in 
11OHD patients with respectively a median concentration of 457 nmol/L (IQR 364-612, 
MWU p=0.003) and 55 nmol/L (IQR 25-119, MWU p=0.003) compared to control 
(median 3.2 (IQR 1.9-5.9), and 0.5 (IQR 0.2-0.8) nmol/L, respectively), but not in 21OHD 
patients (median 1.9 (IQR 1.5-3.8, MWU p=0.083) and 0.4 (IQR 0.3-0.6, MWU p=0.395) 
nmol/L, respectively). Blood 17-hydroxyprogesterone and progesterone concentrations 
were elevated in 21OHD patients (median 610 (IQR 509-762, MWU p<0.001) and 29 
(IQR 20-43, MWU p<0.001) nmol/L, respectively) and 11OHD patients (median 20 (IQR 
16-21, MWU p=0.003), and 3.6 (IQR 2.6-5.8, MWU p=0.003) nmol/L, respectively) 
compared to controls (median 4.8 (IQR 2.7-5.6) nmol/L and 1.0 (IQR 0.5-1.1) nmol/L, 
respectively). 21-deoxycortisol concentrations were only measurable (>1 nmol/L) in 
blood from untreated 21OHD patients (median 73 (IQR 46-112) nmol/L). 
GR transactivation in human embryonic kidney cells 
To determine the potency of steroid precursors for GR transactivation, we performed 
dual-luciferase assays, which allows for the quantification of GR-induced gene 
expression (Table 3.2, Fig. 3.3). We found an EC50 of 11 nM (95%CI: 5.9-20) for cortisol, 
which is used as reference steroid. Similar potencies were found for corticosterone 
(EC50 of 17 nM, 95%CI: 8.9-32) and 21-deoxycortisol (EC50 of 22 nM, 95%CI: 12-42) as 
confidence intervals overlap. 11-hydroxyprogesterone, 11-deoxycortisol, and 
aldosterone exhibited somewhat higher EC50 values: 47, 71, and 111 nM, respectively. 
Exposure to 11-deoxycorticosterone (EC50 of 725 nM), progesterone (EC50 of 1147 nM), 
and 17-hydroxyprogesterone (EC50 of 1668 nM) also resulted in GR transactivation, 
although these EC50 values were at least 65 times higher than that of cortisol. GR 
transactivation was only observed at a very high concentration (100 000 nM) of 16-
hydroxyprogesterone, while no GR transactivation was found for pregnenolone and 17-
hydroxypregnenolone.  
 
Discussion 
Here, we describe a unique group of untreated CAH patients with biochemically 
confirmed severe cortisol deficiency. None of these patients had clinical signs of 
cortisol deficiency and more than half of these patients report a history of severe 
stress-situations, such as surgery or severe infectious diseases, and recovered without 
glucocorticoid stress dosing. We show here that this might be explained by the 
glucocorticoid activity of significantly increased steroid precursor concentrations, that 
at least partially compensate the cortisol deficiency. 
3 
44 | Chapter 3  
 
Table 3.2: (Relative) potency of steroids to activate the glucocorticoid receptor (GR). 
 EC50 (95%CI) nM Relative potency to GR 
cortisol 11 (5.9 - 20) 100% 
corticosterone 17 (8.9 - 32) 64% 
21-deoxycortisol 22 (12 - 42) 49% 
11-hydroxyprogesterone 47 (30 - 73) 23% 
11-deoxycortisol 71 (56 - 92) 15% 
aldosterone 111 (72 - 171) 9.8% 
11-deoxycorticosterone 725 (422 - 1246) 1.5% 
progesterone 1147 (664 - 1981) 0.95% 
17-hydroxyprogesterone 1668 (1300 - 2140) 0.65% 
16-hydroxyprogesterone NC*  
pregnenolone NA  
17OHpregnenolone NA  
 
Data of the transactivation assays in human embryonic kidney cells were used to calculate dose-response 
curves using nonlinear regression. EC50 values could be calculated when a complete dose-response curves 
was available, including a concentration in which maximum transactivation was reached (plateau phase).  
* some transactivation at 100 000 nM, but no maximum transactivation was reached with the concentrations 
tested. Abbreviations: 95%CI, 95% confidence interval; EC50, estimated concentration that causes 50% of the 
maximum transactivation; GR, glucocorticoid receptor; NA, not applicable; NC, not calculable. 
 
To the best of our knowledge we are the first to report on measurement of multiple 
adrenal steroid precursors in an unique cohort of untreated CAH patients. As expected 
from their enzymatic defect, in untreated 21OHD patients 17-hydroxyprogesterone 
(127x higher), progesterone (29x higher), and 21-deoxycortisol (only measurable in 
21OHD) concentrations were significantly increased compared to control. Remarkably, 
this corresponds to the measured concentrations of adrenal steroid precursors in 
blood of treated 21OHD patients (12). Furthermore, in untreated 11OHD patients, we 
found 11-deoxycortisol (457x higher) and 11-deoxycorticosterone (55x higher) to be 
the most important accumulating steroid precursors. We hypothesized that these 
strongly elevated adrenal precursor concentrations may have a stimulating effect on 
the GR. 
Steroid hormone action is initiated by binding of the hormone to its receptor. The 
hormone-receptor complex subsequently will translocate to the nucleus were it binds 
to hormone response elements in the regulatory region of target gene promoters, 
initiating transactivation (13). Several studies have been performed evaluating the 
binding of steroids to the GR and mineralocorticoid receptor (MR) and/or the nuclear 
translocation of the receptor-complex, but only a few studies report on GR 
transactivation (8, 14-18), mainly focusing on aldosterone and cortisol, showing that 
cortisol has higher potency for GR transactivation than aldosterone (14, 15, 17, 18). It is 
nowadays well established that adrenal steroids have steroid hormone cross-reactivity  
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Fig. 3.3: Glucocorticoid receptor transactivation by adrenal steroid precursors. RLU is a measure for 
glucocorticoid receptor transactivation as measured by a dual-luciferase assay in human embryonic kidney 
cells that were exposed to increasing amount of steroids (depicted in black) for 24 hours. Cortisol was used 
as a reference (depicted in gray). All concentrations were measured in triplicate and mean and range are 
depicted. Abbreviations: RLU, relative light units. 
 
explained by the high degree of homology of the DNA binding domain of the GR and 
the MR (19). Only one study showed that 21-deoxycortisol, 17-hydroxyprogesterone 
and progesterone are able to activate the GR (8). To the best of our knowledge, we are 
the first to describe the potency to activate the GR for more than 10 adrenal steroid 
precursors relative to cortisol. We found that 21-deoxycortisol and corticosterone had 
similar potency to activate the GR, while the potency of 11-hydroxyprogesterone, 11-
deoxycortisol and aldosterone was 4-10x lower, and the potency of 11-
3 
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deoxycorticosterone, progesterone, and 17-hydroxyprogesterone more than 65x lower 
compared to cortisol.  
Comparison of the transactivation data with the molecular structure of the adrenal 
steroid precursors shows that dehydrogenation of the steroid precursors by 3β-
hydroxysteroid dehydrogenase is a prerequisite to enable a steroid to activate the GR, 
as pregnenolone and 17-hydroxypregnenolone, which are not dehydrogenated, were 
not able to cause GR transactivation in vitro. We also observed that dehydrogenation 
alone (progesterone) or combined with 21-hydroxylation (11-deoxycorticosterone) or 
17-hydroxylation (17-hydroxyprogesterone) resulted in relatively low potency to 
activate the GR. Combination of dehydrogenation and hydroxylations of position 11 
and 21 (corticosterone), or position 11 and 17 (21-deoxycortisol), or position 17 and 21 
(11-deoxycortisol), increased the potency to activate the GR as EC50 values were similar 
or 7 times higher than of cortisol. Strikingly, the most potent GR activation precursor 
steroids are 11-hydroxylated steroids. This confirms the hypothesis of Hellal-Levy et al. 
(15) and Rousseau et al. (20) that hydroxylation at position 11 enhances glucocorticoid 
activity.  
The strongly increased concentrations of the 11-hydroxylated steroid precursors 21-
deoxycortisol and 11-hydroxyprogesterone in untreated 21OHD patients, that are able 
to activate the GR, might at least partially compensate for their cortisol deficiency. 17-
hydroxyprogesterone and progesterone might also contribute as we found increased 
concentrations in 21OHD and 11OHD patients, although the potential to activate the 
GR is lower. Furthermore, in 11OHD patients, 11-deoxycortisol and 11-
deoxycorticosterone also might compensate for the cortisol deficiency as these 
steroids had good GR activation potency. 
 A clinical threshold of 500 nmol cortisol/L blood after ACTH administration is widely 
used to define adrenal insufficiency, and although lower thresholds also have been 
proposed (9-11, 21), all of our patients had cortisol concentrations far below this 
threshold. Previously, it has been suggested to include serum corticosterone, 11-
deoxycorticosterone and 11-deoxycortisol in addition to serum cortisol to evaluate 
adrenal function (22). Based on our finding of glucocorticoid receptor activation we 
emphasize the importance to use multiple adrenal steroid precursors, such as 11-
deoxycortisol, 11-deoxycorticosterone, 11-hydroxyprogesterone, 21-deoxycortisol, 17-
hydroxyprogesterone, progesterone, and cortisol to evaluate glucocorticoid action. 
More studies are necessary to study the clinical significance of our findings in more 
detail.  
Although our data suggest that CAH patients may survive without glucocorticoid 
treatment, it has to be pointed out that based on our results we do not advocate to 
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withhold treatment in severely affected CAH patients. However, it has to be noted that 
in treated CAH patients blood concentrations of the elevated adrenal steroid 
precursors are generally suppressed and consequently patients become more 
dependent on glucocorticoid treatment and additional glucocorticoid stress dosing in 
the case of severe illness. As knowledge and infrastructure are far from perfect in 
developing countries, such as Indonesia, treated CAH patients may have an increased 
risk to develop adrenal crises as the compensatory effect of steroid precursors is 
absent. Also, acute discontinuation of glucocorticoid treatment, which is very likely in 
developing countries as medication is not always available, can increase the risk to 
develop adrenal crises as the compensatory steroid precursors will be suppressed for 
some time. Patients and clinicians should be aware of the importance of daily 
glucocorticoid supplementation without discontinuation in order to prevent adrenal 
crises. For the same reason, the importance of appropriate stress dosing regimen has 
to be emphasized. 
Despite this being the first study in a relatively large cohort of untreated CAH patients, 
our study has some limitations. In some of the reported stress-situations, there may 
have been an underlying adrenal crisis as some episodes were reported as salt-wasting 
crises or severe vomiting and/or seizures. Still, it is remarkable that all patients 
recovered from these episodes without administration of glucocorticoid medication. 
Furthermore, none of our patients had the most severe type of CAH, a homozygous 
deletion of CYP21A2, although several patients were classified as genotype group 0, 
with an expected enzyme activity of <1%. As neonatal screening is not implemented in 
Indonesia, the prevalence of CAH patients is probably higher than the current number 
of patients diagnosed with CAH, which might have led to selection of our patient group. 
Especially male CAH patients are expected to be under-diagnosed, either because they 
have no complaints or because they have died within the first weeks of life due to a 
salt-wasting crisis. Education programs in these countries should therefore also focus 
on salt requirements in neonates to prevent salt-wasting crises.  
In conclusion, our results show that severely affected untreated CAH patients with 
proven cortisol deficiency might survive due to accumulated adrenal steroid precursors 
which can activate the GR and might at least partially compensate for the cortisol 
deficiency. Especially 21-deoxycortisol, 11-hydroxyprogesterone, 11-deoxycortisol, and 
17-hydroxyprogesterone can contribute to this compensation. Therefore, we suggest 
to measure all relevant GR activating steroids in the evaluation of adrenal function, 
especially in CAH patients. Further research should focus on establishing cut-off values 
for the combined adrenal steroid concentrations and to personalize treatment 
necessities according to the total panel. 
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Supplemental Material: 
LC-MS/MS protocol 
Cortisol, 21-deoxycortisol, 11-deoxycortisol, 17-hydroxyprogesterone, and 
progesterone were analyzed by LC-MS/MS after protein precipitation and solid-phase 
extraction. Internal standard [2H4]-cortisol, [
2H4]-21-deoxycortisol, [
2H5]-11-
deoxycortisol, [13C3]-17-hydroxyprogesterone (Isosciences, King of Prussia, PA) and 
[2H9]-progesterone (CDN isotopes) was added to 100 µL serum. Subsequently 300 µL 
acetonitrile + 0.1% formic acid was added for protein precipitation. 300 µL H2O was 
added to 200 µL supernatant followed by solid phase extraction (Oasis HLB 1cc, 
Waters). The eluate (methanol/isopropanol 95:5) was dried under a stream of N2 gas, 
reconstituted in methanol: water (3:7) and injected (10 µL) into an Agilent 
Technologies 1290 Infinity UHPLC-system (Agilent Technologies, Santa Clara, CA) 
equipped with a BEH C18 (1.7μm 2.1 X 50mm) analytical column (Waters Corp.) at 
60°C. Mobile phase A (methanol:water 20:80 + 2 mM NH4CH3COO + 0.1% formic acid) 
and B (methanol:water 98:2 + 2 mM NH4CH3COO + 0.1% formic acid) were run in a 
gradient (0.4 mL/min). Start gradient 70:30 A:B for 2.5 min; then to 40:60 A:B in 3.5 
min; followed by a gradient in 0.5 min to 2:98 to remain such for 0.5 min and 
thereafter to 70:30 A:B in 0.5 min and remain such for 0.5 min. Retention time was 
1.41 min, 2.13 min, 2.56 min, 4.66 min and 6.04 min for cortisol, 21-deoxycortisol, 11-
deoxycortisol, 17-hydroxyprogesterone and progesterone respectively. Total run time 
was 8 minutes. An 9-point calibration curve was used (cortisol, 21-deoxycortisol, 11-
deoxycortisol, 17-hydroxyprogesterone (Steraloids), progesterone (Sigma). An Agilent 
6490 tandem mass spectrometer (Agilent Technologies) was operated in the 
electrospray positive ion mode, with a capillary voltage 3.5 kV, fragmentor voltage 380 
V, sheath gas temperature 350°C and gas temperature 150 °C with N2 collision gas. 
Two transitions (qualitative and quantitative) were monitored. Transitions (Q1>Q3) 
were m/z 363.4 > 97.1 (34 V) and m/z 363.4 > 121.1 (25 V) for cortisol; m/z 367.4 > 
97.1 (34 V) and m/z 367.4 > 121.1 (25 V) for [2H4]-cortisol. m/z 347.2 > 121.1 (27 V) and 
m/z 347.2 > 269.0 (18 V) for 21-deoxycortisol; m/z 351.2 > 121.0 (29 V) and m/z 351.2 
> 273.0 (18 V) for [2H4]-21-deoxycortisol. m/z 347.2 > 109.1 (31 V) and m/z 347.2 > 
97.1 (29 V) for 11-deoxycortisol; m/z 352.3 > 113.1 (29 V) and m/z 352.3 > 100.1 (31 V) 
for [2H5]-11-deoxycortisol. m/z 331.3 > 109.1 (31 V) and m/z 331.3 > 97.1 (31 V) for 17-
hydroxyprogesterone; m/z 334.3 > 112.1 (33 V) and m/z 334.3 > 100.1 (30 V) for [13C3]-
17-hydroxyprogesterone. m/z 315.3 > 109.1 (29 V) and m/z 315.3 > 97.1 (29 V) for 
progesterone; m/z 324.3 > 113.1 (29 V) and m/z 324.3 > 100.1 (29 V) for [2H9]-
progesterone. Dwell time was 100 ms, 20 ms, 20 ms, 60 ms and 100 ms for cortisol, 21-
deoxycortisol, 11-deoxycortisol, 17-hydroxyprogesterone, and progesterone 
respectively. The method was linear assessed by CLSI EP6 protocol. For cortisol total CV 
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is 3.6% at 300 nmol/L and 3.1% at 1080 nmol/L. For 21-deoxycortisol total CV is 9.6% at 
1.1 nmol/L and 8.6% at 15.2 nmol/L. For 11-deoxycortisol total CV is 5.9% at 2.1 nmol/L 
and 5.2% at 26.9 nmol/L. For 17-hydroxyprogesterone total CV is 5.6% at 2.6 nmol/L 
and 5.1% at 94.3 nmol/L. For progesterone total CV is 5.9% at 5.1 nmol/L and 3.9% at 
30.4 nmol/L.  
Corticosterone and 11-deoxycorticosterone were analyzed by LC-MS/MS after protein 
precipitation and solid-phase extraction. Internal standard [2H4]-corticosterone and 
[13C3]-11-deoxycorticosterone (Isosciences, King of Prussia, PA) was added to 100 µL 
serum. Subsequently 300 µL Acetonitrile + 0.1% formic acid was added for protein 
precipitation. 500 µL H2O was added to 200 µL supernatant followed by solid phase 
extraction (Oasis HLB 1cc, Waters). The eluate (methanol/water 90:10) was dried under 
a stream of N2 gas, reconstituted in methanol: water (3:7) and injected (10 µL) into an 
Agilent Technologies 1290 Infinity UHPLC-system (Agilent Technologies, Santa Clara, 
CA) equipped with a HSS T3 (1.8μm 2.1 X 100mm) analytical column (Waters Corp.) at 
40°C. Mobile phase A (methanol:water 20:80 + 2 mM NH4CH3COO + 0.1% formic acid) 
and B (methanol:water 98:2 + 2 mM NH4CH3COO + 0.1% formic acid) were run in a 
gradient (0.4 mL/min). Start gradient 60:40 A:B for 3.5 min; then to 48:52 A:B in 1 min 
and 38:62 A:B in 3 min; followed by a gradient in 0.01 min to 5:95 A:B to remain such 
for 1 min and thereafter to 60:40 A:B in 0.5 min and remain such for 2 min. Retention 
time was 5.6 min and 7.2 min for corticosterone and 11-deoxycorticosterone, 
respectively. Total run time was 11 minutes. A 9-point calibration curve was used 
(corticosterone and 11-deoxycorticosterone (Sigma)). An Agilent 6490 tandem mass 
spectrometer (Agilent Technologies) was operated in the electrospray positive ion 
mode, with a capillary voltage 3.0 kV, fragmentor voltage 380 V, sheath gas 
temperature 350°C and gas temperature 150 °C with N2 collision gas. Two transitions 
(qualitative and quantitative) were monitored. Transitions (Q1>Q3) were m/z 347.2 > 
97.0 (31 V) and m/z 347.2 > 121.1 (29 V) for corticosterone; m/z 351.3 > 97.1 (31 V) 
and m/z 351.3 > 121.1 (29 V) for [2H4]-corticosterone; m/z 331.3 > 109.1 (31 V) and 
m/z 331.3 > 97.1 (29 V) for 11-deoxycorticosterone; m/z 334.3 > 112.2 (29 V) and m/z 
334.3 > 100.2 (27 V) for [13C3]-11-deoxycorticosterone. Dwell time was 100 ms for both 
corticosterone and 11-deoxycorticosterone. The method was linear assessed by CLSI 
EP6 protocol. For corticosterone total CV is 3.2% at 26.8 nmol/L and 3.6% at 59.4 
nmol/L. For 11-deoxycorticosterone total CV is 3.7% at 0.2 nmol/L and 2.7% at 2.0 
nmol/L.  
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Abstract 
This review provides the reader with current insights on testicular adrenal rest tumors 
(TARTs), a common complication in male patients with congenital adrenal hyperplasia 
(CAH), often leading to sub- or infertility. Presently, more than 300 individual cases of 
CAH-associated TART have been reported since the first description in 1940. In recent 
studies, an overall prevalence of 40% (range 14-89%) is found in classic CAH patients. 
Reported differences in prevalence numbers are mainly caused by the method of 
detection (palpation vs. ultrasound or MRI), and the selected patient population (child 
vs. adult, classic vs. non-classic CAH). Biochemically, histologically, and molecularly 
TARTs exhibit particular adrenal characteristics and were therefore thought to 
originate from aberrant adrenal cells. More recently TART has been found to also 
exhibit testicular characteristics. This has led to the hypothesis of a pluripotent cell 
type as the origin of TART. High concentrations of adrenocorticotropic hormone (ACTH) 
could cause hyperplasia of these pluripotent cells, as TART appears to be associated 
with poor hormonal control with concomitant high ACTH concentrations. 
Unfortunately, as yet there are no treatment options to prevent the development of 
TART, nor are there guidelines to treat patients with TART. Intensified glucocorticoid 
treatment could improve fertility status, although studies report contradicting results. 
As TART can lead to irreversible testicular damage, semen cryopreservation could be 
offered to patients with TART. Further research should focus on druggable targets to 
prevent the development of TART or to treat TART and improve fertility status of 
patients with TART. 
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Introduction 
Congenital adrenal hyperplasia (CAH), a group of autosomal recessive disorders of the 
adrenal cortex affecting adrenal steroid production, is caused by a defect of one of the 
enzymes involved in the adrenal steroidogenesis. In most (>90%) CAH patients the 
enzyme CYP21A2 (21-hydroxylase) is affected. The incidence is 1:12 000 (1, 2). The 
severity of the disease depends on the residual enzyme activity which depends mainly 
on the genotype. Patients classified as genotype null (0) or A have <1% residual enzyme 
activity with cortisol and aldosterone deficiency (also classified as classic salt-wasting 
type). Patients classified as group B genotype have 1-5% residual enzyme activity with 
cortisol deficiency but in general sufficient (or mildly deficient) mineralocorticoids 
(classic simple virilizing type). Patients in group C have a residual enzyme activity of 20-
50% with a less severe phenotype of mildly increased androgens and are considered as 
non-classic CAH (3).  
In CAH, cortisol production is decreased due to the enzymatic defect and, 
consequently, pituitary adrenocorticotropic hormone (ACTH) production is increased 
due to the lack of negative feedback of cortisol to the pituitary gland. This causes 
hyperplasia of the adrenal gland and stimulation of adrenal steroidogenesis, resulting 
in accumulation of steroids before the enzymatic block. These steroids are 
subsequently shunted to the unaffected androgen pathway, leading to prenatal 
virilization of the female external genitalia. Therapy consists of lifelong glucocorticoid 
administration to substitute the cortisol deficiency, thereby also restoring the negative 
feedback on the pituitary gland. This results in lowering ACTH and adrenal androgens 
concentrations. However, supraphysiological dosages of glucocorticoids are often 
needed to adequately suppress adrenal androgen production (1, 2).  
Subfertility is a severe long-term complication in adult CAH patients (4-13), the main 
cause of which is the presence of testicular adrenal rest tumors (TARTs). TARTs are 
benign lesions within the testes that may cause infertility due to obstruction of the 
seminiferous tubules (14) or due to paracrine effects of hormones produced by TART 
(15-18). Longstanding TART can lead to irreversible damage of the testicular tissue (14). 
Therefore, knowledge about the prevalence, pathophysiology and treatment of TART in 
CAH patients is of major clinical importance. In this review we provide an overview on 
current insights in TART in males with CAH due to 21-hydroxylase deficiency, including 
prevalence, characteristics, origin, and treatment options.  
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Prevalence of TART 
Since the first description of TART in 1940 by Wilkins et al. (19) many studies described 
the prevalence of TART mainly in case reports or small cohorts. In Fig. 4.1, we 
summarize 31 original studies that have reported on TART prevalence in the last ten 
years using ultrasound or MRI (7, 8, 10, 11, 13, 20-45). Reported prevalence ranged 
from 14% to 86%, depending on age and genotype. When summed, the overall TART 
prevalence in the reported CAH patients in the last ten years was 38% (472/1251).  
 
 
Fig. 4.1: Prevalence of TART. Reported prevalence of TART within the last ten years. Age classification 
(pediatric, mix, or adult) of the patients was used a defined by the original author of the study. The black dots 
indicate the prevalence of TART reported and the whiskers indicate the 95% confidence intervals. 
 
Method of detection 
Due to its central location within the rete testis, TART can only be detected by 
palpation if the lesion has a diameter of at least two centimeters. MRI and ultrasound 
enable the detection of smaller lesions, even of several millimeters (Fig. 4.2). This 
explains why higher prevalence numbers of TART are found in MRI or ultrasound 
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studies compared to studies using palpation as method of detection (8, 10, 21, 24-28, 
30, 32, 35, 37-41). Ultrasound is the preferred method of detection as it is easy 
accessible and has a good sensitivity to detect small lesions. 
Age  
The broad prevalence range can be partially explained by the variation in patient age. 
Studies in adult CAH patients (defined either as 16+ or 18+) showed a higher 
prevalence of TART (summed prevalence 46%, N=296/642) compared to the studies 
only including children (summed prevalence 25%, N=104/416) (Fig. 4.1). Concordantly, 
some studies also reported an increase in prevalence with age, especially during 
puberty (21, 25, 30, 35, 45). The youngest patient described in the last ten years was 
1.8 years old (21). TARTs have also been previously reported in autopsy material of 
CAH patients less than eight weeks old (46).  
Severity of the CAH 
Several studies describe an association between the prevalence of TART and the 
severity of the disease. In the last ten years a total of 1019 classic CAH males were 
studied in 27 studies, of whom 40% (range 14 - 89%) had TART (n=412) (7, 8, 10, 11, 
13, 21, 22, 24-27, 29-39, 41-45). Overall, prevalence of TART in the most severely 
affected CAH patients (genotype 0 and A, and salt-wasting type) is 51% (228/451) (7, 
11, 13, 21, 22, 24-27, 30, 32-35, 37-39, 41, 42, 44, 45), while this is 23% (53/227) for 
the less severely affected classic CAH patients (genotype B and simple virilizing type) (7, 
13, 21, 22, 24, 25, 27, 30, 32-35, 37-39, 41, 42, 44, 45). Within reported classic CAH 
patients with TART, 80% (228/285) were severely affected (genotype 0 and A, salt-
wasting type), and only 20% (57/285) were less severely affected (genotype B, simple 
virilizing type), indicating that TART is more prevalent in more severely affected CAH 
patients. Nor genotype nor phenotype were significantly associated with TART in five 
studies (11, 30, 36, 38, 42), although this may have been caused by low patient 
numbers and subsequent low statistical power.  
Non-classic CAH patients were included in six studies (21, 25, 29, 30, 36, 45). In none of 
the 37 patients TART was present on ultrasound. In contrast, Falhammar et al. reported 
two patients with non-classic CAH (mildest mutation V281L and P105L+P453S), who 
both had TART (38), but the phenotype was not described in detail. Although the 
majority of patients with a V281L mutation has non-classic CAH, some present with a 
more severe phenotype (47). Moreover, the combination of P105L and P453S 
mutations are synergistic, resulting in more than 90% reduction of enzyme activity in 
vitro (48). Therefore, these patients might be classified as genotype B (more affected 
classic form) according to the classification used by Krone et al.(3). We earlier 
4 
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described (13) two patients with non-classic CAH with TART. Mutation analysis in both 
showed deletion/P30L mutation. However, the P30L mutation can be classified as 
genotype B or genotype C according to the classification used by Krone et al. (3). These 
patients might therefore also belong to the more affected classic form of CAH patients.  
In conclusion, the prevalence of TART in CAH patients is almost 50% and associated 
with method of detection, age, and severity of the disease. 
 
Characteristics of TART 
Ultrasound and MRI features of TART  
Currently, TARTs are mostly detected using ultrasound or MRI techniques (Fig. 4.2). On 
ultrasound imaging, the majority of TARTs (83%) were reported as hypoechogenic 
(220/266), 7% of the TARTs (18/266) were described as hypoechogenic with 
hyperechogenic reflections, and only 6% (17/266) were described as hyperechogenic. 
The remaining 4% was described as isogenic (6/266), disseminated (3/266) or not 
specified (2/266) (21, 23, 26, 28, 30, 32, 35, 40, 41, 49-55). Hypervascularity is common 
in TART and can be detected using color Doppler ultrasound (23, 26, 28, 35, 49, 53, 54). 
In MRI imaging TART shows hypointensity on T2 images, while TARTs appear 
hyperintense or isointense on T1 images compared to the normal testicular 
parenchyma (23, 53, 54, 56). 
 
 
Fig. 4.2: Ultrasound (A) and MRI (B) images and H&E staining (C) of testicular adrenal rest tumor (TART).  
A) Scrotal ultrasound of a 19-year old male CAH patients. The transverse image shows a hypoechogenic 
rounded lesion (between the white indicators) in the left testis. B) T2-weighted MR image of longstanding 
bilateral TARTs in a 33-year old patient. Heterogeneous low-signal intensity tumors (between the white 
indicators) are displacing surrounding high signal normal testicular tissue. C) TART tissue exist of large 
polygonal cells with abundant eosinophilic cytoplasm. Original magnification used 10x.  
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Macroscopic and microscopic features  
TARTs are typically located near or within the mediastinum testis (6, 23, 28, 30, 32, 35, 
39, 42, 45, 49, 51-53, 57-59) with bilateral presence reported in 33 studies (6, 7, 10, 13, 
21-28, 30, 32, 34, 35, 38, 40-42, 44, 45, 49-57, 60, 61) and an overall percentage of 77 
(339/441). Macroscopically, TARTs are described as firm (5, 14, 49, 56-59, 61-63), 
yellow to tan colored tumors (14, 57-59, 61-63), which are round to oval (23, 28, 30, 
40, 42, 51) or multilobular (14, 57, 58, 62, 63). They are sharply delineated from normal 
testicular tissue (14, 16, 23, 28, 52, 54, 56, 57, 59, 62-64). Microscopically (Fig. 4.2C), 
TARTs contain large polygonal cells with abundant eosinophilic cytoplasm (14, 16, 57-
59, 61, 63) and round nuclei (14, 57, 59, 61). These features are consistent with steroid 
secreting cells, such as Leydig cells (59, 61, 65, 66). Sheets, cords or nests of 
hyperplastic cells are separated by bands of fibrous tissue (14, 57-59, 61-63, 65), which 
explains the firm rubbery appearance of TART. Some TART nodules even appear 
calcified (61) or have severe hyalinization (14).  
Differentiation of TART from Leydig cell tumors 
Pathologically, it is challenging to discriminate TART from Leydig cell tumors (LCTs) as 
these tumors are closely related and share morphological characteristics. 
Discrimination of these tumors is of importance as misdiagnosis can lead to incorrect 
treatment (67, 68). Currently, TART is surgically removed only when severe pain 
complaints are present (58), while LCTs are always removed either with testis-sparing 
surgery or orchiectomy, as 10% of these tumors are malignant (66).  
Few characteristics are used to discriminate between TART and LCT, although none of 
them is exclusive for one of the tumor types. CAH patients are more likely to have 
TART, however few cases of LCT in CAH patients have been reported (69-74). 
Furthermore, bilateralism is reported in 77% of the CAH patients with TART 
(summarized in this review), while unilateralism is found in >90% of the patients with 
LCT (66). Imaging and biopsy of the tumor cannot discriminate between the different 
tumor types as these both show (steroidogenic) masses. TART size can decrease after 
intensifying glucocorticoid treatment of which a few cases are known (5, 59, 75-79). 
However, not all TARTs respond to increased glucocorticoid treatment especially in 
longstanding TART when fibrosis of the tumor is present (5, 50, 56, 59, 61, 75-79). Until 
now, no single marker that can discriminate TART from LCT is known, which can lead to 
misdiagnosis and consequently incorrect treatment. Therefore, there is a need for 
better discriminative markers.  
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Gene expression  
Gene expression analyses in TART have been reported in four studies (62, 63, 65, 80). 
Expression of adrenal specific genes, such as CYP11B1 (62, 63, 65), CYP11B2 (62, 63), 
CYP21A2 (65), and DLK1 (65), were found in TART. Moreover, gene expression of the  
-adrenal- ACTH (MC2R (62, 63, 65)) and angiotensin II receptor (AGTR2 (62, 63)) were 
reported. Gene transcripts of enzymes of common pathways in the steroidogenesis 
(testes and adrenal), i.e. STAR (62), CYP11A1 (62, 65), CYP17A1 (62), HSD3B2 (62), 
NR5A1 (62) were also described. GATA transcription factors are involved in 
adrenogonadal development (81). We found GATA3 and GATA6 expression in TART and 
adrenal tissues, while GATA4 was expressed in TART and testicular tissues (80). 
Interestingly, in another study we also found testis-specific gene expression of the 
luteinizing hormone (LH) receptor (LHCGR), INSL3, and HSD17B3 (62). However, gene 
expression of INSL3 was not confirmed by Lottrup et al. (65). An overview of all 
reported gene expression analyses in TART is given in Table 4.1. To summarize, both 
adrenal- and testis-specific gene expression has been found in TART. 
Immunohistochemistry 
Eight studies investigated the expression of multiple proteins with 
immunohistochemistry in TART tissues of CAH patients (14, 28, 50, 57, 59, 61, 65, 82), 
while four additional studies reported on the expression of insulin-like 3 (62), inhibin A 
(27), Reinke crystals (63), or POU domain class 5 transcription factor 1 (83). An 
overview of these findings is given in Table 4.1. As described before, TART is 
morphologically closely related to LCT, a sex-cord-stromal tumor. Several proteins 
specific for sex-cord-stromal tumors were investigated to find immunophenotypic 
differences between TART and LCT. Epithelial membrane antigen and paired box 2 and 
paired box 8 were negative in normal Leydig cells, LCT, TART, and normal adrenal 
tissues (82). Protein S100 showed variable expression in normal Leydig cells, but was 
negative in LCT, TART, and adrenal tissues, while stem cell growth factor receptor c-kit 
was variably expressed in LCT, but negative in normal Leydig cells, TART and adrenal 
tissues (82). However, vimentin staining was reported positive in TART in two studies 
(28, 57) and variable in one study (82), whereas positive staining was also observed in 
normal Leydig cells, LCT and the zona glomerulosa of the adrenal gland (82). 
Synaptophysin also showed variable expression with weak (82) to strong (50, 57) 
intensity in TART, while expression in LCT was reported as variable with weak to 
moderate intensity (50, 57, 82). Variable staining with weak (82) to strong (50) intensity 
can be observed in adrenocortical tissue, while staining in normal Leydig cells was 
rarely seen (50, 82). Neural cell adhesion molecule 1 was the only sex-cord-stromal 
tumor maker reported positive in TART in 3 studies (28, 57, 82) whereas positive 
staining was also observed in LCT (57, 82), normal Leydig cells and the zona 
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glomerulosa (82). To summarize, proteins specific for sex-cord-stromal tumors were in 
general negative in TART. Vimentin, synaptophysin and neural cell adhesion molecule 1 
were expressed variably in TART and could not discriminate TART from LCT.  
As TART is known to have adrenal characteristics several studies also studied protein 
expression of adrenal markers. Inhibin A staining is used as an adrenocortical marker 
(zona reticularis) and was positively expressed in TART (27, 28, 50, 57, 82), although 
positive staining was also found in Leydig cells and LCTs (50, 82). Another adrenal 
marker, protein delta homolog 1 (from DLK1), was expressed in TART, but almost 
absent in LCT (65). Chromogranin, a neuro-endocrine marker, was absent in TART (57, 
82), Leydig cells, LCTs and adrenocortical cells (82). Ki67, a proliferation marker that is 
correlated with the clinical course of neuro-endocrine tumors, was found variably 
expressed and low staining intensity was observed in both TART and LCT (57). Smooth 
muscle actin, a marker for vascularization, was positive in TART, indicating prominent 
vascularization in TART (65). Lipochrome consists of golden-brown lipofuscin pigments, 
which occur in the zona reticularis of the adrenal gland and testis interstitium and was 
observed in TART (14, 16, 50, 57, 59, 61), but not in LCT tissue (57). In addition, the 
ACTH receptor (65) and the angiotensin II receptor (16) were observed in TART. To 
summarize, adrenal markers and receptors are expressed in TART, while neuro-
endocrine markers are absent.  
Furthermore, the occurrence of androgen producing cells have been investigated in 
TART via specific protein markers. Immunohistochemistry of insulin-like 3, a marker of 
Leydig cells, showed negative staining in TART (62, 65). Reinke crystals, another marker 
for Leydig cells and a typical finding in LCT were also absent in TART (14, 16, 50, 54, 57, 
59, 61, 63, 82). The androgen receptor was found variably expressed (82) or not 
expressed (57). LH binding was not observed in a study which examined one TART 
tissue (16). Calretinin a marker for androgen producing cells was variably expressed in 
TART (82). Keratin, another marker for androgen producing cells, was positively (57) or 
negatively (82) expressed in TART. Cholesterol side-chain cleavage enzyme (65), and 
17α-hydroxylase (82) are expressed in TART and normal Leydig cells. Variable 
expression of the testicular enzyme 17β-hydroxysteroid dehydrogenase was observed 
(82). Moreover, enzymes from the adrenal steroidogenesis were studied: 21-
hydroxylase (65), cytochrome P450 11B1 (16, 65), and 3β-hydroxysteroid 
dehydrogenase (16, 65, 82) were all expressed in TART tissue, but not in normal 
testicular tissue. POU domain, class 5 transcription factor 1 (OCT4) is a protein 
expressed in undifferentiated, pluripotent cells, but was not expressed in TART or LCT 
(83). To summarize, markers for androgen producing cells were expressed in TART, but 
specific markers for Leydig cells were absent. 
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Overall, immunohistochemistry results show that proteins routinely investigated in sex-
cord-stromal tumors are in general absent in TART, but TART tissue does express 
markers for androgen-producing cells. Also, adrenocortical markers as well as proteins 
from the adrenal steroidogenesis are expressed in TART.  
 
Table 4.2: Expression of markers in testicular adrenal rest tumor tissue. 
Marker Present in TART Variable in TART Absent in TART 
Adrenal gene expression 
CYP11B1 (62, 63, 65)   
CYP11B2 (62, 63)   
CYP21A2 (65)   
DLK1 (65)   
MC2R (62, 63, 65)   
AGTR2 (62, 63)   
GATA3  (80)   
GATA6 (80)   
Gene transcript of common enzymes in steroidogenesis 
STAR (62)   
CYP11A1 (62, 65)   
CYP17A1 (62)   
HSD3B2 (62)   
NR5A1 (62)   
Testicular gene expression 
GATA4 (80)   
LHCGR (62)   
INSL3 (62)  (65) 
HSD17B3 (62)   
Proteins specific for sex-cord-stromal tumors 
Epithelial membrane antigen   (82) 
Paired box 2    (82) 
Paired box 8   (82) 
S100   (82) 
Stem cell growth factor receptor c-kit   (82) 
Vimentin (28, 57) (82)  
Synaptophysin  (50, 57, 82)  
Neural cell adhesion molecule 1 (28, 57, 82)   
Adrenal markers 
Inhibin A (27, 28, 50, 57, 82)   
Protein delta homolog 1 (from DLK1) (65)   
Neuro-endocrine markers 
Chromogranin   (57, 82) 
Ki67   (57)  
Marker for vasculature 
Smooth muscle actin (65)   
Pigments 
Lipochrome (14, 16, 50, 57, 59, 61)   
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Receptors 
ACTH receptor (65)   
Angiotensin II receptor (16)   
Androgen producing cell markers 
Insulin-like 3   (62, 65) 
Reinke crystals   (14, 16, 50, 54, 57, 
59, 61, 63, 82) 
Androgen receptor  (82) (57) 
Calretinin  (82)  
(Pan)keratin (57)  (82) 
Cholesterol side-chain cleavage enzyme (65)   
17α-hydroxylase (82)   
Testicular enzyme 
17β-hydroxysteroid dehydrogenase  (82)  
Adrenal steroidogenesis enzymes 
21-hydroxylase (65)   
Cytochrome P450 11B1 (16, 65)   
3β-hydroxysteroid dehydrogenase (16, 65, 82)   
Marker for undifferentiated cells 
POU domain, class 5 transcription factor 
1 (from OCT4) 
  (83) 
 
Abbreviations: TART, testicular adrenal rest tumor. 
 
Steroid production 
CAH patients with TART had higher concentrations of androstenedione, 17-
hydroxyprogesterone, and 21-deoxycortisol in spermatic vein blood compared to 
peripheral blood (63), indicating steroid production by TART. Especially 21-
deoxycortisol production is of importance as this is an adrenal-specific steroid hormone 
(11-hydroxylated) and not produced by the testis. Furthermore, Turcu et al. (84) 
showed that 17-hydroxyprogesterone, 21-deoxycortisol, 16-hydroxyprogesterone, and 
progesterone were the most abundant steroids produced by TART cells in vitro.  
Using immunohistochemistry, Mesa et al. found TART tissue to express steroid 
hormones dehydroepiandrosterone, androstenedione, and testosterone (82), which 
reflects the overflow of precursor steroids into the androgen pathway. Turcu et al. (22) 
determined steroid concentrations in serum of CAH patients with TART compared to 
the concentrations in CAH patients without TART. 11-hydroxyandrostenedione, 11β-
hydroxytestosterone, 11-ketotestosterone, 11-ketoandrostenedione, pregnenolone 
sulfate, 17-hydroxypregnenolone sulfate, androsterone, allopregnanolone, and 
androstenedione were significantly higher in CAH patients with TART compared to CAH 
patients without TART indicating higher steroid production in CAH patients with TART 
4 
64 | Chapter 4 
possibly by the TART tissue itself or associated with undertreatment of the CAH patient 
resulting in less androgen suppression (22).  
To summarize, TART is mostly present in both testes, typically located within the rete 
testes and difficult to discriminate from LCT. Several studies have characterized TART 
tissue and found that protein expression in TART shows similarity with normal and 
aberrant Leydig cells (LCT), as well as adrenocortical protein expression. This is in line 
with the published results on gene expression data, indicating both adrenal and 
testicular characteristics. Furthermore, gene and protein expression of adrenal-specific 
enzymes together with the measured steroids implicate that TARTs are able to produce 
steroid hormones.  
 
Characteristics of CAH patients with TART 
Association between hormonal control of CAH and the presence of TART  
Poor hormonal control was reported in more than half of the studied CAH patients with 
TART (55/95) (21, 23, 27, 30, 32, 34, 38, 39, 45, 52, 56, 60, 85). Only two studies 
reported no clear association between (poor) hormonal control and the presence of 
TART (7, 29). Poor hormonal control is biochemically characterized by elevated ACTH 
concentrations and consequently (strongly) elevated 17-hydroxyprogesterone and 
androstenedione concentrations. Higher serum ACTH concentrations were reported in 
CAH patients with TART compared to CAH patients without TART (27, 40, 41, 45). 
However, two studies found no significant association between TART and ACTH 
concentrations (22, 29). Higher concentrations of 17-hydroxyprogesterone were 
reported in CAH patients with TART compared to those without TART (13, 41, 45, 52, 
57, 60), although, again, several other studies did not find an association (25, 27, 29, 
33, 35). Androstenedione concentrations were found to be higher (13, 36, 41, 57, 60), 
or similar (25, 29, 35) in CAH patients with TART compared to CAH patients without 
TART. Signs of long-term poor hormonal control were reported in the majority of the 
CAH patients with TART, such as reduced final height and advanced bone age in 
children (64%: 25/39 (21, 25, 51, 55)). However, advanced bone age was also found in 
CAH patients without TART and the area under the curve of the difference between 
bone age and chronological age over the years did not differ between CAH patients 
with and without TART (33). Lower final adult height in CAH patients with TART was 
found compared to those without TART by Kang et al. (42). Reisch et al. showed that 
TART volume was not associated with any marker of hormonal control (7). The absence 
of such association might be explained by the fact that the TART size in longstanding 
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TART is mostly due to fibrosis or hyalinization instead of presence of hyperplastic TART 
cells (86).  
 
Fig. 4.3: Development of testicular adrenal rest tumor (TART) and proposed staging of Claahsen et al. (86). 
Stage 1 indicates the presence of individual TART cells within the rete testis. These cells become hyperplastic 
and hypertrophic (stage 2). Further growth of the TART cells will lead to obstruction of the seminiferous 
tubules, causing sub- or infertility (stage 3). In longstanding TART, progressive obstruction of the rete testis 
may lead to induction of fibrosis within TART and focal lymphocytic infiltrate. Peritubular fibrosis in the 
surrounding testicular tissue indicates early testicular damage (stage 4). The chronic obstruction will lead to 
hyalinization causing irreversible damaged testicular parenchyma (stage 5).  
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CAH patients receive lifelong substitution therapy to restore the hormonal balance. 
Glucocorticoids are used to treat cortisol deficiency and consequently lower ACTH 
concentration. Remarkably, no differences between glucocorticoid dosages were found 
between CAH patients with and without TART (22, 25, 27, 29, 33, 35, 36, 41). A possible 
explanation for this might be noncompliance, as prescribed glucocorticoid dosages do 
not always reflect intake of the medications. In contrast, CAH patients with TART had 
higher prescribed fludrocortisone dosages compared to CAH patients without TART 
(25, 29, 35, 41) reflecting a more severe salt-wasting form of CAH or noncompliance, 
although interpretation of these results is troublesome as only limited data is available. 
Long-term consequences of TART 
It is thought that TARTs develop from single precursors cells into large (multinodular) 
masses within the rete testis (Fig. 4.3). Claahsen et al. proposed to use 5 stages to 
classify TART (86), starting with individual TART cells (stage 1) that become hyperplastic 
and hypertrophic (stage 2). Further growth of the TART cells will lead to obstruction of 
the seminiferous tubules, causing sub- or infertility (stage 3). In longstanding TART, 
fibrosis within TART increases, focal lymphocytic infiltrate and peritubular fibrosis 
(stage 4) and eventually hyalinization (stage 5) develops causing irreversible damaged 
testicular parenchyma, leading to azoospermia (14). Due to compression of the 
testicular parenchyma, longstanding TART can cause severe pain complaints (58).  
To summarize, poor hormonal control with elevated ACTH concentrations seems to be 
associated with TART, although contradicting results are reported. Furthermore, TART 
can cause severe pain complaints and irreversible damage to the testicular 
parenchyma, leading to infertility.  
 
Origin and development of TART 
Only a few studies have speculated on the origin of TART. Originally, it was 
hypothesized that during adrenogonadal development in utero aberrant adrenal cells 
end up within the testes, which usually show spontaneous regression within the first 
year of life. In CAH patients, these adrenal rest cells may proliferate in the presence of 
increased concentrations of growth promoting factors, such as ACTH. This hypothesis 
was strengthened by the fact that several adrenal-specific characteristics were found in 
TART cells, as described in the section above. Nowadays the hypothesis on the origin of 
TART has shifted. Recently, testicular characteristics were also found in TART, as shown 
by gene expression of LHCGR, INSL3, and HSD17B3 (62) and GATA transcription factors 
(80) and the presence of the testicular enzyme 17β-hydroxysteroid dehydrogenase  
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Fig. 4.4: Adrenogonadal development. The adrenal glands and testes originate from the urogenital ridge of 
which the adrenogonadal primordium is formed. Segregation of this primordium into an adrenal primordium 
and bipotential gonad starts when primordial germ cells enter the gonadal region of the adrenogonadal 
primordium. The fetal adrenal exist of an medulla formed by neural crest cells, a fetal cortex and a definitive 
cortex surrounding the fetal cortex. The fetal cortex regresses after birth and the definitive cortex develops 
in the adult cortex containing three zones: zona glomerulosa, zona fasciculata and zona reticularis. The fetal 
testis develops from the bipotential gonad and somatic cells completely invert germ cells forming testicular 
cords. The adult testis exist of seminiferous tubules and Leydig cells (104). TART exhibit both testicular and 
adrenal characteristics and might therefore originate from cells of the urogenital ridge or adrenogonadal 
primordium as this is the common precursors for both the testis and the adrenal glands (indicated by the 
dashed line). 
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(82). This indicates that TART has both adrenal as well as testicular characteristics and 
the capacity to produce adrenal specific hormones. We therefore hypothesize that 
TART originates from a more pluripotent cell type that is already present in utero, 
probably originating from the adrenogonadal primordium or from the urogenital ridge 
(Fig. 4.4). 
Fetal Leydig cells or adult Leydig cell precursors might be good candidates (87). In 
contrast to the adult Leydig cell the fetal Leydig cell has both Leydig and adrenocortical 
cells features, i.e. fetal Leydig cells contain ACTH and LH receptors and can be 
stimulated by pituitary ACTH and LH. In addition, the adrenocortical specific 
steroidogenic enzyme (CYP11B1) is expressed in fetal mouse testes. The adrenal-like 
cells in the developing mouse testes described by Val et al. (88) have the same 
characteristics, which therefore might also be good candidates for the origin of TART or 
may be consistent with the fetal Leydig cell. TART is not found in deceased non-CAH 
neonates by histological examination (89), which indicates that either the pluripotent 
cells are not present in healthy subjects or that they lack the fetal stimulus for the 
outgrow of these cells.  
We propose that ACTH is the most important stimulating factor causing the hyperplasia 
of pluripotent cells to TART, as ACTH receptors are found in TART tissues and poor 
hormonal control with elevated ACTH concentrations seem to be associated with 
increased TART prevalence. The higher prevalence of TART in the most severe forms of 
CAH and expected higher ACTH concentrations already in utero and the low prevalence 
in non-classic CAH with only moderate ACTH elevations supports this hypothesis. 
Furthermore, TART has been described in conditions with strongly elevated ACTH 
concentrations, such as Cushing's syndrome (50, 90, 91), Nelson's syndrome (90-93), 
and Addison's disease (50), illustrating the importance of early (childhood) and 
longstanding exposure to elevated ACTH concentrations in the development of TART. 
Interestingly, TART was not observed in adult male patients with high ACTH 
concentrations due to acquired Addison disease or bilateral adrenalectomy (94). This 
might suggest that early exposure already in utero or young childhood to ACTH is 
necessary to stimulate proliferation of pluripotent cells into multiple small tumors 
which confluents to a multinodular lesion over time. The further growth of TART may 
depend on the cumulative exposure (duration and concentration) to ACTH and 
probably also angiotensin II (16, 62, 63), as also angiotensin II receptors are present in 
TART. The pubertal rise of LH may also contribute to further proliferation of these 
aberrant cells as LH receptors have been found in TART (21, 25, 30, 35, 45, 62).  
Recently, we described that particular precursor steroids accumulate before the 
enzymatic defect in CAH. These precursor steroids, 21-deoxycortisol, 17-
hydroxyprogesterone, and progesterone, exhibit glucocorticoid activity and because of 
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their increased levels are able to compensate at least partially for the glucocorticoid 
deficiency in CAH patients (95). It is unclear whether these steroids, which do not occur 
in appreciable concentrations in non-CAH patients, have any role in the development 
of TART. 
To summarize, TART originates from still unknown pluripotent cells of the 
adrenogonadal primordium or urogenital ridge. Elevated ACTH seems to be the most 
important stimulating factor for outgrow and hyperplasia of these pluripotent cells. 
However, TART prevalence is only 40% in classic CAH patients, whereas all these 
patients experience high ACTH concentrations. This might indicate the importance of 
initiation of the ACTH stimulus. Pluripotent cells seem to require a prenatal stimulus to 
prevent regression of these cells, in which the timing of increased ACTH concentration 
might play an important role. Further research is needed to establish the role of 
initiation, duration of exposure and concentrations of ACTH on TART development. 
Also, the role of other possible stimulating factors, such as LH and angiotensin II, 
should be established. 
 
Treatment of TART 
Until now, no clear guidelines exist to treat or prevent development of TART (2, 96). 
TART treatment is mostly focused on restoring fertility in adult patients. The first choice 
of treatment is intensifying glucocorticoid treatment to suppress ACTH, especially in 
poorly controlled CAH patients. However, no prospective studies into TART and 
intensified glucocorticoid treatment have been published so far. Few cases are known 
in which intensified glucocorticoid treatment has led to reduction of tumor size and 
improved testicular function in some (5, 59, 75-79) or none (50, 56, 61) of the reported 
patients. Moreover, glucocorticoid treatment can lead to serious side effects, such as 
hypertension, striae, and weight gain (78). Especially in adolescents intensifying 
glucocorticoid treatment is challenging as supraphysiological dosages can impair final 
height especially in hydrocortisone dosages above 17 mg/m2/day (97). Glucocorticoids 
may not lead to shrinkage of the tumor when progressive fibrosis and irreversible 
damage of the surrounding testes tissue of the tumor are present (14).  
One male CAH patient with TART was successfully treated with the adrenal steroid 
synthesis inhibitor mitotane to restore fertility. However, mitotane causes irreversible 
chemical adrenalectomy via an unknown mechanism (98) and is therefore only 
recommended as a last attempt to treat the infertility. Human chorionic gonadotropin 
combined with follicle-stimulating hormone was administered to one CAH patient with 
TART and hypogonadotropic hypogonadism, resulting in restored testicular 
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testosterone production and consequently fertility. Notably, treatment had to be 
performed for as long as 21 months (99). In addition, successful testis-sparing surgery 
in small cohorts of CAH patients with TART has been described in two studies, however 
without long-term follow up and evaluation of gonadal function (56, 100). We 
described eight adult male CAH patients with longstanding TART in whom testis-sparing 
surgery was performed but without significant improvement of gonadal function after 
surgery (58). Testicular biopsies confirmed that these patients already had irreversible 
damage of the surrounding testes tissue (14). Surgery seems therefore only indicated 
when severe pain complaints are present, as it did not restore fertility.  
To summarize, CAH patients should be informed about the risks of the development of 
TART and consequently the risk of infertility. As there is no suitable therapy yet to 
prevent the formation of TART or to treat TART, we advise to monitor CAH patients 
regularly (yearly from eight years old and once every two or three years from 
adulthood on (101)) with ultrasound and offer patients with TART semen 
cryopreservation. Further research should focus on possible druggable targets to 
prevent the formation of TART. A possible candidate might be ACTH inhibitors, as 
increased ACTH concentrations seem to play an important role in the development of 
TART.  
 
TART in other forms of CAH  
TART has also been described in CAH patients with other enzymatic defects than 21-
hydroxylase deficiency. Seven studies reported on 11-hydroxylase deficient patients, of 
which in total 42% (14/33) had TART (13, 21, 23, 26, 30, 34, 44). Incidentally, TART is 
reported in CAH patients with HSD3B2 mutations (38, 102, 103). Patients with 11-
hydroxylase deficiency or HSD3B2 mutations also suffer from deficient cortisol 
concentrations and consequently increased ACTH concentrations. It is therefore likely 
that also in these patients, elevated ACTH contributes to the development of TART.  
 
Future recommendations 
TART is a typical feature in male CAH patients and is the most important cause of 
infertility in these patients. As CAH is a rare condition it is difficult to include high 
patient numbers in a clinical study and thus multicenter multinational investigations 
(which could be based on an international registry of CAH patients with TART that has 
to be established) are indicated to empower studies to investigate associations with 
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poor hormonal control, tumor size, gonadal function, fertility, etcetera and to 
eventually test new treatment options. We proposed that ACTH is the most important 
stimulating factor in the development of TART and possible treatment strategies might 
be based on lowering ACTH concentrations. If other stimulating factors, such as 
angiotensin II, are confirmed therapies on lowering these concentrations might also be 
indicated. In the latest years, next generation sequencing has taken off. TART research 
would benefit from performing transcriptome sequencing as it provides extensive data 
on specific gene expression, thereby enable to elucidate the particular characteristics 
of TART, possible drug targets, and biomarkers to distinguish TART from Leydig cell 
tumors. Unfortunately, no relevant cell line or animal model is available to study the 
development of TART or possible treatment options. More fundamental research is 
therefore needed to establish a TART model.  
 
Conclusions 
TARTs are a common complication in male CAH patients with an overall prevalence of 
40% in classic CAH patients. The prevalence is especially high in adults (up to 89%), but 
it also occurs in children with an increase in prevalence during puberty. TART 
prevalence seems to be associated with the severity of CAH. TART tissue has adrenal as 
well as testicular characteristics and is able to produce steroids. As currently no 
definite therapy is available to treat TART, future research should focus on possible 
drug targets. Lowering ACTH might prevent the formation of TART as ACTH seems to 
be involved in the development of TART. We urge all clinicians to advise male CAH 
patients on the risk of developing TART and its consequences. Furthermore, sperm 
cryopreservation could be offered to TART patients as there is a high risk on infertility.  
 
Search strategy 
Articles were selected after searching PubMed and EMBASE for articles published up to 
February 2018 using the search terms "congenital adrenal hyperplasia", "adrenogenital 
syndrome" in combination with "adrenal rest tumo(u)r", "adrenal rest(s)", "adrenal 
cortical rest tumo(u)r", "TART", "testicular masses / nodules / tumo(u)r / neoplasm", 
"testicular adrenal tissue", "health status", "long term outcome". From the retrieved 
set of papers, duplicates and triplicates were manually deleted from Endnote.  
Based on title/abstract, primary screening was performed by a single review author 
(ME), deleting articles that clearly did not involve TART. Secondary screening involved 
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review of full-text articles in the English language. Inclusion criteria were: original study 
(excluding case reports), outcome measures should include TART, and regarding 
prevalence numbers the study should be published in the last 10 years (2009 - 2018). 
This procedure resulted in 64 studies that focused on TART. Data on prevalence, 
characteristics, origin and treatment options were extracted. Prevalence data on TART 
detected by ultrasound (US) was found in 31/64 studies and further analyzed by 
calculating 95% confidence intervals using the exact binominal confidence interval 
method. Reference lists of included studies were scanned for relevant studies, 
especially for information on the origin and treatment of TART, as no original studies 
were performed. Therefore, for these categories also case reports were included.  
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References 
1. El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet (London, England). 
2017;390(10108):2194-210. 
2. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al. Congenital adrenal 
hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin 
Endocrinol Metab. 2010;95(9):4133-60. 
3. Krone N, Arlt W. Genetics of congenital adrenal hyperplasia. Best practice & research Clinical 
endocrinology & metabolism. 2009;23(2):181-92. 
4. Urban MD, Lee PA, Plotnick LP, Migeon CJ. The diagnosis of Leydig cell tumors in childhood. 
American journal of diseases of children (1960). 1978;132(5):494-7. 
5. Cabrera MS, Vogiatzi MG, New MI. Long term outcome in adult males with classic congenital 
adrenal hyperplasia. The Journal of clinical endocrinology and metabolism. 2001;86(7):3070-8. 
6. Stikkelbroeck NM, Otten BJ, Pasic A, Jager GJ, Sweep CG, Noordam K, et al. High prevalence of 
testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in adolescent and adult 
males with congenital adrenal hyperplasia. The Journal of clinical endocrinology and metabolism. 
2001;86(12):5721-8. 
7. Reisch N, Flade L, Scherr M, Rottenkolber M, Pedrosa Gil F, Bidlingmaier M, et al. High prevalence 
of reduced fecundity in men with congenital adrenal hyperplasia. The Journal of clinical endocrinology and 
metabolism. 2009;94(5):1665-70. 
8. Arlt W, Willis DS, Wild SH, Krone N, Doherty EJ, Hahner S, et al. Health status of adults with 
congenital adrenal hyperplasia: a cohort study of 203 patients. J Clin Endocrinol Metab. 2010;95(11):5110-
21. 
9. Falhammar H, Thoren M. Clinical outcomes in the management of congenital adrenal hyperplasia. 
Endocrine. 2012;41(3):355-73. 
10. Bouvattier C, Esterle L, Renoult-Pierre P, de la Perriere AB, Illouz F, Kerlan V, et al. Clinical 
Outcome, Hormonal Status, Gonadotrope Axis, and Testicular Function in 219 Adult Men Born With Classic 
21-Hydroxylase Deficiency. A French National Survey. The Journal of clinical endocrinology and metabolism. 
2015;100(6):2303-13. 
11. King TF, Lee MC, Williamson EE, Conway GS. Experience in optimizing fertility outcomes in men 
with congenital adrenal hyperplasia due to 21 hydroxylase deficiency. Clinical endocrinology. 2016;84(6):830-
6. 
Testicular adrenal rest tumors: current insights on prevalence, characteristics, origin and treatment | 73 
 
12. Falhammar H, Frisen L, Norrby C, Almqvist C, Hirschberg AL, Nordenskjold A, et al. Reduced 
Frequency of Biological and Increased Frequency of Adopted Children in Males With 21-Hydroxylase 
Deficiency: A Swedish Population-Based National Cohort Study. The Journal of clinical endocrinology and 
metabolism. 2017;102(11):4191-9. 
13. Engels M, Gehrmann K, Falhammar H, Webb EA, Nordenstrom A, Sweep FC, et al. Gonadal 
function in adult male patients with congenital adrenal hyperplasia. European journal of endocrinology. 
2018;178(3):285-94. 
14. Claahsen-van der Grinten HL, Otten BJ, Hermus AR, Sweep FC, Hulsbergen-van de Kaa CA. 
Testicular adrenal rest tumors in patients with congenital adrenal hyperplasia can cause severe testicular 
damage. Fertility and sterility. 2008;89(3):597-601. 
15. Dominguez OV. Biosynthesis of steroids by testicular tumors complicating congenital 
adrenocortical hyperplasia. J Clin Endocrinol Metab. 1961;21:663-74. 
16. Clark RV, Albertson BD, Munabi A, Cassorla F, Aguilera G, Warren DW, et al. Steroidogenic enzyme 
activities, morphology, and receptor studies of a testicular adrenal rest in a patient with congenital adrenal 
hyperplasia. The Journal of clinical endocrinology and metabolism. 1990;70(5):1408-13. 
17. Combes-Moukhovsky ME, Kottler ML, Valensi P, Boudou P, Sibony M, Attali JR. Gonadal and 
adrenal catheterization during adrenal suppression and gonadal stimulation in a patient with bilateral 
testicular tumors and congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1994;79(5):1390-4. 
18. Murphy H, George C, de Kretser D, Judd S. Successful treatment with ICSI of infertility caused by 
azoospermia associated with adrenal rests in the testes: case report. Human reproduction (Oxford, England). 
2001;16(2):263-7. 
19. Wilkins L, Fleischmann W, Howard JE. MACROGENITOSOMIA PRECOX ASSOCIATED WITH 
HYPERPLASIA OF THE ANDROGENIC TISSUE OF THE ADRENAL AND DEATH FROM CORTICOADRENAL 
INSUFFICIENCY CASE REPORT1. Endocrinology. 1940;26(3):385-95. 
20. Chaudhari M, Johnson EK, DaJusta D, Nahata L. Testicular adrenal rest tumor screening and 
fertility counseling among males with congenital adrenal hyperplasia. Journal of pediatric urology. 2017. 
21. Dumic M, Duspara V, Grubic Z, Oguic SK, Skrabic V, Kusec V. Testicular adrenal rest tumors in 
congenital adrenal hyperplasia-cross-sectional study of 51 Croatian male patients. European journal of 
pediatrics. 2017;176(10):1393-404. 
22. Turcu AF, Mallappa A, Elman MS, Avila NA, Marko J, Rao H, et al. 11-Oxygenated Androgens Are 
Biomarkers of Adrenal Volume and Testicular Adrenal Rest Tumors in 21-Hydroxylase Deficiency. The Journal 
of clinical endocrinology and metabolism. 2017;102(8):2701-10. 
23. Yilmaz R, Sahin D, Aghayev A, Erol OB, Poyrazoglu S, Saka N, et al. Sonography and magnetic 
resonance imaging characteristics of testicular adrenal rest tumors. Polish Journal of Radiology. 2017;82:583-
8. 
24. Ohana Marques Coelho de Carvalho L, Miguel Garcia Lora R, Renata Rezende Penna C, Calland 
Ricarte Beserra I. Testicular Adrenal Rests Tumors and Testicular Microlithiasis in a Brazilian Case Series with 
Classic Congenital Adrenal Hyperplasia. International journal of endocrinology and metabolism. 
2017;15(1):e40611. 
25. Kim MS, Goodarzian F, Keenan MF, Geffner ME, Koppin CM, De Filippo RE, et al. Testicular Adrenal 
Rest Tumors in Boys and Young Adults with Congenital Adrenal Hyperplasia. The Journal of urology. 
2017;197(3 Pt 2):931-6. 
26. Chihaoui M, Kanoun F, Chaker F, Yazidi M, Bouchrit K, Mizouni H, et al. Testicular adrenal rest 
tumours in young adult males with congenital adrenal hyperplasia: prevalence and impact on testicular 
function. Andrologia. 2016;48(1):45-50. 
27. Yu MK, Jung MK, Kim KE, Kwon AR, Chae HW, Kim DH, et al. Clinical manifestations of testicular 
adrenal rest tumor in males with congenital adrenal hyperplasia. Annals of pediatric endocrinology & 
metabolism. 2015;20(3):155-61. 
28. Wang Z, Yang Z, Wang W, Chen LD, Huang Y, Li W, et al. Diagnosis of testicular adrenal rest tumors 
on ultrasound a retrospective study of 15 cases report. Medicine (United States). 2015;94(36):e1471. 
29. Bachelot A, Golmard JL, Dulon J, Dahmoune N, Leban M, Bouvattier C, et al. Determining clinical 
and biological indicators for health outcomes in adult patients with childhood onset of congenital adrenal 
hyperplasia. European journal of endocrinology. 2015;173(2):175-84. 
30. Claahsen-van der Grinten HL, Dehzad F, Kamphuis-van Ulzen K, de Korte CL. Increased prevalence 
of testicular adrenal rest tumours during adolescence in congenital adrenal hyperplasia. Hormone research in 
paediatrics. 2014;82(4):238-44. 
4 
74 | Chapter 4 
31. Dudzinska B, Leubner J, Ventz M, Quinkler M. Sexual well-being in adult male patients with 
congenital adrenal hyperplasia. International journal of endocrinology. 2014;2014:469289. 
32. Kamoun M, Mnif MF, Charfi N, Ben Naceur B, Mnif F, Rekik N, et al. Fertility outcome in male and 
female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Middle East Fertility 
Society Journal. 2014;19(2):89-95. 
33. Reisch N, Rottenkolber M, Greifenstein A, Krone N, Schmidt H, Reincke M, et al. Testicular adrenal 
rest tumors develop independently of long-term disease control: a longitudinal analysis of 50 adult men with 
congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency. The Journal of clinical endocrinology 
and metabolism. 2013;98(11):E1820-6. 
34. Aycan Z, Bas VN, Cetinkaya S, Yilmaz Agladioglu S, Tiryaki T. Prevalence and long-term follow-up 
outcomes of testicular adrenal rest tumours in children and adolescent males with congenital adrenal 
hyperplasia. Clinical endocrinology. 2013;78(5):667-72. 
35. Pierre P, Despert F, Tranquart F, Coutant R, Tardy V, Kerlan V, et al. Adrenal rest tissue in gonads 
of patients with classical congenital adrenal hyperplasia: multicenter study of 45 French male patients. 
Annales d'endocrinologie. 2012;73(6):515-22. 
36. Finkielstain GP, Kim MS, Sinaii N, Nishitani M, Van Ryzin C, Hill SC, et al. Clinical characteristics of a 
cohort of 244 patients with congenital adrenal hyperplasia. The Journal of clinical endocrinology and 
metabolism. 2012;97(12):4429-38. 
37. Cakir ED, Mutlu FS, Eren E, Pasa AO, Saglam H, Tarim O. Testicular adrenal rest tumors in patients 
with congenital adrenal hyperplasia. Journal of clinical research in pediatric endocrinology. 2012;4(2):94-100. 
38. Falhammar H, Nystrom HF, Ekstrom U, Granberg S, Wedell A, Thoren M. Fertility, sexuality and 
testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia. European journal of 
endocrinology. 2012;166(3):441-9. 
39. Mnif MF, Kamoun M, Mnif F, Charfi N, Kallel N, Ben Naceur B, et al. Long-term outcome of 
patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. The American journal of the 
medical sciences. 2012;344(5):363-73. 
40. Delfino M, Elia J, Imbrogno N, Argese N, Mazzilli R, Toscano V, et al. Testicular adrenal rest tumors 
in patients with congenital adrenal hyperplasia: prevalence and sonographic, hormonal, and seminal 
characteristics. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in 
Medicine. 2012;31(3):383-8. 
41. Nermoen I, Rorvik J, Holmedal SH, Hykkerud DL, Fougner KJ, Svartberg J, et al. High frequency of 
adrenal myelolipomas and testicular adrenal rest tumours in adult Norwegian patients with classical 
congenital adrenal hyperplasia because of 21-hydroxylase deficiency. Clinical endocrinology. 2011;75(6):753-
9. 
42. Kang MJ, Kim JH, Lee SH, Lee YA, Shin CH, Yang SW. The prevalence of testicular adrenal rest 
tumors and associated factors in postpubertal patients with congenital adrenal hyperplasia caused by 21-
hydroxylase deficiency. Endocrine journal. 2011;58(6):501-8. 
43. Reisch N, Scherr M, Flade L, Bidlingmaier M, Schwarz HP, Muller-Lisse U, et al. Total adrenal 
volume but not testicular adrenal rest tumor volume is associated with hormonal control in patients with 21-
hydroxylase deficiency. J Clin Endocrinol Metab. 2010;95(5):2065-72. 
44. Poyrazoglu S, Saka N, Agayev A, Yekeler E. Prevalence of testicular microlithiasis in males with 
congenital adrenal hyperplasia and its association with testicular adrenal rest tumors. Hormone research in 
paediatrics. 2010;73(6):443-8. 
45. Mouritsen A, Jorgensen N, Main KM, Schwartz M, Juul A. Testicular adrenal rest tumours in boys, 
adolescents and adult men with congenital adrenal hyperplasia may be associated with the CYP21A2 
mutation. International journal of andrology. 2010;33(3):521-7. 
46. Shanklin DR, Richardson AP, Jr., Rothstein G. TESTICULAR HILAR NODULES IN ADRENOGENITAL 
SYNDROME. THE NATURE OF THE NODULES. American journal of diseases of children (1960). 1963;106:243-
50. 
47. New MI, Abraham M, Gonzalez B, Dumic M, Razzaghy-Azar M, Chitayat D, et al. Genotype-
phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase 
deficiency. Proc Natl Acad Sci U S A. 2013;110(7):2611-6. 
48. Nikoshkov A, Lajic S, Holst M, Wedell A, Luthman H. Synergistic effect of partially inactivating 
mutations in steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab. 1997;82(1):194-9. 
49. Jedrzejewski G, Ben-Skowronek I, Wozniak MM, Brodzisz A, Budzynska E, Wieczorek AP. Testicular 
adrenal rest tumors in boys with congenital adrenal hyperplasia: 3D US and elastography--do we get more 
information for diagnosis and monitoring? Journal of pediatric urology. 2013;9(6 Pt B):1032-7. 
Testicular adrenal rest tumors: current insights on prevalence, characteristics, origin and treatment | 75 
 
50. Ashley RA, McGee SM, Isotaolo PA, Kramer SA, Cheville JC. Clinical and pathological features 
associated with the testicular tumor of the adrenogenital syndrome. The Journal of urology. 
2007;177(2):546-9; discussion 9. 
51. Claahsen-van der Grinten HL, Sweep FC, Blickman JG, Hermus AR, Otten BJ. Prevalence of 
testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase 
deficiency. European journal of endocrinology. 2007;157(3):339-44. 
52. Martinez-Aguayo A, Rocha A, Rojas N, Garcia C, Parra R, Lagos M, et al. Testicular adrenal rest 
tumors and Leydig and Sertoli cell function in boys with classical congenital adrenal hyperplasia. J Clin 
Endocrinol Metab. 2007;92(12):4583-9. 
53. Stikkelbroeck NM, Suliman HM, Otten BJ, Hermus AR, Blickman JG, Jager GJ. Testicular adrenal 
rest tumours in postpubertal males with congenital adrenal hyperplasia: sonographic and MR features. 
European radiology. 2003;13(7):1597-603. 
54. Avila NA, Premkumar A, Merke DP. Testicular adrenal rest tissue in congenital adrenal hyperplasia: 
comparison of MR imaging and sonographic findings. AJR American journal of roentgenology. 
1999;172(4):1003-6. 
55. Avila NA, Shawker TS, Jones JV, Cutler GB, Jr., Merke DP. Testicular adrenal rest tissue in 
congenital adrenal hyperplasia: serial sonographic and clinical findings. AJR American journal of 
roentgenology. 1999;172(5):1235-8. 
56. Walker BR, Skoog SJ, Winslow BH, Canning DA, Tank ES. Testis sparing surgery for steroid 
unresponsive testicular tumors of the adrenogenital syndrome. J Urol. 1997;157(4):1460-3. 
57. Wang Z, Yang S, Shi H, Du H, Xue L, Wang L, et al. Histopathological and immunophenotypic 
features of testicular tumour of the adrenogenital syndrome. Histopathology. 2011;58(7):1013-8. 
58. Claahsen-van der Grinten HL, Otten BJ, Takahashi S, Meuleman EJ, Hulsbergen-van de Kaa C, 
Sweep FC, et al. Testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia: evaluation 
of pituitary-gonadal function before and after successful testis-sparing surgery in eight patients. The Journal 
of clinical endocrinology and metabolism. 2007;92(2):612-5. 
59. Rutgers JL, Young RH, Scully RE. The testicular "tumor" of the adrenogenital syndrome. A report of 
six cases and review of the literature on testicular masses in patients with adrenocortical disorders. The 
American journal of surgical pathology. 1988;12(7):503-13. 
60. Jaaskelainen J, Kiekara O, Hippelainen M, Voutilainen R. Pituitary gonadal axis and child rate in 
males with classical 21-hydroxylase deficiency. J Endocrinol Invest. 2000;23(1):23-7. 
61. Srikanth MS, West BR, Ishitani M, Isaacs H, Jr., Applebaum H, Costin G. Benign testicular tumors in 
children with congenital adrenal hyperplasia. Journal of pediatric surgery. 1992;27(5):639-41. 
62. Smeets EE, Span PN, van Herwaarden AE, Wevers RA, Hermus AR, Sweep FC, et al. Molecular 
characterization of testicular adrenal rest tumors in congenital adrenal hyperplasia: lesions with both 
adrenocortical and Leydig cell features. The Journal of clinical endocrinology and metabolism. 
2015;100(3):E524-30. 
63. Claahsen-van der Grinten HL, Otten BJ, Sweep FC, Span PN, Ross HA, Meuleman EJ, et al. 
Testicular tumors in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency show 
functional features of adrenocortical tissue. The Journal of clinical endocrinology and metabolism. 
2007;92(9):3674-80. 
64. Willi U, Atares M, Prader A, Zachmann M. Testicular adrenal-like tissue (TALT) in congenital 
adrenal hyperplasia: detection by ultrasonography. Pediatric radiology. 1991;21(4):284-7. 
65. Lottrup G, Nielsen JE, Skakkebaek NE, Juul A, Rajpert-De Meyts E. Abundance of DLK1, differential 
expression of CYP11B1, CYP21A2 and MC2R, and lack of INSL3 distinguish testicular adrenal rest tumours 
from Leydig cell tumours. European journal of endocrinology. 2015;172(4):491-9. 
66. Rich MA, Keating MA. Leydig cell tumors and tumors associated with congenital adrenal 
hyperplasia. The Urologic clinics of North America. 2000;27(3):519-28, x. 
67. Ali HH, Samkari A, Arabi H. Testicular adrenal rest "tumor" or Leydig cell tumor? A report of a 
challenging case with literature review. Avicenna journal of medicine. 2013;3(1):15-9. 
68. Vukina J, Chism DD, Sharpless JL, Raynor MC, Milowsky MI, Funkhouser WK. Metachronous 
Bilateral Testicular Leydig-Like Tumors Leading to the Diagnosis of Congenital Adrenal Hyperplasia 
(Adrenogenital Syndrome). Case reports in pathology. 2015;2015:459318. 
69. Davis JM, Woodroof J, Sadasivan R, Stephens R. Case report: congenital adrenal hyperplasia and 
malignant Leydig cell tumor. The American journal of the medical sciences. 1995;309(1):63-5. 
4 
76 | Chapter 4 
70. Inaba H, Suzuki S, Shigematsu S, Shinomiya K, Ohfusa H, Shimojo Y, et al. Leydig cell tumor and 
malignant lymphoma in a patient with nonclassical 21-hydroxylase deficiency. Internal medicine (Tokyo, 
Japan). 2009;48(8):601-5. 
71. Santoriello A, Benevento R, Petronella P, Perna G, Canonico S. Congenital adrenal hyperplasia and 
Leydig cell tumor of testis. Case report and review of literature. Annali italiani di chirurgia. 2010;81(6):445-8. 
72. Charfi N, Kamoun M, Feki Mnif M, Mseddi N, Mnif F, Kallel N, et al. Leydig Cell Tumor Associated 
with Testicular Adrenal Rest Tumors in a Patient with Congenital Adrenal Hyperplasia due to 11beta-
Hydroxylase Deficiency. Case reports in urology. 2012;2012:648643. 
73. Entezari P, Kajbafzadeh AM, Mahjoub F, Vasei M. Leydig cell tumor in two brothers with 
congenital adrenal hyperplasia due to 11-beta hydroxylase deficiency: a case report. International urology 
and nephrology. 2012;44(1):133-7. 
74. Ferrari M, Raber M, Capitanio U, Russo G, Ferrario M, Rizzo N, et al. Leydig cell tumor of the 
spermatic cord in an adolescent affected by congenital adrenal hyperplasia. International journal of urology : 
official journal of the Japanese Urological Association. 2012;19(10):954-6. 
75. Tanaka M, Enatsu N, Chiba K, Fujisawa M. Two cases of reversible male infertility due to 
congenital adrenal hyperplasia combined with testicular adrenal rest tumor. Reproductive medicine and 
biology. 2018;17(1):93-7. 
76. Claahsen-van der Grinten HL, Otten BJ, Sweep FC, Hermus AR. Repeated successful induction of 
fertility after replacing hydrocortisone with dexamethasone in a patient with congenital adrenal hyperplasia 
and testicular adrenal rest tumors. Fertility and sterility. 2007;88(3):705.e5-8. 
77. Moore GW, Lacroix A, Rabin D, McKenna TJ. Gonadal dysfunction in adult men with congenital 
adrenal hyperplasia. Acta endocrinologica. 1980;95(2):185-93. 
78. Stikkelbroeck NM, Hermus AR, Suliman HM, Jager GJ, Otten BJ. Asymptomatic testicular adrenal 
rest tumours in adolescent and adult males with congenital adrenal hyperplasia: basal and follow-up 
investigation after 2.6 years. Journal of pediatric endocrinology & metabolism : JPEM. 2004;17(4):645-53. 
79. Rich MA, Keating MA, Levin HS, Kay R. Tumors of the adrenogenital syndrome: an aggressive 
conservative approach. The Journal of urology. 1998;160(5):1838-41. 
80. Engels M, Span PN, Mitchell RT, Heuvel J, Marijnissen-van Zanten MA, van Herwaarden AE, et al. 
GATA transcription factors in testicular adrenal rest tumours. Endocr Connect. 2017;6(8):866-75. 
81. Viger RS, Guittot SM, Anttonen M, Wilson DB, Heikinheimo M. Role of the GATA family of 
transcription factors in endocrine development, function, and disease. Molecular endocrinology (Baltimore, 
Md). 2008;22(4):781-98. 
82. Mesa H, Gilles S, Datta MW, Murugan P, Larson W, Dachel S, et al. Immunophenotypic differences 
between neoplastic and non-neoplastic androgen-producing cells containing and lacking Reinke crystals. 
Virchows Archiv : an international journal of pathology. 2016;469(6):679-86. 
83. Jones TD, Ulbright TM, Eble JN, Baldridge LA, Cheng L. OCT4 staining in testicular tumors: a 
sensitive and specific marker for seminoma and embryonal carcinoma. The American journal of surgical 
pathology. 2004;28(7):935-40. 
84. Turcu AF, Rege J, Chomic R, Liu J, Nishimoto HK, Else T, et al. Profiles of 21-Carbon Steroids in 21-
hydroxylase Deficiency. The Journal of clinical endocrinology and metabolism. 2015;100(6):2283-90. 
85. Bachelot A, Chakhtoura Z, Rouxel A, Dulon J, Touraine P. Hormonal treatment of congenital 
adrenal hyperplasia due to 21-hydroxylase deficiency. Annales d'endocrinologie. 2007;68(4):274-80. 
86. Claahsen-van der Grinten HL, Otten BJ, Stikkelbroeck MM, Sweep FC, Hermus AR. Testicular 
adrenal rest tumours in congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab. 
2009;23(2):209-20. 
87. Shima Y, Morohashi KI. Leydig progenitor cells in fetal testis. Molecular and cellular endocrinology. 
2017;445:55-64. 
88. Val P, Jeays-Ward K, Swain A. Identification of a novel population of adrenal-like cells in the 
mammalian testis. Developmental biology. 2006;299(1):250-6. 
89. Bouman A, Hulsbergen-van de Kaa C, Claahsen-van der Grinten HL. Prevalence of testicular 
adrenal rest tissue in neonates. Horm Res Paediatr. 2011;75(2):90-3. 
90. Krieger DT, Samojlik E, Bardin CW. Cortisol and androgen secretion in a case of Nelson's syndrome 
with paratesticular tumors: response to cyproheptadine therapy. J Clin Endocrinol Metab. 1978;47(4):837-
44. 
91. Puar T, Engels M, van Herwaarden AE, Sweep FC, Hulsbergen-van de Kaa C, Kamphuis-van Ulzen K, 
et al. Bilateral Testicular Tumors Resulting in Recurrent Cushing Disease After Bilateral Adrenalectomy. J Clin 
Endocrinol Metab. 2017;102(2):339-44. 
Testicular adrenal rest tumors: current insights on prevalence, characteristics, origin and treatment | 77 
 
92. Johnson RE, Scheithauer B. Massive hyperplasia of testicular adrenal rests in a patient with 
Nelson's syndrome. Am J Clin Pathol. 1982;77(4):501-7. 
93. Ntalles K, Kostoglou-Athanassiou I, Georgiou E, Ikkos D. Paratesticular tumours in a patient with 
Nelson's syndrome. Horm Res. 1996;45(6):291-4. 
94. Verhees MJM, Kamphuis-Van Ulzen K, Hermus A, Stikkelbroeck N, Mooij CF, Claahsen-van der 
Grinten HL. Re: Testicular Adrenal Rest Tumors in Boys and Young Adults with Congenital Adrenal 
Hyperplasia: M. S. Kim, F. Goodarzian, M. F. Keenan, M. E. Geffner, C. M. Koppin, R. E. De Filippo and P. J. 
Kokorowski J Urol 2017;197:931-936. J Urol. 2018. 
95. Pijnenburg-Kleizen KJ, Engels M, Mooij CF, Griffin A, Krone N, Span PN, et al. Adrenal Steroid 
Metabolites Accumulating in Congenital Adrenal Hyperplasia Lead to Transactivation of the Glucocorticoid 
Receptor. Endocrinology. 2015;156(10):3504-10. 
96. Auchus RJ. Management considerations for the adult with congenital adrenal hyperplasia. 
Molecular and cellular endocrinology. 2015;408:190-7. 
97. Bonfig W, Pozza SB, Schmidt H, Pagel P, Knorr D, Schwarz HP. Hydrocortisone dosing during 
puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation. J Clin 
Endocrinol Metab. 2009;94(10):3882-8. 
98. Bry-Gauillard H, Cartes A, Young J. Mitotane for 21-hydroxylase deficiency in an infertile man. N 
Engl J Med. 2014;371(21):2042-4. 
99. Rohayem J, Tuttelmann F, Mallidis C, Nieschlag E, Kliesch S, Zitzmann M. Restoration of fertility by 
gonadotropin replacement in a man with hypogonadotropic azoospermia and testicular adrenal rest tumors 
due to untreated simple virilizing congenital adrenal hyperplasia. European journal of endocrinology. 
2014;170(4):K11-7. 
100. Tiryaki T, Aycan Z, Hucumenoglu S, Atayurt H. Testis sparing surgery for steroid unresponsive 
testicular tumors of the congenital adrenal hyperplasia. Pediatric surgery international. 2005;21(10):853-5. 
101. Claahsen-van der Grinten HL, Stikkelbroeck NM, Otten BJ, Hermus AR. Congenital adrenal 
hyperplasia--pharmacologic interventions from the prenatal phase to adulthood. Pharmacol Ther. 
2011;132(1):1-14. 
102. Benkert AR, Young M, Robinson D, Hendrickson C, Lee PA, Strauss KA. Severe Salt-Losing 3beta-
Hydroxysteroid Dehydrogenase Deficiency: Treatment and Outcomes of HSD3B2 c.35G>A Homozygotes. The 
Journal of clinical endocrinology and metabolism. 2015;100(8):E1105-15. 
103. Lolis E, Juhlin CC, Nordenstrom A, Falhammar H. Extensive Bilateral Adrenal Rest Testicular 
Tumors in a Patient With 3beta-Hydroxysteroid Dehydrogenase Type 2 Deficiency. J Endocr Soc. 
2018;2(6):513-7. 
104.     Schoenwolf G, Bleyl S, Brauer P, Francis-West P. Larsen's Embryology 4th edition: Churchill 
Livingstone; 2008. 712p. 
4 

Chapter 5
GATA transcription factors in testicular adrenal 
rest tumors
Engels M1,2, Span PN3, Mitchell RT4, Heuvel JJTM2, Marijnissen-van 
Zanten MA5, van Herwaarden AE2, Hulsbergen-van de Kaa CA5, 
Oosterwijk E6, Stikkelbroeck NM7, Smith LB4, Sweep FCGJ2 and 
Claahsen-van der Grinten HL1
1Radboud university medical center, Radboud Institute for Molecular Life Sciences, 
Amalia Children's Hospital, Department of Pediatrics, Nijmegen, the Netherlands; and 
2Radboud university medical center, Radboud Institute for Molecular Life Sciences, 
Department of Laboratory Medicine, Nijmegen, the Netherlands; and 3Radboud 
university medical center, Radboud Institute for Molecular Life Sciences, Department 
of Radiation Oncology, Radiotherapy & OncoImmunology laboratory, Nijmegen, the 
Netherlands; and 4MRC Centre for Reproductive Health, University of Edinburgh, The 
Queen’s Medical Research Institute, Edinburgh, UK; and 5Radboud university medical 
center, Department of Pathology, Nijmegen, The Netherlands; and 6Radboud university 
medical center, Department of Urology, Nijmegen, The Netherlands; and 7Radboud 
university medical center, Department of Internal Medicine, Nijmegen, The 
Netherlands.
Endocrine Connections. 2017 Nov;6(8): 866-875
80 | Chapter 5 
 
Abstract 
Testicular adrenal rest tumors (TARTs) are benign adrenal-like testicular tumors that 
frequently occur in male patients with congenital adrenal hyperplasia. Recently, GATA 
transcription factors have been linked to the development of TARTs in mice. The aim of 
our study was to determine GATA expression in human TARTs and other steroidogenic 
tissues. We determined GATA expression in TARTs (n=16), Leydig cell tumors (LCTs; 
n=7), adrenal (fetal (n=6) + adult (n=10)), and testis (fetal (n=13) + adult (n=8)). We 
found testis-like GATA4, and adrenal-like GATA3 and GATA6 gene expressions by qPCR 
in human TARTs, indicating mixed testicular and adrenal characteristics of TARTs. 
Currently, no marker is available to discriminate TARTs from LCTs, leading to 
misdiagnosis and incorrect treatment. GATA3 and GATA6 mRNAs exhibited excellent 
discriminative power (area under the curve of 0.908 and 0.816, respectively), while 
immunohistochemistry did not. GATA genes contain several CREB-binding sites and 
incubation with 0.1 mM dibutyryl cAMP for 4 hours stimulated GATA3, GATA4, and 
GATA6 expressions in a human fetal testis cell line (hs181.tes). Incubation of 
adrenocortical cells (H295RA) with adrenocorticotropic hormone (ACTH), however, did 
not induce GATA expression in vitro. Although ACTH did not dysregulate GATA 
expression in the only human ACTH-sensitive in vitro model available, our results do 
suggest that aberrant expression of GATA transcription factors in human TARTs might 
be involved in TART formation. 
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Introduction 
Congenital adrenal hyperplasia (CAH) is a genetic disorder in which adrenocortical 
steroid synthesis is impaired due to a deficiency in particular steroidogenic enzymes, 
most often steroid 21-hydroxylase (CYP21A2). A wide range of the male CAH patients 
from 12.5% up to 94% are reported to develop testicular adrenal rest tumors (TARTs), 
which are an important cause of infertility (1, 2). TARTs are benign tumors with 
steroidogenic characteristics, located near the mediastinum testis (1, 3). Until now, the 
etiology and origin of TARTs have remained uncertain. TARTs were originally thought to 
arise from adrenal rest cells, based on the presence of adrenal characteristics, such as 
expression of adrenal enzymes and receptors (4, 5). However, recently we also 
described testicular characteristics of TARTs (6). This has shifted the hypothesis toward 
a more pluripotent steroidogenic cell type as the origin of TARTs (6), possibly from cells 
originating in the urogenital ridge or adrenogonadal primordium. 
Besides exhibiting both adrenal and testicular characteristics, TARTs also share 
morphological similarities with steroid-producing testicular Leydig cells. As a 
consequence, it is difficult to discriminate TARTs from Leydig cell tumors (LCTs). Both 
TARTs and LCTs are rare tumors (7). Although rare entities, several cases of LCTs in CAH 
patients have been described (8-13). Discrimination between LCTs and TARTs is 
important as these require different treatment strategies. TARTs are detected using 
ultrasound or MRI investigation. Currently, TARTs will only be surgically removed from 
the testis when pain complaints are present (3), while LCTs will be surgically removed 
using a testis-sparing procedure or total orchiectomy (7). No single marker is available 
yet to accurately discriminate TARTs from LCTs, increasing the chance of misdiagnosis 
and consequently incorrect treatment, of which at least 2 cases have been reported in 
literature (14, 15). 
GATA transcription factors are involved in development (by regulating cell fate 
specification) and differentiation in all eukaryotic organisms. These factors are able to 
bind to a consensus DNA element, WGATAR, known as the GATA motif (16, 17). 
Historically, GATA transcription factors are divided into two families: GATA1, GATA2, 
and GATA3 are classified as hematopoietic factors, while GATA4, GATA5, and GATA6 
are classified as endodermal factors. Their expression is also described in almost all 
fetal and adult tissues, and they are involved in adrenogonadal development. Three 
GATA factors (GATA 1, 4, 6) are expressed in the somatic cell population of the testis, 
while GATA3 is expressed in the adrenal medulla (reviewed in Viger et al. (18)). 
A possible relation between the expression of GATA transcription factors during 
adrenogonadal development and TART development was proposed in commentaries in 
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the study of Padua et al. (19) by Heikinheimo et al. (20) and Pihlajoki (21). Padua et al. 
(19) developed a mouse model lacking both GATA4 and GATA6 expressions in 
steroidogenic cells. These mice suffer from adrenal aplasia, and female mice die within 
days after birth. However, male mice survive because of corticoid production by 
adrenal-like cells in the testes, which Heikinheimo (20) and Pihlajoki (21) proposed 
might be similar to TART cells. Interestingly, GATA genes contain cyclic adenosine 
monophosphate (cAMP) response element-binding protein (CREB) sites, and cAMP 
induces expressions of GATA4 and GATA6 in gonadal cell lines (22-24). Levels of ACTH, 
the receptor of which signals via cAMP, are raised in CAH patients, due to lack of 
negative feedback on the hypothalamus-pituitary-adrenal axis, caused by low or absent 
cortisol levels due to the adrenal enzyme deficiency. Furthermore, ACTH levels are 
associated with the occurrence of TARTs (25-27). Therefore, we hypothesized that 
dysregulation of GATA transcription factors by increased ACTH levels in utero might be 
involved in the etiology of TARTs. 
The aim of our study was therefore to determine the expression of GATA transcription 
factors in TARTs and other steroidogenic tissues. We determined their discriminative 
potential to discern TARTs from LCTs and studied the role of cAMP and ACTH in the 
etiology of TARTs in vitro. 
 
Methods 
GATA expression analysis in human material 
Tissues and patients  
Sixteen TART samples from 8 adult CAH patients (tumor left and right testis) were 
previously collected as described by Claahsen et al. (3, 5) (informed consent was 
obtained). Paraffin-embedded material for immunohistochemistry was available for all 
tumors, while frozen material for RNA isolation was available for 12 samples. 
Additionally, 2 frozen histologically proven TART samples from one anonymous CAH 
patient were obtained. Frozen material of normal testis (n=8), normal adrenal (n=10) 
and benign LCT (n=7) was obtained. Furthermore, paraffin-embedded material was 
available for 4 benign LCTs and 3 metastases of malignant LCTs. These coded 
(identifiable anonymous) testis tissues, adrenal tissues, benign LCTs, metastases of 
malignant LCTs and TART samples were obtained from the Pathology and Urology 
departments and used in accordance with the Code of Conduct of the Federation of 
Medical Scientific Societies in the Netherlands (http://www.federa.org/codes-conduct; 
research approved by institutional review board: CMO Radboudumc #2016-2977 and 
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CMO-nr 2004/007). To study the etiology of TARTs, we also included fetal adrenal and 
testis tissues. Six human fetal adrenals (first and second trimesters) and cDNA from 13 
fetal testis tissues (second trimester) were obtained from the MRC Centre for 
Reproductive Health, University of Edinburgh. Tissues were obtained following elective 
termination of pregnancy and anonymized. Women gave informed consent in 
accordance with national guidelines (28) and ethical approval was obtained from the 
Lothian Research Ethics Committee. 
RNA isolation  
Frozen tissue sections (at least 10×20 µm) or cultured cells were used for RNA isolation 
(Total RNA Purification kit, Norgen, Thorold, Canada) according to manufacturer’s 
instructions. Samples were treated with DNase (RNase-free DNase set, Qiagen). RNA 
concentrations and purity were determined using a NanoDrop 2000 
Spectrophotometer. 
Reverse transcription and qPCR  
0.1 µg (fetal testis), 0.2 µg (first trimester adrenal) or 0.5 µg (second trimester adrenal 
and adult samples) of total RNA was used for cDNA synthesis using Superscript II 
reverse transcriptase (Thermo Fisher Scientific), performed according to the 
manufacturer’s protocol with a 2720 Thermal cycler (Applied Biosystems) in a final 
volume of 20 µL. Gene-specific primers of GATA1, GATA3, GATA4, and GATA6 were 
self-designed (Supplementary Method and Supplementary Table 5.1). For qPCR, the 
cDNA of adult samples was diluted 5 times, while the cDNA of fetal samples was diluted 
20 times, and 2 µL was added to 7.5 µL IQSYBR Green Supermix (Bio-Rad Laboratories), 
in a total amount of 15 µL on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad 
Laboratories). As fetal testis cDNA was not DNase-treated, a non-RT control was used 
to determine genomic DNA contamination. 
Immunohistochemistry  
GATA3 immunostaining was performed using a standardized protocol optimized for the 
localization of GATA3 in urothelial carcinoma (antibody L50-823, 1:50 dilution, Biocare 
Medical/ Klinipath, Duiven, The Netherlands). Kidney sections were used as positive 
control. GATA6 immunostaining (sc-9055; 1:200 dilution, SantaCruz Biotechnology) was 
performed manually including negative control sections with only primary antibody 
diluent. All sections were visualized with VisionTek (Sakura, Tokyo, Japan). 
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Regulation of GATA transcription factors 
Cell culture  
The hs181.tes cell line was obtained from American Type Culture Collection (ATCC CRL-
7131), while the H295RA cell line was obtained from the University of Michigan (29). 
Cells were grown as a monolayer culture, although the H295RA cells tend to grow in 
clumps. Media for hs181.tes cells consisted of DMEM with 4.5 g/L glucose with  
L-glutamine (Lonza; Leusden, Netherlands), whilst DMEM/F12 (Lonza) was used for 
H295RA cells. Both media were supplemented with 10% fetal bovine serum (Gibco; 
Thermo Fisher Scientific) and 1% antibiotics (penicillin-streptomycin 10 000 U/mL; 
Gibco). Cells were cultured at 37°C in a humidified 95% air/5% CO2 atmosphere. 
Medium was changed 2-3 times a week and hs181.tes cells were passaged when 
confluent using 0.25% trypsin (BD Diagnostic Systems, Breda, The Netherlands), while 
for H295RA cells 0.05% trypsin-EDTA (Gibco) was used. 
Dibutyryl cAMP and ACTH studies  
Hs181.tes and H295RA cells were washed, harvested and plated (1:6 dilution) into a 6-
well plate (Costar, Corning Life Sciences). After 24 hours, cells were starved overnight 
using serum-free medium (hs181.tes) or low-serum experimental medium (1% FBS; 
H295RA). RNA was isolated after cells were treated with 0.1 mM dibutyryl cAMP 
(Sigma) for either 30 minutes, 4 hours or not treated at all. ACTH incubation 
experiments were only performed in the H295RA cells, as hs181.tes cells are insensitive 
to ACTH. RNA was isolated after cells were not treated or treated with 2 or 10 nM 
ACTH (Synacthen, Radboudumc Pharmacy, Nijmegen, The Netherlands) for either 30 
minutes, 4 hours or 24 hours. 
Data analysis 
Gene expression  
mRNA expression of all genes was calculated using the delta Ct method (2−∆Ct). All 
values were normalized to the corresponding HPRT value (30). Data were transferred 
to GraphPad Prism 5 and IBM SPSS 22.0 (SPSS Inc.) for further analyses. Differences 
between different tissues and conditions were tested for statistical significance with 
non-parametric tests. To determine the diagnostic properties of GATA in discriminating 
TARTs from LCTs, Mann-Whitney U was performed and following Receiver Operating 
Characteristic (ROC) analyses were performed. The area under the curve (AUC) 
represents the probability that the outcome correctly classifies the tissue as TART or 
benign LCT (range 0.5 (no accuracy) to 1 (prefect accuracy)). To determine the role of 
GATA in the etiology of TARTs, a comparison between TARTs and testes (fetal and 
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adult), TARTs and adrenals (fetal and adult) was made. Furthermore, expressions in 
fetal tissues were compared with each other (adrenal vs. testis), as well as expressions 
in adult tissues (adrenal vs. testis). Also, expressions in fetal and adult testis, and fetal 
and adult adrenal tissues were compared. These comparisons were analyzed with the 
Kruskal–Wallis test followed by Dunn’s post hoc test. Gene expression analyses within 
cell culture studies were also compared using the Kruskal–Wallis test followed by 
Dunn’s post hoc test. Values of P≤0.05 (*), or P≤0.01 (**), or P≤0.001 (***), were 
considered statistically significant. 
Protein immunohistochemistry  
IHC stainings for GATA3 and GATA6 in TARTs and LCTs were visually examined by two 
independent investigators (MAMvZ, ME). GATA3 and GATA6 were scored based on 
pseudoquantative histoscore: intensity of staining was recorded as negative, weak, 
moderate or strong. Furthermore, an estimation of the percentage of positive cells was 
made. For GATA3, only nuclear staining was scored as GATA3 staining is already 
validated for urothelial cell carcinoma, indicating only nuclear staining as a positive 
reaction. In contrast, as GATA6 staining is still experimental, we considered both 
nuclear and cytoplasmic stainings as positive. For GATA3, nuclear reactivity of the 
tubular cells of the kidney was used as external positive control for the staining 
procedure. For GATA6, tissue sections without primary antibody were used as a 
negative control for the staining procedure. Cytoplasmic staining in GATA6 was 
corrected for any lipofuscin present by comparing the negative control directly with 
the GATA6 staining. In the cases of staining heterogeneity, the highest level was 
reported. Staining scores were compared between the two investigators (MAMvZ, ME) 
and both agreed on reported (consensus) scores. 
 
Results 
Adrenal and testicular expression levels of GATA transcription factors in TARTs 
To test whether expression of GATA1, GATA3, GATA4, and GATA6 is a marker of 
different tissues or disease states, qPCR was performed (Fig. 5.1). Separate analyses 
were performed to determine their discriminative potential between TARTs and LCTs 
(Fig. 5.1 underlined significance) and to determine their role in the etiology of TARTs by 
comparison with fetal and adult testis and adrenal tissues (Fig. 5.1 non-underlined 
significance). 
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Fig. 5.1: Gene expressions of GATA1 (A), GATA3 (B), GATA4 (C), and GATA6 (D) in human TARTs, adult testes, 
fetal testes, adult adrenals, and fetal adrenals. mRNA expression was calculated using the delta Ct method. All 
values were normalized to corresponding HPRT expression. The symbols in the graph represent all samples 
used and the error bars indicate median and 25th and 75th percentiles. Significance was tested with the 
Mann-Whitney U (MWU) test or Kruskal–Wallis and Dunn’s post hoc test comparing selected pairs of 
variables. Underlined significances are from the biomarker analysis comparing TARTs and LCTs (MWU). Non-
underlined significances are from the etiology analysis comparing TART, adult adrenal, adult testis, fetal 
adrenal, and fetal testis tissues. *P≤0.05; **P≤0.01; ***P≤0.001; ct>40 means that mRNA was not detected 
in these samples. Abbreviations: LCTs, Leydig cell tumors; TARTs, testicular adrenal rest tumors. 
 
Expression of GATA1 was significantly higher in fetal adrenals compared to fetal testes 
(28.4-fold, P≤0.01) and adult adrenals (61.1-fold, P≤0.01) (Fig. 5.1A). 
GATA3 expression was maximal in fetal adrenals, which was 190-fold higher compared 
to fetal testis tissues (P≤0.001). GATA3 expression was also significantly higher in adult 
GATA transcription factors in testicular adrenal rest tumors | 87 
 
 
 
adrenals compared to adult testes (73.7-fold, P≤0.001), and expression in TARTs was 
significantly higher compared to fetal (17.8-fold, P≤0.05) and adult (26.9-fold, P≤0.01) 
testes (Fig. 5.1B). 
Gene expression of GATA4 was significantly higher (32.4-fold) in TARTs compared to 
adult adrenals (P≤0.01). Significantly higher GATA4 expression (33.5-fold) was found in 
fetal testis tissues compared to fetal adrenal tissues (P≤0.001) (Fig. 5.1C). 
GATA6 expression levels were 16.6-fold higher in adult adrenals compared to adult 
testes (P≤0.001), while GATA6 expression in TARTs was higher compared to fetal (6.3-
fold, P≤0.05) and adult (9.3-fold, P≤0.05) testes (Fig. 5.1D). 
The results of the gene expression analyses are summarized in Fig. 5.2: GATA3 and 
GATA6 are highly expressed in fetal and adult adrenal tissues, while GATA4 is highly 
expressed in fetal and adult testis tissues. TARTs express high levels of GATA3, GATA4 
and GATA6, indicating adrenal- and testis-like expression patterns of GATA 
transcription factors. 
 
Fig. 5.2: Gene expression of GATA transcription factors during gonadal and adrenal development. The figure 
summarizes the results of our gene expression analysis in relation to adrenogonadal development. Cells from 
the adrenal primordium combined with neural crest cells give rise to the fetal adrenal, which will mature into 
the adult adrenal. The testis develops from the bipotential gonad. In this study, we measured gene 
expression levels of GATA1, GATA3, GATA4, and GATA6 in human TART, fetal and adult adrenal, and fetal and 
adult testis tissues. Of note, we are uncertain of cell-specific expression as we measured expression in total 
tissue. GATA3 and GATA6 were expressed in both fetal and adult adrenals, while GATA4 was expressed in the 
fetal as well as the adult testes. GATA3, GATA4, and GATA6 gene expressions were all found in TARTs. 
Abbreviations: TARTs, testicular adrenal rest tumors. 
5 
88 | Chapter 5 
 
GATA3 and GATA6 mRNA levels can discriminate TARTs from LCTs, while protein levels 
cannot 
Next, we compared GATA expression and their discriminative potential between TART 
and LCT tissues, as there is currently no single marker that can distinguish between 
these two pathologies. GATA3 gene expression was 15.8-fold higher expressed in TART 
compared to LCT tissues (P≤0.01 Fig. 5.1B), and GATA6 was 16.5-fold higher expressed 
in TARTs compared to LCTs (P≤0.05 Fig. 5.1D), while GATA4 showed no significant 
difference between TARTs and LCTs (Fig. 5.1C). To determine the discriminative 
potential in distinguishing TARTs from LCTs based on GATA3 or GATA6 gene expression, 
we performed ROC analyses. GATA3 showed excellent discriminative potential to 
differentiate TARTs from LCTs with an AUC of 0.908, while GATA6 showed good 
discriminative potential with an AUC of 0.816 (Fig. 5.3). 
To enhance the clinical applicability of GATAs as TART biomarkers and to determine 
which cells express GATA, we set out to assess GATA3 and GATA6 expressions using 
immunohistochemistry on paraffin-embedded formalin-fixed tissues. Protein 
expression was analyzed in TARTs (n=16), benign LCTs (n=4) and metastases of 
malignant LCTs (n=3). GATA3 protein expression was undetectable in all TART samples 
as well as in all LCTs, while the tubular cells of kidney sections (positive control) showed 
nuclear expression (Fig. 5.4). In TARTs and LCTs, GATA6 protein expression was 
heterogeneous (Supplementary Fig. 5.1 and Supplementary Fig. 5.2), while expression 
was absent in negative control samples (Fig. 5.4). Both nuclear and cytoplasmic 
stainings were observed, with a high variability in intensity and percentage of positive 
cells. TARTs and benign LCTs show similar intensity and percentage of cells with GATA6 
protein expression, while protein expression of GATA6 in metastases of malignant LCTs 
is almost absent as there are only very few cells with staining (Fig. 5.4). 
GATA transcription factors and their possible role in the etiology of TARTs 
We hypothesized that prenatal exposure of fetal steroidogenic pluripotent cells to 
ACTH might induce TARTs via GATA transcription factors. ACTH acts on the ACTH 
receptor (MC2R), a G-coupled protein, using cAMP as a second messenger. Indeed, one 
or multiple CREB-binding sites occur inside the gene body or up to 10 kb upstream of 
the transcription start site of multiple GATA genes 
(http://sabiosciences.com/chipqpcrsearch.php?app=TFBS), suggesting that cAMP could 
be a GATA expression-inducing second messenger, involved in de- and/or upregulation 
of GATAs in TARTs. 
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Fig. 5.3: Discriminative potential of GATA3 and GATA6 gene expressions in distinguishing TARTs from LCTs. 
Receiver operating characteristic analyses were performed. An area under the curve of 0.908 was observed 
for GATA3, while this was 0.816 for GATA6. Abbreviations: LCTs, Leydig cell tumors; TARTs, testicular adrenal 
rest tumors. 
 
 
Fig. 5.4: GATA3 and GATA6 protein expressions in human TARTs, benign LCTs, metastases of malignant LCTs 
and control tissues. GATA3 and GATA6 expressions (positive staining) are indicated by brown nuclei and/or 
brown cytoplasm. Protein expression of GATA3 is present in the positive control tissue (kidney) but absent in 
TARTs, benign LCTs and metastases of malignant LCTs. Protein expression of GATA6 is present in the 
cytoplasm and nuclei of TARTs and benign LCTs, however absent in metastases of malignant LCTs and the 
negative control (tissue slides without primary antibody). Representative pictures are shown. Scale bar 
represents a distance of 50 µm. Abbreviations: LCTs, Leydig cell tumors; TARTs, testicular adrenal rest 
tumors. 
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Incubation of a fetal testis cell line (hs181.tes) with 0.1 mM of dibutyryl cAMP for 4 
hours showed a moderate increase in gene expressions of GATA3, GATA4, and GATA6, 
although this did not reach statistical significance (Fig. 5.5A). However, there is no in 
vitro model of fetal testis cells expressing MC2R. Therefore, we used an ACTH-sensitive 
adrenocortical cell line (H295RA). ACTH incubation with 2 nM (results not shown) or 10 
nM (Fig. 5.5B) for 30 minutes, 4 hours or 24 hours increased MC2R and CYP11B1 gene 
expressions (positive controls), indicating that the system is indeed responsive to 
ACTH. However, no altered gene expressions for GATA3, GATA4, or GATA6 were found. 
 
 
Fig. 5.5: GATA transcription factors and their possible role in the etiology of TARTs. Long-term exposure to 
elevated levels of ACTH is present in patients with congenital adrenal hyperplasia and this is associated with 
the development of TARTs. ACTH binds to its receptor (MC2R), using cAMP as a second messenger. CREB-
binding sites are present within the gene body or up to 10 kb upstream of the transcription start site in 
GATA3, GATA4, and GATA6. cAMP could therefore be a GATA expression-inducing second messenger. 
Source: http://sabiosciences.com/chipqpcrsearch.php?app=TFBS. A) Hs181.tes cells were incubated with 0.1 
mM dibutyryl cAMP (hs181.tes cells do not express ACTH receptor) for 0, or 30 minutes, or 4 hours. Gene 
expression was calculated using the delta Ct method and corresponding HPRT expression was used to 
normalize. B) H295RA cells were incubated with 10 nM ACTH for 0, or 30 minutes, or 4, or 24 hours. Delta Ct 
method and corresponding HPRT value were used to calculate normalized gene expression. 
 
Discussion 
To the best of our knowledge, this is the first description of GATA transcription factors 
in human TARTs. TARTs expressed both testicular (GATA4) and adrenal (GATA3 and 
GATA6) characteristics, thereby confirming our previous findings of both adrenal and 
testicular features of TARTs (6). Furthermore, differences in GATA3 and GATA6 mRNA 
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expression levels might be used to discriminate TARTs (high) from LCTs (low 
expression), indicated by good AUCs (>0.8) in ROC analyses, although at the protein 
expression level, immunohistochemistry did not discriminate. In addition, as long-term 
exposure to elevated ACTH levels is linked to occurrence of TART (25-27), we 
hypothesized that (prenatal) exposure of (primordial) steroidogenic cells in the testes 
to ACTH might induce TARTs via deregulation of GATA transcription factors. Human 
fetal testis cells indeed show increased GATA expression after incubation with cAMP. 
However, adrenocortical cells (the only human ACTH-sensitive model available) did not 
show increased expression after ACTH incubation. 
Although interesting to again find both adrenal- and testis-like characteristics of TARTs, 
this expression pattern does not correspond to the expression pattern observed in the 
adrenal-like cells of the GATA4/GATA6 double-knockout mice described earlier (19). 
The steroidogenic cells in the double-knockout mice should not express GATA4 and 
GATA6, as the model eliminated expression in all steroidogenic cells. In addition, the 
adrenal-like cells in these mice lacked HSD17B3 and INSL3 expressions, whereas these 
genes are expressed in human TARTs (19). Therefore, the observed gene expression 
patterns of adrenal-like cells found in these mice do not resemble the observed gene 
expression pattern of human TART. 
We assessed the potential of GATA transcription factors as differential diagnostic tools 
to discriminate TARTs from LCTs, which are difficult to distinguish due to their 
morphological resemblance. Misdiagnosis can have profound consequences for the 
treatment of a patient with a testicular tumor (8, 11). Therefore, a clinical need for 
differential diagnostic markers that can differentiate between both pathologies exists. 
Bilateralism of the tumors (25, 31), presence of Reinke crystals (1, 5, 25, 32-35) and 
expressions of synaptophysin, Inhibin α, CD56, androgen receptor, DLK1, INSL3, 
CYP11B1, CYP21A2, and MC2R (34-37) have all been studied as potential markers, but 
none of these markers individually can reliably discriminate TARTs from LCTs. We found 
significantly higher gene expressions of GATA3 and GATA6 in TARTs compared to LCTs 
with good discriminative potential. This suggests that measurement of these genes 
may be used in a diagnostic setting as a discriminative marker between TART and LCT 
tissues. To improve the usefulness of these markers in the clinic and to determine 
which cells express GATA, we determined protein expressions of GATA3 and GATA6 on 
paraffin-embedded tumor samples using standard immunohistochemical techniques. 
GATA3 protein expression, however, was undetectable in TARTs and LCTs. On the other 
hand, GATA6 protein expression was heterogeneous both within and between TART, 
benign LCT and metastases of malignant LCT tissue samples. We observed high 
variability in the location, intensity of staining and percentage of GATA6-positive cells. 
We identified very low expression of GATA6 in metastases of malignant LCTs, which 
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might reflect a change in the status in the primary tumor cells promoting invasion. 
Nevertheless, GATA6 expression is heterogeneously expressed within and between 
TARTs and benign LCTs, and it can therefore not be used as a discriminatory biomarker 
for these pathologies. 
We also determined GATA expression in human fetal adrenal and testis tissues. GATA1 
was the only GATA gene in which a significant change in expression was identified 
between fetal and adult adrenal tissues. We found GATA4 expression in fetal and adult 
testis tissues, and GATA6 expression in fetal and adult adrenal. Previous findings are in 
agreement with our data. Viger et al. summarized all known literature on GATA 
expression in adrenogonadal development, mainly based on mice models (18). 
However, as we studied human TARTs, we will focus on reported expression in human 
tissues. Ketola et al. found GATA4 and GATA6 mRNAs and protein expressions in 
human fetal testis tissues, although a decreasing trend with advanced fetal 
development was observed for GATA6 expression (38). In fetal testis tissues, GATA4 
was the predominantly expressed GATA gene. Jiminez et al. found GATA6 expression in 
human adult adrenal tissues but no GATA4 expression (39). This is in agreement with 
Kiiverii et al. who showed GATA4 and GATA6 expressions in human fetal adrenal, but 
only GATA6 mRNA and protein expression in human adult adrenal (40). In summary, 
and in correspondence with known literature, we found expression of GATA4 in fetal 
and adult testis tissues, and GATA6 expression in fetal and adult adrenal tissues. In 
addition, we found GATA3 expression in fetal and adult adrenal tissues. 
We found high relative gene expression levels of GATA3, GATA4 and GATA6 in TARTs, 
suggesting that dysregulation of these transcription factors is involved in the etiology 
of TARTs. GATA genes contain one or several CREB sites and previously cAMP was 
described to induce GATA4 and GATA6 expressions in the gonadal cell lines MSC-1, 
mLT and MA-10 (22-24). We therefore stimulated fetal testis cells with cAMP and 
indeed found moderate increase in expressions of GATA3, 4 and 6. The ACTH receptor 
(MC2R) signals via cAMP and elevated ACTH levels are present in CAH patients and 
associated with the development of TARTs (25-27). We hypothesized that 
dysregulation of GATA expression by ACTH in fetal steroidogenic cells could eventually 
lead to the formation of TARTs. Regretfully, no human fetal cell lines are available that 
express functional MC2R. Human cell lines, in general, tend to have low (functional) 
ACTH receptor expression, although several adrenocortical cell lines, including H295R 
cells, are known to have at least moderate expression of MC2R (41, 42). ACTH 
responsiveness in H295R cells was increased by over-expression of MRAP, resulting in 
the H295RA cell line, the only human ACTH-sensitive cell line available (29). We are 
aware of the limitation of using a differentiated cell line as a model for the involvement 
of ACTH in fetal steroidogenic cells. In the present study, we demonstrated that ACTH 
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does not influence GATA expression in H295RA cells. Timing of ACTH exposure might 
play an important role in GATA dysregulation. Therefore, dysregulation of GATA might 
still be a key player in the formation of TART and is possibly regulated by ACTH 
prenatally. 
In conclusion, testis-like expression of GATA4 and adrenal-like expressions of GATA3 
and GATA6 were observed in TARTs, suggesting that dysregulation of GATA 
transcription factors in a pluripotent fetal cell is involved in TART formation. 
Furthermore, gene expression of GATA transcription factors showed good 
discriminative potential to differentiate TARTs from LCTs, but further studies have to 
be performed establishing thresholds in less-invasive material, such as blood or urine, 
to be of applicable use. 
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Supplement 
Primer design and optimization  
Genes were searched in the NCBI database and imported in PerlPrimer (43). Primers 
were derived based on an amplicon size of 75-125 base pairs, a length of 17-24 
nucleotides, a GC-content of 40-65%, melting temperature of 56-62 °C, an exon-exon 
junction spanning amplicon and where possible boundary-overlapping primers. Primers 
were checked for dimers, hairpins and secondary amplicon structures and a set of 
forward and reverse primers for each gene was ordered (Biolegio, Nijmegen, the 
Netherlands). The HPRT gene was used as normalizing gene (30). Sequences and 
specifications of all primers are listed in Supplemental Table 1. Efficiency and specificity 
of the primers were tested using the IQ™SYBR® Green Supermix on a CFX96 Touch 
Real-Time PCR Detection System (Bio-Rad Laboratories, Veenendaal, Netherlands). The 
PCR products were checked for quality and product size by melting curve analysis and 
agarose gel electrophoresis.  
 
Supplemental Table 5.1: Primer sequences and specifications. 
Gene Accession Number Sequence 5' → 3' Exon 
boundary 
overlapping 
GATA1 
GATA binding protein 1 
NM_002049.3 FP: AAGAAGCGCCTGATTGTC 
RP: GCATTTCTCCGCCACAG 
yes 
GATA3 
GATA binding protein 3 
NM_001002295.1  
NM_002051.2 
FP: CAGACCACCACAACCACAC 
RP: TGCCTTCCTTCTTCATAGTCAG 
no 
GATA4 
GATA binding protein 4 
NM_001308093.1 
NM_002052.4 
NM_001308094.1 
FP: TCTACATGAAGCTCCACGGG 
RP: TATTCAGGTTCTTGGGCTTCC 
no 
GATA6 
GATA binding protein 6 
NM_005257.5 FP: GAGGGAATTCAAACCAGGA 
RP: GTTGGAGTCATGGGAATGG 
no 
MC2R, melanocortin 2 
receptor (ACTH receptor) 
NM_000529.2 FP: CAGAGCTGAAGGTGATTGGGA 
RP: AAGGCGGGGATGTTACTTGG 
no 
CYP11B1 
11β-hydroxylase 
NM_000497.3 FP: GGCAGAGGCAGAGATGCTG 
RP:TCTTGGGTTAGTGTCTCCACCTG 
yes 
HPRT NM_000194.2 FP: TATTGTAATGACCAGTCAACAG 
RP: GGTCCTTTTCACCAGCAAG 
yes 
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Supplementary Fig. 5.1: Heterogeneous GATA6 expression in testicular adrenal rest tumor tissue (TART). 16 
random views within a TART. Abbreviations: TART, testicular adrenal rest tumor. 
 
Supplementary Fig. 5.2: Heterogeneous GATA6 expression in Leydig cell tumor tissue (LCT). 16 random views 
within a benign LCT. Abbreviations: LCT, Leydig cell tumor. 
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Abstract 
Context: Recurrence of hypercortisolism in patients after bilateral adrenalectomy for 
Cushing disease is extremely rare. 
Patient: We present a 27-year-old man who previously underwent bilateral 
adrenalectomy for Cushing disease with complete clinical resolution. Cushingoid 
features recurred 12 years later, with bilateral testicular enlargement. Hormonal tests 
confirmed adrenocorticotropic hormone (ACTH)-dependent Cushing disease. Surgical 
resection of the testicular tumors led to clinical and biochemical remission. 
Design and Results: Gene expression analysis of the tumor tissue by quantitative 
polymerase chain reaction showed high expression of all key steroidogenic enzymes. 
Adrenocortical-specific genes were 5.1 105 (CYP11B1), 1.8 102 (CYP11B2), and 6.3 104 
(MC2R) times higher than nonsteroidogenic fibroblast control. This correlated with 
urine steroid metabolome profiling showing 2 fivefold increases in the excretion of the 
metabolites of 11-deoxycortisol, 21-deoxycortisol, and total glucocorticoids. Leydig-
specific genes were 4.3 101 (LHCGR) and 9.3 100 (HSD17B3) times higher than control, 
and urinary steroid profiling showed twofold increased excretion of the major 
androgen metabolites androsterone and etiocholanolone. These distinctly increased 
steroid metabolites were suppressed by dexamethasone but unresponsive to human 
chorionic gonadotropin stimulation, supporting the role of ACTH, but not luteinizing 
hormone, in regulating tumor-specific steroid excess. 
Conclusion: We report bilateral testicular tumors occurring in a patient with recurrent 
Cushing disease 12 years after bilateral adrenalectomy. Using mRNA expression 
analysis and steroid metabolome profiling, the tumors demonstrated both 
adrenocortical and gonadal steroidogenic properties, similar to testicular adrenal rest 
tumors found in patients with congenital adrenal hyperplasia, suggesting the presence 
of pluripotent cells even in patients without congenital adrenal hyperplasia.  
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Introduction 
Bilateral adrenalectomy is considered a definitive cure for Cushing disease, but some 
patients may have residual adrenal function from postsurgical remnants or ectopic 
adrenal tissue (1, 2). Rarely, patients with Nelson syndrome (and high 
adrenocorticotropic hormone (ACTH) levels) after bilateral adrenalectomy have been 
reported to develop testicular tumors, with variable cortisol and androgen production 
(3-5). Some tumors were removed due to symptoms of mass effects, but detailed 
molecular investigations were not conducted.  
In contrast, testicular adrenal rest tumors (TARTs) are seen in up to 94% of male 
patients with congenital adrenal hyperplasia (CAH), with increasing prevalence during 
adolescence (6, 7). Elevated ACTH levels, and possibly luteinizing hormone (LH), may 
play a role in its development (8). We recently demonstrated that TARTs have both 
adrenocortical and Leydig cell features, suggesting a pluripotent embryonic cell origin 
(9).  
We report a rare case of bilateral testicular tumors resulting in recurrent 
hypercortisolism in a patient with Cushing disease who had previously undergone 
bilateral adrenalectomy. We characterized the steroidogenic potential of these tumors 
by mRNA expression analysis and serum and urinary steroid profiling. Our findings 
demonstrate that the tumor tissue featured both adrenal and gonadal steroidogenic 
properties, resembling TART tissue found in patients with CAH. 
 
Case Report 
An 11-year-old boy presented with rapid weight gain, rounded facies, and abdominal 
striae. He was diagnosed with Cushing disease and underwent transsphenoidal removal 
of a corticotrophin-producing pituitary adenoma. Recurrence occurred within the first 
postoperative year. After failure of radiotherapy and ketoconazole to control his 
symptoms, he underwent bilateral adrenalectomy 4 years later (age 15 years), resulting 
in undetectable serum cortisol after ACTH stimulation (<20 nmol/L). Spontaneous 
pubertal development ensued. One year later, he developed Nelson syndrome 
(hyperpigmentation with ACTH 1089 pmol/L) and pituitary apoplexy requiring 
trepanation and partial extirpation. Subsequently, the pituitary tumor remained stable 
in size with ACTH levels ranging from 158 to 2921 pmol/L while receiving 
hydrocortisone 25 mg and fludrocortisone 0.1 mg daily. 
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At the age of 27 years, 12 years postadrenalectomy, he experienced increased lethargy 
and weight gain over a period of 6 months. He had a Cushingoid habitus and abdominal 
striae. His testes were nodular, hard, and enlarged bilaterally. Corticosteroid 
replacement was stopped, and recurrent ACTH-dependent Cushing disease was 
confirmed biochemically (Table 6.1). Magnetic resonance imaging showed a small,  
 
Table 6.1: Serum hormones and steroids during dynamic tests and testicular venous sampling after surgery. 
  Dynamic testing Testicular venous sampling   
 Base-
line 
Base-
line b 
Post-
HDDST 
c 
Post-
hCG d 
peri-
pheral  
vein 
left  
testicular 
 vein 
right  
testicular 
vein 
Post-
surgery e 
Reference 
Range 
24hour urinary 
free cortisol 
1020        20-135 
nmol/24hours 
Midnight salivary 
cortisol 
5.6        < 2.2 nmol/L 
ACTH 193 293 181 282    1010 2.2-13.2 pmol/L 
Renin  27 45 78    54 4.4-85 mU/L 
FSH  0.18 0.15 0.19    4.9 1.5-11 U/L 
LH  <0.10 <0.10 <0.10    2.8 1.4-8.5 U/L 
Inhibin B  63.1 60.9 69.6    <10 150-400 ng/L 
Progesterone  3.8 1.0 4.8 2.1 15 69 0.020 <1.3 nmol/L 
Corticosterone  14.1 9.2 19.2 27.4 35.5 337 2.6 5.8-56 nmol/L 
Aldosterone  <0.09 0.12 0.10 0.43 NA f 0.89 <0.03 0.08-0.69 nmol/L 
17-hydroxy-
pregnenolone 
 4.17 3.15 3.33 NA f NA f NA f NA 0.9-10.5 nmol/L 
17-hydroxy-
progesterone 
 126 38 165 85 880 1780 <0.070 2.0-10.8 nmol/L 
11-deoxycortisol  6.1 1.5 6.6 4.0 111 136 <0.17 0.2-4.3 nmol/L 
Cortisol   530 g 180 g 570 g 230 2730 2650 <20 190-550 nmol/L 
DHEA  2.4 1.3 2.4 1.7 2.1 15.1 <0.2 15-45 nmol/L 
DHEAS  3.8 2.8 4.2 2.8 NA f 4.1 <0.41 1-7 µmol/L 
Androstenedione  58 21 63 36 390 790 <0.060 1.15-4.7 nmol/L 
Testosterone  27.0 10.1 27.1 16.9 658 443 <0.1 11.0-45.0 nmol/L 
5α-dihydro-
testosterone 
 2.19 1.39 2.39 1.61 NA f 5.31 <0.098 1-2.9 nmol/L 
Estrone  470 370 430 NA f NA f NA f NA 80-250 pmol/L 
Estradiol  80 67 57 81 74 210 25 75-220 pmol/L 
11-deoxy-
corticosterone 
 NA NA NA <0.30 0.43 11.7 NA 0.03-1 nmol/L 
 
aTesticular vein sampling done during surgery. Testicular veins were cannulated prior to surgical removal. 
Peripheral sample was taken from a cubital vein during the sampling. bBaseline tests were done after 
exogenous glucocorticoids and mineralocorticoids had been stopped for 1 week. cDexamethasone was 
administrated orally as 2 mg every 6 hours for 48 hours, with investigations done at 8 AM on the third day, 6 
hours after last dose. dDaily intramuscular injections of 1500 U hCG were administered subcutaneously on 3 
consecutive days at 8 AM. eTaken 1 week after surgery, 24 hours after last hydrocortisone dose. fLevels not 
taken due to inadequate serum volume collected. gCortisol levels were measured with immunoassay. Other 
cortisol levels were measured with liquid chromatography-tandem mass spectrometry. Abbreviations: DHEA, 
dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; FSH, follicle-stimulating hormone; hCG, 
human chorionic gonadotropin; LH, luteinizing hormone; NA, not available. 
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stable pituitary remnant. Ultrasound and magnetic resonance imaging of the testes 
revealed a single, large right testicular tumor and multiple left testicular tumors with a 
small remnant of normal tissue (Fig. 6.1A and 6.1B) Abdominal CT showed a small 
nodule (<1 cm) in the left adrenal region, suggesting incomplete surgical resection or 
postsurgical scar tissue. Semen analysis showed azoospermia. 
The patient underwent bilateral testicular nodulectomy, with preservation of his left 
residual normal testicular tissue (Fig. 6.1C-D). One week after surgery, early-morning (8 
AM) cortisol was undetectable (<20 nmol/L) (Table 6.1). His symptoms resolved and he 
was started on corticosteroid and testosterone replacement. 
 
Materials and Methods 
A detailed description of the materials and methods is provided in the Supplemental 
materials and methods. Written informed consent with permission for publication was 
obtained from the patient and the study was approved by the local ethics committee. 
 
Results 
Serum and urine steroid metabolite profiling before and after surgery 
Serum and urine were collected at baseline, after high-dose dexamethasone 
suppression test (HDDST), and after human chorionic gonadotropin (hCG) stimulation. 
Serum cortisol and its precursors (11-deoxycortisol and 17-hydroxyprogesterone) and 
androstenedione were elevated at baseline, suppressed by HDDST, and unresponsive 
to hCG stimulation (Table 6.1). Levels were undetectable after surgery. Testicular vein 
sampling performed during surgery demonstrated excess steroid production bilaterally 
(Table 6.1). 
Urine steroid metabolite profiling (Fig. 6.1E) showed increased excretion of 
glucocorticoid metabolites, androgen metabolites (etiocholanolone), and precursor 
steroid metabolites from all three steroidogenic pathways. The metabolites of 11-
deoxycortisol and 21-deoxycortisol were increased up to fivefold, and 17-
hydroxyprogesterone metabolites were increased >10-fold of the upper reference 
range. Dehydroepiandrosterone, which is reflective of the classic androgen synthesis 
pathway, was low. In contrast, there was highly increased excretion of the alternative 
androgen pathway intermediates 3α,5α-17-hydroxyprogesterone (485 µg/24hours;  
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Fig. 6.1: A) MRI Axial T2 turbo inversion recovery magnitude (TIRM) image showing the irregular tumor in the 
right testis (R), surrounded by a rim of normal testicular tissue (*) and the tumor in the left testis (L).  
B) Sagittal ultrasound image showing the irregular mass in the right testis (R), surrounded by a rim of normal 
testicular tissue (*).C) Macroscopically, both right and left tumors were nodular brown homogeneous 
tumors, partly encapsulated, measuring up to 5 respectively 6 cm. D) Microscopically, the tumors were 
located in and near the rete testis (*). They had a multinodular aspect consisting of sheets or confluent cords 
of large polygonal cells with abundant eosinophilic cytoplasm, which infiltrated in between seminiferous 
tubules, into the rete testis and sporadically intravascular. No other criteria for malignancy (mitosis, necrosis) 
were met. Incomplete spermatogenesis with maturation arrest at the primary spermatocytic level was seen 
in the surrounding seminiferous tubules. E) Heat map depicting results of 24 hour urine steroid metabolite 
profiling at baseline, after high-dose dexamethasone suppression test, after hCG stimulation, and after 
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surgical removal of testicular tumors. Red indicates excretion amounts higher than the adult male reference 
range, and blue indicates decreased levels. For comparison, 24 hour urine steroid profiling from two adult 
male patients with ACTH-dependent Cushing’s syndrome and two adolescent patients (male on the left, 
female on the right) with non-classic 21-hydroxylase deficiency are also displayed. F) Gene expression profile 
of 8 markers measured in testicular adrenal rest tumors of congenital adrenal hyperplasia patients (9) (black) 
and the right testis tumor of the patient (red). The genes were subdivided into common genes for both 
adrenal cortex and Leydig cells of the testis, adrenocortical specific genes (including mineralocorticoids and 
glucocorticoids), and Leydig cell specific genes. Symbols and error bars in the graph represent median and 
25th and 75th percentile of all normalized relative expression values. Abbreviations: CAH, congenital adrenal 
hyperplasia; hCG, human chorionic gonadotropin; HDDST, high-dose dexamethasone suppression test. 
 
control group median 26 (range 5 to 118) µg/24hours) and 11-hydroxy-androsterone 
(15 766 µg/24hours; control group median 588 (range 181 to 1290) µg/24hours).  
By comparison, urine steroid metabolite profiling of two newly diagnosed and hence 
untreated adolescent patients with 21-hydroxylase deficiency demonstrated a similar 
pattern of increased steroid metabolites, in particular those derived from 
progesterone, 17-hydroxyprogesterone, 21-deoxycortisol, and the alternative pathway 
metabolites 3α,5α-17-hydroxyprogesterone and 11β-hydroxy-androsterone. 
Conversely, these changes were not observed in two adult patients with Cushing 
disease, who predominantly excreted increased amounts of corticosterone, 11-
deoxycortisol, and, in particular, cortisol metabolites (Fig. 6.1E). Thus, the steroid 
excretion pattern observed in our patient resembled a combination of CAH and 
Cushing disease. 
Gene expression analysis of right testicular tumor tissue 
Using quantitative polymerase chain reaction (Fig. 6.1F), the expression of adrenal 
cortex-specific genes determined to be 5.1 105 (CYP11B1), 1.8 102 (CYP11B2), and 
6.3 104 (MC2R) times higher in the patient’s tumor tissue compared with the non-
steroidogenic control (fibroblast), whereas the expression for AGTR2 was 2 times 
lower. Genes common to both adrenal and testis tissue were 3.8 105 (CYP17A1) and 
2.1 104 (HSD3B2) times higher, and Leydig cell genes were 4.3 101 (LHCGR) and 9.3 
(HSD17B3) times higher compared with nonsteroidogenic control. Compared with 
TART samples from patients with CAH that we had previously similarly analyzed (9), the 
patient’s tumor was above the interquartile range for glucocorticoid-related factors 
(CYP11B1, MC2R) and below the interquartile range for androgen-related factors 
(LHCGR, and HSD17B3). 
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Discussion 
In this rare case of bilateral testicular tumors causing recurrence of Cushing disease 
after bilateral adrenalectomy, we were able to demonstrate by gene expression and 
steroid metabolome studies that the tumor tissue has shared adrenocortical and 
gonadal steroidogenic properties. 
TARTs are historically considered to originate from adrenal rests descending together 
with the testes during embryonic development (8). However, we recently found 
evidence that they develop from pluripotent cells within the testes with adrenal and 
Leydig cell features (9). Our patient’s tumor shared morphological and biochemical 
features with adrenal tissue, Leydig cell tumors, and virilizing adrenocortical tumors, 
illustrating the difficulty of differentiating adrenocortical cells from Leydig cells. In a 
previous similar case, Hamwi et al. (10) demonstrated via in vitro studies that the 
testicular tumor in a patient with recurrent Cushing disease was able to produce 
cortisol and cortisone, although it did not produce androgens. We now demonstrate 
expression of adrenal-specific genes in the tumor tissue and have correlated this with 
increased glucocorticoid excretion. In addition, androgen excretion from both classic 
and alternative synthesis pathways (11, 12) was significantly increased, although 
relative gene expression of Leydig cell-specific genes was only slightly increased. 
Interestingly, the steroid excretion profile of the TART tumor in this patient resembled 
a combination of steroid excretion in CAH and Cushing disease with ACTH-mediated 
stimulation of intact steroidogenesis. 
It is postulated that chronically elevated ACTH, LH, and angiotensin II contribute to 
differentiation of the early cell (even prenatally) and TART development (8, 13, 14). In 
our patient, the response to dexamethasone and the high MC2R expression support 
the role of ACTH, which was persistently elevated. However, in this case, exposure was 
only postnatal, suggesting the presence of pluripotent cells within the testes also in 
postnatal life and adulthood. Conversely, no cases of post bilateral adrenalectomy 
TART development have been described in adults older than 23 years, suggesting that 
regression of pluripotent cells ensues shortly after puberty. 
There was relatively higher expression of CYP11B1 and MC2R, but lower expression of 
HSD17B3 and LHCGR compared with TARTs in patients with CAH (9). This suggests that 
our patient’s tumor was more adrenal like, whereas TARTs in patients with CAH are 
more Leydig cell like, similar to other findings (3, 10). It has also been suggested that a 
LH surge during puberty is important for TART development and progression in 
patients with CAH (6). Although our patient had low relative expression of LHCGR and 
no response to hCG, he entered into puberty soon after adrenalectomy, where he was 
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exposed to high LH levels. Hence, it remains conceivable that early prepubertal LH 
stimulation of testicular tissue contributed to TART development. 
In conclusion, we present a rare case of recurrent Cushing disease after bilateral 
adrenalectomy from testicular tumors with adrenal and Leydig cell-specific features. 
Endocrinologists should consider this possibility if symptoms recur after adrenalectomy 
while patients are on maintenance steroids. Further research is needed to understand 
the mechanism of development of these testicular tumors. 
 
Disclosure Summary: The authors have nothing to disclose. 
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Supplemental Materials 
Serum Hormonal Assays 
Serum androstenedione, cortisol, 11-deoxycortisol, 17-hydroxyprogesterone, and 
testosterone, were assessed by an in-house SPE-LCMSMS. Samples underwent solid 
phase extraction (Oasis, HLB) after protein precipitation (ACN, 0.1% HCOOH). Analysis 
was performed by LCMSMS (Agilent 6490) with use of an Acquity BEH C18 1.7uM 
2.1X50 mm column. Aldosterone, corticosterone, DHEA, dihydrotestosterone, 11-
deoxycorticosterone and estrone were assessed by in-house RIAs after extraction and 
chromatography with recovery correction. Inhibin B was measured by ELISA (gen II; 
Beckman-Coulter, Woerden, the Netherlands). ACTH, DHEAS, estradiol, LH and FSH 
were measured by ECLIA (E170, Roche). Plasma renin was measured by 
immunoradiometric assay provided by CIS Bio (Codolet, France). All methods used have 
been validated for use in routine clinical diagnostics. 
Urine steroid metabolite profiling  
Measurement of 24 hour urinary steroid metabolite excretion was carried out by a 
well-established method employing gas chromatography-mass spectrometry (GC/MS) 
in selected-ion-monitoring mode for quantification of 38 distinct steroid metabolites. 
Urine samples had been stored at -20°C before analysis, which was carried out within 
three months of collection. A detailed description of this methodology has been 
published previously (15). In summary, free and conjugated steroids were extracted 
from 1 mL urine by solid-phase extraction. Steroid conjugates were enzymatically 
hydrolyzed, re-extracted, and chemically derivatized to form methyloxime trimethyl 
silyl ethers. GC/MS was carried out on Agilent 5973 instrument operating in selected-
ion-monitoring (SIM) mode to achieve sensitive and specific detection and 
quantification of 32 selected steroid metabolites. These represented important steroid 
groups, such as androgen metabolites, glucocorticoid metabolites, mineralocorticoid 
metabolites, and 3β-hydroxy-∆5 steroid precursors (16).  
Spermatic vein sampling 
The patient underwent bilateral testicular tumor enucleation under general anesthesia. 
Spermatic vein sampling was done prior to enucleation as described before (17). 
Briefly, via an inguinal incision and after opening of the inguinal canal, the right 
spermatic cord was exposed. Care was taken not to manipulate the testes to prevent 
unwanted secretion of hormones into the circulation. The spermatic vein was 
cannulated and blood samples were collected to measure serum hormones. The same 
procedure was performed on the left side. Peripheral blood was collected from a 
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cubital vein to measure the same hormones. All sera were stored at -20°C until 
measurements.  
Tissue processing and qPCR 
All removed tumor tissue was investigated macroscopically and microscopically. Shortly 
after resection, a portion of the right testicular tumor sample was snap-frozen and kept 
in liquid nitrogen for mRNA analysis. Frozen tissue sections (30x30 µm) were used for 
RNA isolation (Total RNA Purification Kit: Norgen Biotek Corporation, Thorold, Canada). 
Tissue sections were homogenized by addition of lysis buffer and pushing the 
homogenate through a 21 gauge needle using a 1 mL syringe. Further steps of the 
isolation were performed according to the manufacturer’s protocol. RNA concentration 
and quality were determined using a NanoDrop 2000 Spectrophotometer (Thermo 
Fisher Scientific, Waltham, USA). In addition, previous isolated RNA of TART samples of 
patients with CAH (9) and RNA of healthy control fibroblasts was included as a non-
steroidogenic control. 
Eight genes were selected for the characterization of the tumor tissue, including the 
genes encoding 5 key steroidogenic enzymes involved in the adrenocortical and 
testicular steroid synthesis. The steroidogenic pathways were divided in three parts: 
common to both adrenal cortex and Leydig tissue (CYP17A1, HSD3B2), adrenocortical-
specific (CYP11B1, CYP11B2, AGTR2, MC2R), or Leydig-specific (HSD17B, LHCGR), as 
previously described (9). Gene-specific primers were obtained and tested as previously 
described (9). 0.5 µg of total RNA in a volume of 20 µL was used for cDNA synthesis 
using Superscript II (200U/µL, Gibco) random primers (0.25 µg/µg RNA, Promega), and 
oligo dTs (0.25 µg/µg RNA, Santa Cruz). cDNA synthesis was performed using the 
following cycle conditions: 10 minutes at 21°C, 45 minutes at 42°C, 15 minutes at 70°C, 
10 minutes at 4°C, on a 2720 Thermal cycler (Applied Biosystems). For qPCR, the cDNA 
samples were diluted 5 times and 5 µL was added to 7.5 µL iQ™ SYBR® Green supermix 
(Bio-Rad Laboratories), in a total amount of 15 µL on a CFX96 Touch Real-Time PCR 
detection system (Bio-Rad Laboratories). The PCR products were checked for quality by 
melting curve analysis. 
Data analysis 
For the gene expression analysis, we calculated the mRNA expression of the genes 
using the delta-delta Ct method (2
-∆∆Ct). All expression values of the patient's tumor 
were normalized to the corresponding HPRT expression value and then relative to a 
non-steroidogenic control. Results, previously published, of patients with TART are also 
shown in Fig. 6.1F for comparison (9). 
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For the urine steroid metabolites, the patient’s results are presented with the median 
and interquartile ranges of a normal healthy control population, and we used the 
Cleveland algorithm implemented in SigmaPlot (Systat Software Inc., Chicago, IL).  
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Abstract 
Context: Current knowledge on gonadal function in congenital adrenal hyperplasia 
(CAH) is mostly limited to single-center/country studies enrolling small patient 
numbers. Overall data indicate that gonadal function can be compromised in men with 
CAH. 
Objective: To determine gonadal function in men with CAH within the European ‘dsd-
LIFE’ cohort. 
Design: Cross-sectional clinical outcome study, including retrospective data from 
medical records. 
Methods: Fourteen academic hospitals included 121 men with CAH aged 16-68 years. 
Main outcome measures were serum hormone concentrations, semen parameters and 
imaging data of the testes. 
Results: At the time of assessment, 14/69 patients had a serum testosterone 
concentration below the reference range; 7 of those were hypogonadotropic, 6 
normogonadotropic and 1 hypergonadotropic. In contrast, among the patients with 
normal serum testosterone (55/69), 4 were hypogonadotropic, 44 normogonadotropic 
and 7 hypergonadotropic. The association of decreased testosterone with reduced 
gonadotropin concentrations (odds ratio (OR)=12.8 (2.9-57.3)) was weaker than the 
association between serum androstenedione/testosterone ratio ≥1 and reduced 
gonadotropin concentrations (OR=39.3 (2.1-732.4)). Evaluation of sperm quality 
revealed decreased sperm concentrations (15/39), motility (13/37) and abnormal 
morphology (4/28). Testicular adrenal rest tumor (TART)s were present in 39/80 
patients, with a higher prevalence in patients with the most severe genotype (14/18) 
and in patients with increased current 17-hydroxyprogesterone (20/35) or 
androstenedione (12/18) serum concentrations. Forty-three children were fathered by 
26/113 patients. 
Conclusions: Men with CAH have a high risk of developing hypothalamic-pituitary-
gonadal disturbances and spermatogenic abnormalities. Regular assessment of 
endocrine gonadal function and imaging for TART development are recommended, in 
addition to measures for fertility protection. 
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Introduction 
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder resulting in 
impaired adrenocortical steroid synthesis by several enzyme deficiencies. The most 
common form (>95%) is 21-hydroxylase deficiency (21OHD) with an incidence of  
1:15 000, leading to glucocorticoid and often also mineralocorticoid deficiency in 
combination with androgen excess (1, 2). 
Reported fertility and fecundity in men with CAH on routine steroid replacement 
therapy range from normal to severely impaired. Fertility can be compromised due to 
primary (hypergonadotropic) hypogonadism or central (hypogonadotropic) 
hypogonadism (3-11). In addition, reduced fertility and fecundity rates in CAH can be 
caused by psychosexual factors (4). Central or secondary hypogonadism is defined as 
decreased testosterone concentrations in combination with either low or low-normal 
LH or FSH concentrations. In men with CAH, secondary hypogonadism is most likely 
caused by the suppressive effect of elevated adrenal androgens (that are aromatized to 
estrogens) on the hypothalamus-pituitary-gonadal (HPG) axis (6). Differentiation 
between gonadal and adrenal testosterone is difficult, complicating the diagnosis of 
hypogonadism in men with CAH. One of the commonest complications in men with 
CAH is the presence of testicular adrenal rest tumor (TART)s, which can cause 
disturbances of gonadal function, including mechanical obstruction of the seminiferous 
tubules. The reported prevalence of TARTs ranges between 12.5% and 94% in the 
populations studied (4-10, 12-22). 
Until now, the data on fertility outcome in men with CAH are scarce (3-11) and often 
derived from studies with patients from a single center or country. Our aim was to 
study gonadal function in a large European multicenter cohort of male patients with 
CAH by evaluating hormone concentrations, semen parameters and TART frequency. 
 
Subjects and methods 
Subjects 
dsd-LIFE is a cross-sectional clinical outcome study of individuals with 
disorders/differences of sex development (DSD). Fourteen study centers in 6 European 
countries (France (n = 4), Germany (n = 4), United Kingdom (n = 1), Poland (n = 2), 
Sweden (n = 1) and the Netherlands (n = 2)) included former and current patients as 
participants from February 2014 to September 2015. In addition to DSD participants, 
121 male participants with CAH (46XY karyotype) aged 16-68 years were recruited as 
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they may face similar clinical challenges as DSD patients, including sex hormone 
imbalances and fertility problems, although male patients with CAH do not fit into the 
classification of DSD. Written informed consent was obtained from all participants 
and/or their parents, with assent of minors. Ethical approvals were obtained as 
appropriate for each country. The theoretical and methodological framework of the 
dsd-LIFE study have been published in detail (23). Patients were investigated in their 
local treatment center. Cross-sectional data were obtained for serum hormone 
concentrations, semen parameters and testicular imaging. The genotype of patients 
with 21OHD was classified into genotype groups null, A, B, and C (24). General patient 
characteristics and clinical parameters included: country of inclusion, age, age at 
diagnosis, CAH genotype and phenotype, socioeconomic status and obesity, as well as 
height, weight and BMI throughout the years (at diagnosis, 9 months old, 6 years old, 
Tanner stage 2, 16 years old and current age). Patients’ educational levels were 
established according to the EU classification. We combined the standardized ES-ISCED 
(international standard classification of education) scale to low (ES-ISCED I = less than 
lower secondary and ES-ISCED II = lower secondary); medium (ES-ISCED IIIb = lower tier 
upper secondary; ES-ISCED IIIA = upper tier upper secondary; ES-ISCED IV = advanced 
vocational, sub-degree) and high (ES-ISCED V1 = lower tertiary education, BA level; ES-
ISCED V2 = higher tertiary education, ≥MA level). Data were collected during medical 
examination at study inclusion (cross-sectional) and retrieved from medical records 
(retrospective data). 
Hormonal analysis 
Blood samples were taken during daytime, but mostly in the morning, before intake of 
the glucocorticoid medication (23). Total testosterone, sex hormone-binding globulin 
(SHBG), luteinizing hormone (LH), follicle-stimulating hormone (FSH), inhibin B, Anti-
Müllerian hormone (AMH), androstenedione, 17-hydroxyprogesterone concentrations 
and renin/plasma renin activity were measured in the local hospital laboratory and 
compared to local references. Values are reported in SI or international units and 
reported as ‘below reference range’, ‘within reference range’, ‘above reference range 
up to twice the upper limit’ and ‘more than twice the upper limit of the reference 
range’. To increase the number of patients per category, we combined the latter 2 
categories into the category ‘above reference range’. 
The serum androstenedione/testosterone ratio (AD/T) was calculated and divided into 
normal (<0.5; interpreted as testosterone mainly of testicular origin), ≥0.5 and <1 
(significant fraction of testosterone is of adrenal origin) and ≥1 (testosterone mainly of 
adrenal origin) as suggested by others (25). 
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Semen analysis 
Semen analysis was performed by the local hospital laboratory and interpreted in 
accordance with the 2010 World Health Organization criteria (26), including sperm 
concentration (lower reference limit (LRL): 15×106/mL), motility (LRL: 40%), 
morphology (LRL: 4%), vitality (LRL: 58%) and volume (LRL: 1.5 mL). 
Imaging of testes 
At the study visit, 68 patients (56.2%) underwent testicular ultrasound. The presence of 
TART at the age of 16 years was also reported retrospectively (in 30/68 patients with 
cross-sectional TART data). In addition, retrospective data were available for 12 
participants based on ultrasound findings or MRI (n=11) and on histological findings 
(n=1). 
Paternity 
Data about paternity and relationships were collected from the dsd-LIFE questionnaires 
(23). 
Medication and estimation of metabolic control in the past 
Patients used different formulations of glucocorticoids, including hydrocortisone, 
prednisone, prednisolone and dexamethasone. Furthermore, we converted all 
glucocorticoid preparations to hydrocortisone equivalents, using the following factors 
for the glucocorticoid equivalent dose: 1 (hydrocortisone), 4 (prednisone or 
prednisolone), 30 (dexamethasone) and 15 (fludrocortisone) (27). We also calculated 
mineralocorticoid equivalent dose using the following factors: 1 (hydrocortisone), 0.8 
(prednisone or prednisolone), 0 (dexamethasone) and 200 (fludrocortisone) (27). In 
addition to the serum 17-hydroxyprogesterone concentrations presented in the 
section hormonal analysis, we also assessed metabolic control by a subjective rating, of 
the local examining physician at 5 different time points: at diagnosis, at the age of 9 
months, at Tanner stage 2, at age 16 years and at study inclusion, using the following 
scores: ‘poor’, ‘moderate’, ‘good’, ‘excellent’ or ‘unknown’. 
Statistical analysis 
SPSS Statistics 22 (SPSS) was used for all analyses. Descriptive analyses were performed 
for all variables. Depending on normality, mean and 95% confidence intervals (95%CI) 
or median and interquartile ranges (IQR) were calculated. We compared patients with 
values below or above reference range to patients with normal values (within the 
reference range). Odds ratios (OR) with 95%CI were calculated if at least 3 cases were 
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present in both subgroups. If any cell count in the contingency table was zero, OR and 
95%CI were calculated manually by using a continuity correction (+0.5 in each cell). 
Missing data were evaluated for each variable and the total number of participants in a 
particular analysis was reported exactly. Analysis of the variables was performed only if 
the number of participants was ≥25% of the total cohort of male patients with CAH. 
Three patients were excluded from part of the analyses as they received testosterone 
substitution, which directly affects testosterone and gonadotropin concentrations. Two 
of these patients had data on TART available; these are described in the ‘Results’ 
section. Furthermore, we excluded 22 patients with missing genotype information and 
2 patients with 11β-hydroxylase deficiency from all comparative analyses. 
 
Results 
General characteristics of the male CAH cohort 
A total of 121 male patients were included in the CAH cohort in the dsd-LIFE study. 
General characteristics are shown in Table 7.1. The median age of the study population 
was 28 years (IQR: 18.5-37.5, range 16-68). Mean height was 170.7 (95%CI: 169.3-
172.0) cm and median BMI was 25.6 (IQR: 22.0-29.2) kg/m2 (data available for 119 
patients). Nearly all patients had 21OHD (119/121), and 97 were confirmed by 
molecular genetic analysis. The remaining 2 patients had 11β-hydroxylase deficiency. 
Among the 97 patients with genetically confirmed 21OHD, 24.7% were classified as 
genotype null, 38.1% as genotype A, 34.0% as genotype B and 3.1% as genotype C. 
Glucocorticoids were used by 116 (95.9%) patients, most commonly hydrocortisone, 
followed by prednisone or prednisolone and dexamethasone. Fludrocortisone was 
used by 86 patients (71.1%). The patients’ education was intermediate or high in 54.5% 
and 22.3%, respectively. Furthermore, 54.6% of the patients were in a relationship at 
the time of study. 
We analyzed all variables mentioned in the ‘Methods’ section, but we only present in 
detail the data that differed between the analyzed groups (no overlap in the 
confidence intervals). In the following sections, we will present data regarding 
hormone concentrations, semen analysis and TART. 
Hormone concentrations 
Univariate descriptive analyses of hormone concentrations were performed. The 
proportion of patients with normal, decreased or increased serum testosterone, LH, 
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FSH, inhibin B, AMH and SHBG concentrations is illustrated in Fig. 7.1A. Hormone 
concentrations were below the reference range in 19/97 (19.6%: testosterone), 8/43 
(18.6%: inhibin B), 12/90 (13.3%: LH), 9/90 (10.0%: FSH) and 1/69 (1.4%: SHBG) of the 
participants. SHBG concentrations were above the reference range in 14.5% (10/69). 
 
Table 7.1: General characteristic of 121 male patients with congenital adrenal hyperplasia. Continuous 
variables are displayed as median (IQR) or mean (95%CI), depending on normality of the data. Categorical 
variables are displayed as number of patients and percentage. Patients with 21-hydroxylase deficiency were 
classified according to severity of the disease. Genotype was classified in genotype group null (0) to group C 
(24). 
Parameter N Level Cohort results 
Age 121   28 (IQR: 18.5-37.5) years 
Severity of 
disease 
121 Genotype  
 21OHD group 0 
21OHD group A 
21OHD group B 
21OHD group C 
No mutation analysis done 
CYP11B1 mutation 
24 (19.8%) 
37 (30.6%) 
33 (27.3%) 
3 (2.5%) 
22 (18.2%) 
2 (1.7%) 
Medication  
 
121 Hydrocortisone* 67 (55.4%) 
 Prednisone, Prednisolone or 
Hydrocortisone & Prednisolone^ 
32 (26.4%) 
 Dexamethasone or 
Hydrocortisone & Dexamethasone# 
17 (14.0%) 
 No medication 3 (2.5%) 
 Fludrocortisone alone 2 (1.7%) 
 Fludrocortisone given in addition to 
any of the glucocorticoid combinations 
above 
84 (69.4%) 
Testosterone 
substitution  
121  3 (2.5%) 
Height  119  170.7 (95%CI: 169.3 - 172.0) cm 
BMI  119  25.6 (IQR: 22.0 - 29.2) kg/m2 
Education  
 
112 Low 
Intermediate 
High 
other, n/a 
15 (13.4%) 
61 (54.5%) 
25 (22.3%) 
11 (9.8%) 
Partnership 
situation  
108 In current relationship - yes 
In current relationship - no 
59 (54.6%) 
49 (45.4%) 
 
*Hydrocortisone retard was used by 2 patients. ^A combination of prednisolone and hydrocortisone was 
used by 1 patient, 17 patients were on prednisolone, 13 on prednisone, and 1 on prednisone retard. 
#Dexamethasone was used combined with hydrocortisone in 9 patients, while 8 patients were on 
dexamethasone. †Fludrocortisone given in addition to any of the glucocorticoid combinations listed. 
Abbreviations: 21OHD, 21-hydroxylase deficiency; 95%CI, 95% confidence interval; IQR, interquartile range; 
N, number of patients. 
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Table 7.2 compares testosterone and gonadotropin concentrations in all patients with 
data on testosterone, LH and FSH available. Seven patients (50%) with decreased 
testosterone concentrations had decreased gonadotropins, while 6 (42.9%) had normal 
LH and FSH concentrations and 1 (7.1%) patient had gonadotropin concentrations 
above reference range. Normal testosterone concentrations were found in 55/69 
(79.7%) patients, 44 (80.0%) of whom had normal gonadotropin concentrations, 
whereas 7 (12.7%) had increased and 4 (7.3%) had decreased concentrations. 
Decreased testosterone concentrations were clearly associated with decreased LH 
and/or decreased FSH concentrations (OR: 12.8, 95%CI: 2.9-57.3).  
A serum AD/T ratio was calculated in 49 patients, 22 of whom (44.9%) had an AD/T 
ratio ≥1. Ten patients (45.5%) with an AD/T ≥1 had decreased gonadotropins, while 11 
(50.0%) patients had normal gonadotropins and only 1 (4.5%) patient had increased 
gonadotropins. Normal AD/T ratios were found in 27/49 (55.1%) patients, 21 of whom 
had normal gonadotropin concentrations (77.8%), 5 had increased concentrations, but 
none had decreased gonadotropin concentrations. An AD/T ratio ≥1 was strongly 
associated with decreased LH and/or decreased FSH concentrations (OR: 39.3, 95%CI: 
2.1-732.4). 
 
Table 7.2: Testosterone concentrations, androstenedione/testosterone ratios and gonadotropin 
concentrations in 83 male patients with congenital adrenal hyperplasia. Testosterone, gonadotropin 
concentrations and androstenedione/testosterone (AD/T) ratio are presented to identify patients with 
hypogonadism and with prevalent adrenal-derived hyperandrogenism. The number and percentage of 
patients in each category are given. Odds ratios with 95% confidence intervals were calculated (testosterone 
concentrations vs. decreased or normal gonadotropins and testosterone concentrations vs. increased or 
normal gonadotropins). 
 decreased LH and/or 
decreased FSH, n (%) 
normal LH and 
normal FSH, n 
(%) 
increased LH 
and/or increased 
FSH, n (%) 
Decreased 
gonadotropins,  
OR (95%CI) 
decreased T 7 (50%.0) 6 (42.9%) 1 (7.1%) 12.8 (2.9 - 57.3) 
normal T 4 (7.3%) 44 (80.0%) 7 (12.7%)  
AD/T>1* 10 (45.5%) 11 (50.0%) 1 (4.5%) 39.3 (2.1 - 732.4) 
normal AD/T 0 21 (77.8%) 6 (22.2%)  
 
*An AD/T ratio >1 suggests that the testosterone is mainly of adrenal origin. Abbreviations: AD/T, 
androstenedione/testosterone ratio; T, testosterone. 
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Fig. 7.1: Hormone concentrations (A) and semen quality (B) in male patients with congenital adrenal 
hyperplasia. Stacked bars represent percentage of patients within a category. Numbers in the bars represent 
the specific number of patients within a category, while the total number of patients included in this analysis 
is stated underneath the x-axis. A) Hormone concentrations of each patient were measured in the local 
hospital and compared to the hospitals standard reference ranges. B) Semen analysis was performed and 
scored according to World Health Organization 2010 criteria (26): sperm concentration, motility, 
morphology, and vitality, and semen volume were assessed. Abbreviations: AMH, anti-Müllerian hormone; 
INHB, inhibin B; N, number of patients; T, testosterone. 
 
Semen analysis 
Semen analysis was performed in approximately one-third of the patients (Fig. 7.1B). 
Normal values for all known (at least 3 out of 5) semen parameters (normozoospermia) 
were seen in 11/39 patients in whom semen analysis was performed. Sperm 
concentration, motility and volume were below the normal ranges in 38.5% (15/39), 
35.1% (13/37) and 25.6% (10/39) of the patients, respectively, while morphology and 
vitality were both impaired in 14.3% (4/28 and 2/14) of the patients. Five of 8 patients 
(62.5%) with decreased testosterone and gonadotropin concentrations underwent 
semen analysis, with 4 (80.0%) of them showing abnormal semen parameters (Table 
7.3). In only 2/10 patients with decreased testosterone but normal gonadotropin 
concentrations, semen analysis was performed and both had decreased sperm 
concentrations (7.0 and 10.0 106/mL). No statistically significant associations were 
found. 
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Table 7.3: Semen parameters of 5 male patients with CAH and decreased testosterone and gonadotropin 
concentrations. 
 sperm concentration, 
LRL: 15x106/mL 
sperm motility, 
LRL: 40% 
sperm 
morphology, LRL: 
4% 
sperm 
vitality, LRL 
58% 
sperm volume, 
LRL: 1.5mL 
p1 15x106/mL 35% 2% n.d. normal 
p2 normal 2% n.d. 58% 1.1mL 
p3 7x106/mL normal normal n.d. normal 
p4 normal 35% normal n.d. 1.4mL 
p5 normal normal normal n.d. normal 
 
Eight patients had decreased testosterone and gonadotropin concentrations, of which 5 provided semen 
samples. Semen analysis was performed and scored according to World Health Organization 2010 criteria 
(26): sperm concentration, motility, morphology, and vitality, and semen volume were assessed. 
Abbreviations: LRL, lower reference limit; n.d., not determined. 
 
Testicular adrenal rest tumors 
TARTs were visualized by ultrasound or MRI at cross-sectional investigation in 28/68 
patients. For 1 patient, the diagnosis was based on retrospective histology data. 
Furthermore, retrospective imaging data were available for 11 men: TARTs were 
present in 10 of these individuals. In the total population screened, TARTs were 
present in 39/80 patients (48.8%) of which 34 were bilateral TARTs (87.2%). 
Documented retrospective TARTs at age 16 years were reported in 16/30 patients 
(53.3%), all of which were bilateral. In only 2/16 patients (12.5%) with TART reported to 
be present at age 16 years, TART was no longer observed during the cross-sectional 
investigation: 1 patient was misdiagnosed with TART as it appeared to be a varicocele, 
and in the other patient, TART (size 2 mm) disappeared after treatment with 
prednisone. This patient was still considered as a patient with TART in all analyses. 
Comparison of patients with and without TART 
Table 7.4 shows associations of TART with various variables in the 68 patients with 
gonadal imaging data (12 patients were excluded due to testosterone substitution, 
11β-hydroxylase deficiency or unconfirmed 21-hydroxylase deficiency), comprising 33 
patients with and 35 without TARTs. Genotype was associated with the presence of 
TART: The null genotype group had the highest prevalence of TART (14/18: 77.8%), 
while the prevalence was 10/27 (37.0%) for genotype group A and 7/21 (33.3%) for 
genotype group B. The odds of having TART in the null genotype group was 6.0 (1.5-
23.1) and 7.0 (1.7-29.4) times higher compared to the genotype groups A and B, 
respectively. TARTs were also present in both men in the genotype C group and also in 
1 CYP11B1-deficient patient (the other CYP11B1 patient did not undergo assessment 
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for TART). The OR of having TART when having a serum androstenedione concentration 
above the upper limit of normal at the time of the cross-sectional investigation was 3.6 
(1.0-12.7). Similar associations were found for serum 17-hydroxyprogesterone at the 
cross- sectional investigation, with an OR of 28.0 (3.1-252.5) for having TART when 17-
hydroxyprogesterone concentrations were more than twice the upper level of the 
reference range and an OR of 18.7 (2.2-158.1) when these concentrations were above 
the reference range compared to concentrations within the reference range. 
 
Table 7.4: Comparison of genetic and hormonal characteristics between patients with (n=33) and without 
testicular adrenal rest tumors (n=35).  
Characteristics With TARTs Without TARTs OR (95% CI) 
Genotype *    
Group null 14 (77.8%) 4 (22.2%)  
Group A 10 (37.0%) 17 (63.0%)  
Group B 7 (33.3%) 14 (66.6%)  
Group null - Group A   6.0 (1.5-23.1) 
Group null - Group B   7.0 (1.7-29.4) 
Androstenedione   3.6 (1.0-12.7) 
> ref range 12 (66.7%) 6 (33.3%)  
Within ref range 9 (36.0% 16 (64.0%)  
17-hydroxyprogesterone    
>2x UL ref range 16 (66.7%) 8 (33.3%)  
> ref range 20 (57.1%) 15 (42.9%)  
Within ref range 1 (6.7%) 14 (93.3%)  
>2xUL - within   28.0 (3.1-252.5) 
> ref - within   18.7 (2.2-158.1) 
 
Odds ratios with 95% confidence intervals were calculated for many comparisons, but only odds ratios that 
clearly or potentially differ from unity are presented. Data are presented as number and percentage for each 
characteristic. *Genotype group C and CYP11B1 category contained only 2 and 1 case(s), respectively and are 
not included in the analysis. Abbreviations: 95%CI, 95% confidence interval; OR, odds ratio; ref, reference; 
TART, testicular adrenal rest tumor; UL, upper limit. 
 
Paternity 
Data on paternity were available for 113 of the 121 patients, 26 (23.0%) of whom (age 
range 26-68 years) had fathered a total of 43 children. Three couples had used assisted 
reproductive techniques (ART) resulting in 4/43 children. One of the men who had 
used ART had decreased testosterone concentrations, while another had increased 
FSH, decreased sperm concentration and TART. No information was available about the 
third patient who had used ART. 
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Discussion 
This unique and relatively large European multicenter study shows that gonadal 
dysfunction is a common complication in male patients with CAH. Approximately half of 
the patients were affected by endocrine disturbances of the HPG axis at an adult age 
and TARTs were present in approximately half of the patients as well. 
The difficulty in diagnosing hypogonadism in men with CAH is related to the fact that 
testosterone measured in serum is a mixture of testosterone of gonadal and adrenal 
origin (25, 28). Circulating testosterone in male patients with well-controlled CAH is 
predominantly derived from testicular production, but when there is poor hormonal 
control, a relevant contribution arises from adrenal steroidogenesis. Until now, no 
method is able to discriminate between testosterone derived from the testes or the 
adrenal gland. Therefore, it has been suggested to use the serum AD/T ratio in male 
patients with CAH, as this precursor steroid is elevated in serum when serum 
androgens are predominantly of adrenal origin (25). Our data point toward an 
association between an AD/T ratio ≥1 (testosterone mainly of adrenal origin) and 
decreased LH and/or decreased FSH concentrations, suggesting that adrenal androgens 
in men with CAH contribute to the suppression of gonadotropins. In approximately half 
of the patients, either aberrant testosterone or AD/T ratios, or aberrant gonadotropin 
concentrations or a combination of both were found. In previous studies, the reported 
prevalence of endocrine HPG axis disturbances ranged from 20% to 52% (5-7, 9, 10). 
However, only 1 other study provided information on testosterone and gonadotropin 
concentrations in each patient and also indicated hypogonadism in approximately half 
of the patients (6). We recommend to include the evaluation of the AD/T ratio in the 
regular follow-up of male patients with CAH and interpret this ratio in combination 
with gonadotropin concentrations in order to detect a disturbance of the HPG axis. Our 
study does not include data on 11-oxygenated androgens, that are generated through 
conversion of androstenedione and are reported to be elevated in patients with CAH 
(29, 30). Recent studies indicate that 11-oxygenated androgens are almost entirely 
derived from the 11β-hydroxylation of androstenedione in the adrenal, and as they are 
potent androgens they can contribute to suppression of the HPG axis (31). However, 
their exact role in the evaluation of hormonal control and gonadal function in men with 
CAH has to be established in further studies. Serum AMH and inhibin B are also used as 
markers for male fertility (32). However, it has been demonstrated that serum AMH 
concentrations do not correlate with sperm concentration and other male fertility 
parameters (33). Serum inhibin B, a marker of Sertoli cell function, is known to 
correlate with spermatogenesis in healthy men (34) and was decreased in 18.6% of our 
cohort. Semen quality, assessed in one third of the study cohort, was reduced in 40% 
of the men. Except for the study of Urban et al. (3), all other studies on fertility in male 
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patients with CAH showed decreased sperm concentrations ranging from 47.8% to 66% 
(4-7, 9, 10). More strikingly, in all studies, only half of the participants participated in 
semen analysis. Taken together, these data indicate the need for increased awareness 
on fertility status in patients with CAH and to start performing semen analysis and 
gonadal function biomarkers assessment from adolescence on, in order to detect 
disturbances early and allow semen preservation for later fertility purposes. 
Data from our cohort indicate, in agreement with previous studies (4-10, 12-22), that 
TART is a common complication in males with CAH (with a prevalence of 48.8%) and 
can have onset as early as in adolescence. In fact, 14 patients with TART at the time of 
the dsd-LIFE study already had TART at the age of 16 years. TARTs disappeared on 
treatment with prednisone in only 1 patient, thus indicating that complete regression 
of TART might only be achieved in a small proportion of the patients. Hence, 
prevention of the development of TART should be pursued, by optimizing treatment 
strategies already in childhood. Current standard of care does not include imaging of 
testes; however, we recommend incorporating testicular ultrasound in routine clinical 
practice. 
In contrast to previous studies (4, 9, 10), we observed an association between the 
CYP21A2 genotype and the presence of TARTs, with the prevalence of this complication 
being highest in men with the null CYP21A2 genotype. This supports the current 
perception that TARTs are more frequently observed in patients with a more severe 
form of CAH, as these patients are exposed to higher concentrations of ACTH, already 
in utero, which is thought to be a possible causative factor for TART development (6, 7, 
15, 22). However, a clinically relevant finding in this study is that TARTs occur even in 
less severe forms of 21OHD. In fact, in our study, 2 patients in genotype group C (both 
compound heterozygous for deletion and P30L mutation) had TARTs. In our current 
dataset, we could not find an association between genotype and semen quality or 
genotype and hypogonadism. 
We found an association between increased 17-hydroxyprogesterone concentrations 
at cross-sectional data assessment and the presence of TART. Although a single 17-
hydroxyprogesterone measurement may not be representative of overall metabolic 
control, these results could be interpreted as a possible indicator of the patient’s 
metabolic control in the recent past. Therefore, our results seem to be in accordance 
with literature reporting higher TART prevalence in patients with poor hormonal 
control compared to patients with adequate hormonal control (5, 7, 13, 35-38). The 
association between increased androstenedione concentrations at cross-sectional data 
assessment and the presence of TARTs adds evidence to this pathophysiologic concept, 
even if the AD/T ratios were not clearly associated with TART within this subgroup of 
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patients. Primary gonadal dysfunction may be suggested by raised FSH concentrations. 
In our dataset, 10 patients (11.1%) had elevated FSH concentrations. Seven of these 
patients had data on the presence of TART and 4 had evidence of TART. King et al. 
found that testicular failure was a consequence of TART in the majority of cases (10). 
However, our data are limited and do not allow firm conclusions concerning this issue. 
Despite this being the first international multicenter study describing gonadal function 
in male patients with CAH, the study also has some limitations. All centers included in 
this consortium are tertiary care centers; therefore, it is possible that the patient 
groups were selected and that the patients included were more severely affected. 
Furthermore, serum hormone concentrations were not measured centrally, but in 
various centers, with a range of different assays. Accounting for this fact, only range 
variables were used in the data analyses. The median BMI in our patient cohort was 
25.6 kg/m2 (range: 22.0-29.2), which is slightly overweight. It has been demonstrated 
that excess of total and abdominal body fat could represent one cause of fertility 
impairment in men with CAH (25). Serum total testosterone can be decreased in 
patients with obesity, as a result of the decreased serum concentration of SHBG. In 
case of increased serum SHBG (induced by hepatitis, hyperthyroidism or a genetic 
variant), total testosterone may be increased. Ideally, free testosterone should be 
measured in these cases, but this requires complex equilibrium dialysis (39). Free 
testosterone can also be calculated from total testosterone, SHBG, and albumin 
concentrations, but it is crucial that the results of such calculations are compared with 
the normal range of each separate laboratory. Such data were not available. We are 
aware that assessment of fertility by paternity numbers in our study was incomplete, as 
many other factors, including female fertility, were not available. Furthermore, 
participation in the medical examination was not compulsory for study inclusion. This 
may have led to even more selection, especially concerning the ultrasound 
examination and semen analysis. It is likely that only the very motivated patients and 
the more severely affected patients consented to these additional examinations. Due 
to the resulting low numbers of available data, multivariable logistic regression 
analyses were not possible. 
In summary, impaired gonadal function is common in adult men with CAH. This is 
indicated by the presence of TART and/or hypogonadotropic or hypergonadotropic 
hypogonadism. The risk of TART is highest in men with the most severe enzyme 
deficiencies underlying CAH. Our data suggest that an association with poor previous 
hormonal control is likely but requires confirmation by prospective studies. 
Determination of the serum AD/T ratio, in addition to serum concentrations of 
testosterone, androstenedione, LH, and FSH may help to differentiate between 
testicular and adrenal androgens in male patients with CAH and to diagnose gonadal 
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dysfunction. Routinely performed semen analysis, measurement of serum inhibin B 
and testicular ultrasound investigation already in adolescence are recommended to 
detect upcoming reproductive problems and to allow for fertility preserving measures, 
such as sperm banking. 
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Abstract 
Objective: Congenital Adrenal Hyperplasia (CAH) due to 21-hydroxylase deficiency 
(21OHD) is a disorder of adrenal steroid biosynthesis, leading to hypocortisolism, 
hypoaldosteronism, and hyperandrogenism. Impaired quality of life (QoL) has been 
demonstrated in females with CAH, but data in males with CAH is scarce. We 
hypothesize that disease severity and poor treatment control are inversely associated 
with QoL. 
Design: European multicenter, cross-sectional study: 'dsd-LIFE'. 
Methods: Adult (16-68 years) males with 21OHD were included (n=109). The WHOQOL-
BREF questionnaire was used to measure self-reported QoL domain scores on a 0-100 
scale, where higher scores reflect better QoL. QoL domain scores were compared to 
published data on healthy and chronically ill reference populations from Germany, 
France, the Netherlands, and the United Kingdom. Associations between QoL and 
disease severity and poor treatment control were tested (Mann-Whitney U test).  
Results: Median domain scores were 78.6 (IQR: 67.9-85.7 physical health), 79.2 (IQR: 
66.7-87.5 psychological health), 75.0 (IQR: 58.3-83.3 social relationships) and 81.3 (IQR: 
71.9-90.6 environment). Overall, these scores were similar to WHOQOL-BREF domain 
scores in healthy references and higher compared to chronically ill reference 
populations. Domain scores did not differ between genotype groups, while patients 
with undertreatment or increased 17-hydroxyprogestrone concentrations scored 
significantly higher on QoL (p<0.05). Significantly higher QoL domain scores were 
observed in patients on prednisone and dexamethasone (p<0.05).  
Conclusions: Males with CAH appear to rate their QoL as good as healthy, and better 
than chronically ill, reference populations. The use of prednisone or dexamethasone 
and undertreatment were associated with higher QoL domain scores.  
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Introduction 
Congenital Adrenal Hyperplasia (CAH) is an inherited disorder of adrenal steroid 
biosynthesis. The most common cause is a mutation in the CYP21A2 gene leading to 
21-hydroxylase deficiency (21OHD), which results in impaired production of cortisol 
and increased production of adrenal androgens leading to virilization of the female 
external genitalia. Aldosterone production is also impaired to a variable degree, 
depending on the severity of the enzyme deficiency (1, 2). Treatment consists of 
glucocorticoid substitution and, if necessary, also substitution of mineralocorticoids. 
Common long-term complications are disturbed pubertal development, reduced final 
height, decreased bone mineral density, decreased reproductive function including 
testicular adrenal rest tumor development, and an increased risk on obesity, 
cardiovascular morbidity and adrenal crises (3-5).  
In patients with CAH, several factors may affect quality of life (QoL), such as the 
development of long-term complications. The use of medication and poor treatment 
control may also contribute to impaired QoL. Impaired QoL has been reported in CAH, 
but mostly in women (reviewed by Reisch et al. (3)). Data on QoL in men with CAH are 
scarce, although separate analysis of QoL in male and female patients is important 
since clinical presentation and complications vary greatly between the 2 sexes. Results 
are contradictory with some papers describing impaired QoL (6-8), and others equal (9) 
or better (10) QoL in males with CAH compared to a control population.  
The dsd-LIFE study provides a unique opportunity to study a large European 
multicenter cohort of males with CAH. We aimed to analyze QoL in males with CAH 
using the WHOQOL-BREF questionnaire and to assess factors that may contribute to 
QoL.  
 
Subjects and methods 
Subjects 
Adult males with CAH were included from the dsd-LIFE study, a cross-sectional clinical 
outcome study of individuals with disorders/differences of sex development (DSD). 
Fourteen study centers in 6 European countries (France (n=4), Germany (n=4), United 
Kingdom (UK) (n=1), Poland (n=2), Sweden (n=1), and the Netherlands (n=2)) included 
participants with DSD, from February 2014 until September 2015. In addition, 121 
males with CAH (46XY karyotype) aged 16-68 years, not classified as DSD patients, were 
included as an add-on study, as these patients might face similar challenges as patients 
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with DSD. Written informed consent was obtained from all participants. The study was 
approved by the medical ethics committee at the Charité Universitätsmedizin Berlin 
(reference number EA2/069/13) and the local ethics committees of the other study 
centers (Ethik-Kommission der Universität zu Lübeck (13-144), Ethik-Kommission der 
Medizinischen Fakultät der Westfälischen Wilhelms-Universität Münster (2013-500-b-
S), Ethik-Kommission bei der LMU München (450-13), Comite de Protection des 
Personnes-Ile de France 1 (13352), Komisja Bioetyki Uniwersytetu Medycznego w Lodzi 
(RNN/242/13/KE), Komisja Bioethycnej przy intytucie ‘Pomnik-centrum Zdrowia 
Dziecka (103/KBE/2013), Regionala etikprövningsnämnden I Stockholm (2013/1163-
31/1), Medisch Ethische Toetsingscommissie VU medisch centrum (2013.336), 
Radboud universitair medisch centrum (NL46220.029.13), NHS National Health 
Research Ethics Service, NRES Committee North West-Greater Manchester East 
(14/NW/1123)). The methodological background of the dsd-LIFE study was described 
previously (11). The same cohort of males with CAH was included previously in a study 
reporting on gonadal function (12).  
Patients were investigated in their local medical center. All patients underwent medical 
examination and filled out several questionnaires, including the WHOQOL-BREF (13). 
Additional data were retrieved from medical records. General patient characteristics 
and clinical parameters included: country of inclusion, height, weight, BMI, age, age at 
diagnosis, CYP21A2 genotype, medication use, subjective treatment control, 
satisfaction with care in childhood, smoking behavior, work, life activity, sports, and 
educational level. The variable age was dichotomized into <30 years and ≥30. The 
patients were classified into genotype groups null (0), A, B, and C (14), as described 
earlier (12). The patients with genotype group 0 are most severely affected, while 
genotypes A, B, and C have decreasing severity. The patients’ educational levels were 
established according to the EU classification as low, medium, and high as described 
earlier (12). 
WHOQOL-BREF 
To assess QoL in this study, the WHOQOL-BREF questionnaire was used according to 
guidelines provided by the World Health Organization (13). The WHOQOL-BREF is a 
shortened version of the WHOQOL-100, consisting of 24 questions concerning QoL on 
4 different domains: physical health, psychological health, social relationships, and 
environment. Questions are rated on a 5-point Likert scale and domain scores 
represent the mean score of items within each domain. Scores are multiplied by 4, 
resulting in a score ranging from 4-20, to be directly comparable with scores derived 
from the WHOQOL-100. These scores can then be converted to a 0-100 scale. High 
scores reflect good QoL. Healthy as well as chronically ill reference populations 
available from Germany(15), France (16), the Netherlands (17), and the UK (18) were 
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used for comparison. Reference populations form the Netherlands and the UK 
contained both men and women, as Germany and France reported gender-specific QoL 
scores. 
Medication 
All glucocorticoid preparations were converted to hydrocortisone equivalents per day, 
as described earlier (12) using the following factors for the glucocorticoid equivalent 
dose: 1 (hydrocortisone), 4 (prednisone or prednisolone), 30 (dexamethasone), and 15 
(fludrocortisone) (19). 
Treatment control 
Treatment accuracy was estimated by the treating physicians in subjective scores: 
undertreatment, accurate treatment, or overtreatment. Blood hormone 
concentrations can also indicate treatment accuracy as high concentrations of 
androstenedione and 17-hydroxyprogesterone indicate inadequate adrenal androgen 
suppression. Therefore, blood samples were obtained at study inclusion. Samples were 
mostly taken in the morning, before intake of the glucocorticoid medication (11). 
Androstenedione and 17-hydroxyprogesterone concentrations were measured in the 
local hospital laboratory and compared to local reference values. Results were 
reported as “below reference range”, “within reference range”, “above reference 
range up to twice the upper limit", and "more than twice the upper limit of the 
reference range”. To increase the number of patients per category, we combined the 
latter 2 categories into the category ‘above reference range’.  
Statistical Analysis 
SPSS Statistics 22 (SPSS Inc., Chicago, IL, USA) was used for all analyses. First, missing 
data were evaluated for each variable. Following, descriptive analyses were performed 
for all variables. After checking the distributions of the QoL scores for normality, 
median and interquartile ranges (IQR=Q1-Q3) were calculated. Comparative analyses 
were performed when subgroups contained at least 5 cases for QoL domain scores and 
age, age at diagnosis, CYP21A2 genotype, medication use, treatment control, smoking 
behavior, work, life activity, sports, and educational level. Differences were assessed 
using the Mann-Whitney U (MWU) test or Spearman’s correlation for categorical and 
continuous variables, respectively. P-values less than 0.05 were considered as 
statistically significant.  
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Results 
Subjects 
After exclusion of 10 males with CAH who did not complete the WHOQOL-BREF and 2 
males with 11β-hydroxylase deficiency, 109 males with CAH due to 21-hydroxylase 
deficiency were included in this study on QoL. General characteristics are shown in 
Table 8.1. The median age of the study population was 29 years (range 16-68, IQR  
21-41). Educational level was low in 14 (14.3%), medium in 59 (60.2%), and high in 25 
(25.5%) patients. Genotypes 0, A, B, and C comprised 20.2%, 30.3%, 27.5%, and 2.8% of 
the participants, respectively. In 21 males with clinical and biochemically proven CAH  
 
Table 8.1: General characteristics of 109 adult males with congenital adrenal hyperplasia due to 21-hydroxylase 
deficiency.  
Variable N  Median (IQR) or number (%) 
Age 109   
Country of inclusion 109 Germany 
France 
The Netherlands 
United Kingdom 
Sweden 
46 (42.2%) 
30 (27.5%) 
12 (11.0%) 
12 (11.0%) 
9 (8.3%) 
Height 108  170.0 (116.3-175.0) cm 
BMI 108  25.4 (22.6-29.8) kg/m2 
Education level 98 Low 
Medium 
High 
14 (14.3%) 
59 (60.2%) 
25 (25.5%) 
Genotype 109 Group 0 
Group A 
Group B 
Group C 
No mutation reported 
22 (20.2%) 
33 (30.3%) 
30 (27.5%) 
3 (2.8%) 
21 (19.2%) 
Glucocorticoids 109 No glucocorticoids 
Hydrocortisone 
Prednisolone 
Prednisone 
Dexamethasone 
More than one glucocorticoid* 
5 (4.6%) 
63 (57.8%) 
15 (13.8%) 
12 (11.0%) 
7 (6.4%) 
7 (6.4%) 
Glucocorticoid dose** 108  27.9 (22.3-31.5) mg / day 
Mineralocorticoids 109 Fludrocortisone 
No fludrocortisone 
79 (72.5%) 
30 (27.5%) 
Fludrocortisone dose 79  100.0 (75.0-150.0) mcg/day 
 
Continuous variables are displayed as median (IQR: Q1-Q3). Categorical variables are displayed as number of 
participants with percentage. Patients were classified according to severity of the disease into genotype 
group null (0) to group C (14). Abbreviations: 21OHD, 21-hydroxylase deficiency; BMI, body mass index; IQR, 
interquartile range. *6 patients used hydrocortisone and dexamethasone, and 1 patient hydrocortisone and 
prednisolone. **Hydrocortisone equivalent scores were calculated for the total dose of glucocorticoids used 
per day (19). 
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(19.2%), no mutation was reported. Glucocorticoids were used by 104 (95.4%) of the 
participants: most commonly hydrocortisone (57.8%), followed by prednisolone 
(13.8%), prednisone (11.0%), and dexamethasone (6.4%). In this cohort, 7 males used 2 
different glucocorticoids (hydrocortisone and dexamethasone (n=6) or hydrocortisone 
and prednisolone (n=1)). Overall, median glucocorticoid dose in hydrocortisone 
equivalents was 27.9 (IQR: 22.3-31.5) mg/day (n=108). Fludrocortisone was used by 79 
participants (72.5%) with a median dosage of 100.0 (IQR: 75.0-150.0) mcg/day. 
QoL domain scores 
Overall, males with CAH rated their QoL with median domain scores of 78.6 (IQR: 67.9-
85.7), 79.2 (IQR: 66.7-87.5), 75.0 (IQR: 58.3-83.3), and 81.3 (IQR: 71.9-90.6) for physical 
health, psychological health, social relationships, and environment, respectively (Table 
8.2). Median scores appeared to be lowest on all domains in UK males, and highest in 
Dutch males (Table 8.2). Males <30 years (n=56) gave significantly higher scores 
(median: 75.0, IQR: 60.4-91.7) compared to males ≥30 years (n=53, median: 66.7, IQR: 
50.0-83.3) on the social relationships domain (MWU: p=0.028). Highly educated males 
gave significant lower scores (median: 70.8, IQR: 60.4-83.3) on the psychological 
domain compared to medium educated males (median: 79.2, IQR: 70.8-87.5, p=0.049). 
No significant differences were observed on the other QoL domains for age or 
education level. 
Physical health and social relationships domain scores appeared to be similar in the 
total cohort of males with CAH compared to healthy subjects from Germany, France, 
and the UK (Table 8.2). On the psychological health domain, the total group of males 
with CAH appeared to have a similar score compared to the healthy reference 
population from Germany, although seemingly higher QoL scores were observed 
compared to healthy references from France, the Netherlands, and the UK (Table 8.2). 
Country-specific analyses indicated that males with CAH from France and the 
Netherlands rated their psychological health higher compared to the corresponding 
healthy reference populations, while males with CAH from the UK had lower scores 
compared to the corresponding healthy references. On the environmental domain, the 
total cohort of males with CAH appeared to report higher scores compared to healthy 
reference populations from Germany, the Netherlands, and the UK. Regarding the 
country-specific domain scores, males with CAH from Germany and the Netherlands 
rated their QoL on the environmental domain seemingly higher compared to reference 
populations from the corresponding countries, whereas males with CAH from the UK 
had similar scores as the healthy UK reference population.  
In comparison to chronically ill reference populations from Germany, France, and the 
UK (chronic endocrine disorders), higher scores were reported in the total cohort of  
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Table 8.2: Quality of Life domain scores in adult males with CAH due to 21-hydroxylase deficiency and country 
specific reference populations.  
Domain 
Total 
cohort 
Germany* France The Netherlands United Kingdom Sweden 
CAH 
n=109 
CAH 
n=46 
healthy 
n=925 
ill^ 
n=261 
CAH 
n=30 
healthy 
n=5157 
ill 
n=1638 
CAH 
n=12 
healthy^ 
n=218 
CAH 
n=12 
healthy^ 
n=1328 
ill^ 
n=524 
CAH 
n=9 
Physical 
health 
78.6 
(67.9 - 
85.7) 
83.9 
(75.0-
92.9) 
78.8 53.4 71.4 
(63.4-
78.6) 
81.6 68.4 89.3 
(66.1- 
96.4) 
70.1 58.9 
(45.5- 
85.7) 
76.5 67.8 82.1 
(67.9- 
85.7) 
Psycho-
logical 
health 
79.2 
(66.7 - 
87.5) 
79.2 
(70.8-
87.5) 
75.9 62.7 77.1 
(66.7-
87.5) 
69.5 67.5 81.3 
(59.4- 
91.7) 
64.8 60.4 
(32.3- 
72.9) 
67.8 67.7 79.2 
(66.7- 
81.3) 
Social 
relation-
ships 
75.0 
(58.3 - 
83.3) 
75.0 
(58.3-
83.3) 
72.3 68.0 66.7 
(50.0- 
75.0) 
75.6 71.8 87.5 
(68.8- 
100.0) 
71.3 41.7 
(10.4- 
75.0) 
70.5 70.1 66.7 
(50.0- 
79.2) 
Environ-
ment 
81.3 
(71.9 - 
90.6) 
84.4 
(75.0-
90.6) 
71.2 67.2 76.6 
(71.1-
82.0) 
- - 89.1 
(67.2- 
96.9) 
74.0 65.6 
(52.3- 
78.1) 
68.2 71.1 81.3 
(68.8- 
93.8) 
 
Median WHOQOL-BREF domain scores and interquartile range (Q1-Q3) from the overall cohort and from 
country-specific analysis were calculated. Median domain scores were compared to mean domain scores of 
country-specific reference populations from the literature (15-18). If available, both healthy and chronically ill 
reference populations were used. Chronically ill reference populations comprised patients with a chronic 
physical illness: in the United Kingdom only patients with a chronic endocrine disorder were included. *The 
German healthy reference populations contains all male patients from the cohort including chronically ill 
patients. ^Quality of life scores were obtained from a reference population containing both men and women.  
 
males with CAH compared to patients with other physical chronic diseases in these 
reference studies. An exception was the social relationships domain where reference 
patients from France and the UK had comparable scores. Country-specific analyses also 
indicated lower median scores in males with CAH from the UK (physical health and 
social relationships) compared to corresponding chronically ill reference population. 
QoL domain scores in different genotypes  
QoL domain scores were not significantly different between the different genotype 
groups (Fig. 8.1A-D, MWU: p>0.05). Interestingly, median QoL domain scores seemed 
among the highest on all 4 domains in males with genotype 0, who are most severely 
affected.  
Associations of medication use and treatment control with QoL domain scores 
No clinically relevant correlations were observed between glucocorticoid dose in 
hydrocortisone equivalents and median QoL domain scores. Significantly higher 
domain scores were observed in patients on prednisone and dexamethasone on the 
physical health, psychological health and social relationships domain (see Fig. 8.2A-D). 
No significant differences between the glucocorticoids types were observed in the 
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environmental domain. Patients who were treated with fludrocortisone had 
significantly lower QoL scores on the physical health domain (n=79, median: 78.6, IQR: 
64.3-85.7) compared to patients that did not receive fludrocortisone (n=30, median: 
82.1, IQR: 74.1-92.9, MWU: p=0.033), although fludrocortisone dose was not 
correlated. 
 
 
Fig 8.1: Quality of Life domain scores in genotypes. Patients with 21-hydroxylase deficiency were classified 
into genotype group 0, A, B, or C (14). Genotype C was excluded from comparative analysis due to low 
patient numbers (n=3). WHOQOL-BREF scores in different CAH genotype groups were calculated for 4 
different domains: A) physical health, B) psychological health, C) social relationships, and D) environment. 
Boxes represent median and 25th-75th percentile, while whiskers show minimum-maximum domain scores. 
Differences between groups were assessed using Mann-Whitney U test, where p<0.05 was considered 
significant. Abbreviations: NM, no mutation reported. 
 
Subjective treatment accuracy differed significantly as patients with undertreatment 
(n=13) had significantly higher domain scores on the social relationships (median: 83.3, 
IQR:70.8-100.0, MWU: p=0.037) and environmental domain (median: 87.5, IQR: 79.7-
95.3, MWU: p=0.010) compared to patients on accurate treatment (n=71, median: 
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75.0, IQR: 58.3-83.3, and median: 81.3, IQR: 71.9-87.5, respectively). On the other 2 
domains, no differences were observed. Furthermore, patients with 17-
hydroxyprogesterone concentrations above reference range (n=57), indicating 
inadequate adrenal suppression, reported significantly higher domain scores on the 
psychological health (median: 79.2, IQR: 70.8-87.5, MWU: p=0.011) and environmental 
 
 
Fig. 8.2: Quality of Life domain scores in adult males with CAH due to 21-hydroxylase deficiency divided by 
glucocorticoid type. WHOQOL-BREF scores in different glucocorticoid type groups were calculated for 4 
different domains: A) physical health, B) psychological health, C) social relationships, and D) environment. 
Boxes represent median and 25th-75th percentile, while whiskers show minimum-maximum domain scores. 
Differences between groups were assessed using Mann-Whitney U test, where p<0.05 was considered 
significant. 
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domain (median: 81.3, IQR: 75.0-90.6, MWU: p=0.049) compared to males with 17-
hydroxyprogesterone concentrations within reference range (n=23, median: 70.8, IQR: 
58.3-79.2, and median: 78.1, IQR: 68.8-81.3, respectively). No significant differences in 
QoL domain scores were found for androstenedione concentrations.  
 
Discussion 
This is the first international multicenter study examining QoL using the WHOQOL-BREF 
questionnaire in adult males with CAH. This study shows that males with CAH rate their 
QoL as good, with median domain scores between 75.0 and 81.3. Overall, these scores 
appeared to be similar to scores obtained with the WHOQOL-BREF questionnaire in 
healthy reference populations from Germany (15), France (16), and the UK (18), and 
higher compared to a healthy reference population from the Netherlands (17). We also 
compared our results to chronically ill reference populations, as having a chronic 
disease may affect expectations of life, leading to higher QoL scores due to overrating 
(20). These data show that males with CAH appeared to rate their QoL higher 
compared to patients with other chronic diseases. 
Although adult males with CAH may face different complications of their chronic 
disease and often require lifelong therapy, they do not report a worse QoL on the 
physical health domain compared to healthy or chronically ill references. On the 
psychological health domain, males with CAH also report similar or higher QoL scores 
compared to reference populations. Although lower QoL scores were found in highly 
educated males, these males still reported good psychological health with a median 
QoL score of 71. These findings suggest that psychological wellbeing does not seem to 
be largely affected in males with CAH, which is in contrast to previously reported 
higher prevalence of psychiatric morbidity in males with CAH (21). However, patients 
with mental health issues might be less likely to participate in studies or fill out 
questionnaires on QoL, and might be underrepresented in the dsd-LIFE database. 
Social relationships as well as environmental QoL domain scores appeared to be higher 
in males with CAH compared to reference scores. Higher QoL domain scores were 
observed in patients with CAH < 30 years old compared to patients ≥ 30 years on the 
social relationships domain. This is supported by Skevington et al., who report 
decreasing WHOQOL-BREF domain scores with increasing age in a large healthy 
international cohort (22). 
In country-specific analyses, we observed high scores on all 4 domains in the Dutch 
males with CAH compared to males with CAH from other countries. This result is not 
reflected in the reference literature, as the Dutch healthy reference population had the 
8 
142 | Chapter 8 
 
lowest scores on 3 out of 4 domains compared to reference populations from the 
other countries (15-18). Possibly, the Dutch reference study does not accurately reflect 
the current Dutch general population as the data were collected 15 years earlier than 
the dsd-LIFE study from a matched control group. Another notable finding in the 
country-specific analyses was that males with CAH from the UK reported low scores on 
all 4 domains. Compared to healthy references from the UK (18), males with CAH rated 
QoL with rather comparable scores on the environmental domain, while scores seemed 
lower on the physical health, psychological health, and social relationships domains. 
However, the healthy reference population from the UK consisted of both male and 
female university students and student nurses, resulting in a most likely young and 
highly educated cohort. This may have led to overestimation of the QoL scores of the 
general population. 
Few other studies have reported QoL in males with CAH, and these studies used 
different questionnaires than the WHOQOL-BREF questionnaire to assess QoL. Our 
results indicate a good QoL in males with CAH, which corresponds to the results found 
by Falhammar et al. (9), although impaired QoL has also been reported (6-8). Strikingly, 
Reisch et al. showed impaired QoL in males with CAH on the GBB-24, while QoL 
measured with the HADS and SF-36 did not differ from a healthy reference population 
(8). This stresses the importance of using similar questionnaires to assess QoL in 
patients with CAH to make comparison between different study populations possible. 
As no disease-specific questionnaires are available, we propose the use of the 
WHOQOL-BREF questionnaire as it provides a broad aspect of self-perceived QoL on 
different QoL domains.  
QoL in males with CAH in our study was also higher compared to patients with primary 
adrenal insufficiency, although QoL in this study was not measured by WHOQOL-BREF 
(8). Furthermore, QoL measured by WHOQOL-BREF in males with CAH was higher 
compared to patients with DSD, including Turner Syndrome, Klinefelter syndrome, XY 
female DSD, and XY male DSD (23). One of the differences between these diseases is 
the presence of increased adrenal steroid precursors in CAH, in contrast to patients 
with primary adrenal insufficiency or DSD. Previously, we showed that several adrenal 
steroid precursors that are elevated in CAH patients are able to activate the 
glucocorticoid receptor, which might explain why patients with CAH experience fewer 
complications of their cortisol deficiency than expected (24), possibly leading to better 
QoL. The QoL observed in males with CAH is also higher compared to QoL observed in 
females with CAH (23). This may reflect the difference in clinical presentation and 
complications, as female patients have more problems due to increased adrenal 
androgens, such as virilization, masculinization and consequently corrective surgery, 
which may affect QoL negatively. 
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QoL domain scores did not differ between the different genotypes, confirming the 
findings in a previous study (9). However, we did find that fludrocortisone therapy, 
given to the most severely affected CAH patients, was associated with lower QoL 
scores on the physical domain. Remarkably, males with genotype 0, who are most 
severely affected, had high median QoL scores. Possibly, altered expectations of life are 
more pronounced in this group of patients, who received their diagnosis directly 
postnatal. It can be speculated that an early start of follow-up postnatal may have led 
to improved QoL.  
In accordance to previous studies (8, 9), we did not find an association between 
glucocorticoid equivalent dose and median QoL domain scores. However, patients on 
prednisone or dexamethasone rated QoL significantly higher compared to patients that 
used other types of glucocorticoids on the physical health, psychological health and 
social relationships domain. In contrast, Han et al. reported worse QoL in patients using 
dexamethasone (25). However, patients included in the dexamethasone group could 
have been on any regimen including dexamethasone mono-therapy, as well as multiple 
glucocorticoids, which may have influenced the QoL scores negatively. In addition, our 
dexamethasone group only contained 7 males, which might have skewed the results 
positively. Males with CAH using multiple glucocorticoids scored among the lowest on 
physical health and social relationships domain. Possibly, patients with poor hormonal 
control are more likely to be eventually treated with more than 1 glucocorticoid. We 
observed higher scores in patients who were undertreated according to the subjective 
rating of the treating physician, as well as patients with increased 17-
hydroxyprogesterone concentrations compared to patients on accurate treatment. In 
addition, Falhammar et al. reported significantly better QoL on PGWB questionnaire in 
males with CAH in undertreated compared to overtreated patients (9). It can be 
hypothesized that male patients with CAH suffer less from androgen excess due to 
undertreatment than from glucocorticoid excess in overtreatment.  
Although we were able to include a large cohort of adult males with CAH, our study 
design did not include a reference population. Therefore, we compared our domain 
scores with scores reported in literature, although only mean domain scores were 
available and only the German and France cohort reported gender-specific QoL scores. 
This complicated the comparison to our median domain scores. Until now, no cut-off 
values for ‘good QoL’ have been described in literature for the WHOQOL-BREF. 
Although we set a minimum of 5 cases per group, subgroups were still relatively small. 
Furthermore, it should be taken into account that all centers involved in the dsd-LIFE 
study are tertiary care centers. This may have led to selection of the patients groups, 
including more severely affected patients. However, this substantiates our finding of 
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good QoL in patients with CAH even more. In contrast, selection of highly motivated 
patients may have occurred, leading to an overestimation of QoL.  
In conclusion, adult males with CAH in this study rated their QoL as good. Their QoL 
domain scores appeared to be comparable to healthy reference populations and higher 
compared to patients with a chronic illness. QoL was not influenced by genotype, while 
undertreatment and use of prednisone or dexamethasone led to higher QoL.  
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The adrenal glands have important endocrine functions in our body. They are 
responsible for the production of steroid hormones and catecholamines, thereby 
regulating important functions, such as the stress response. The adrenal cortex 
produces three types of steroid hormones: mineralocorticoids, glucocorticoids, and 
adrenal androgens. Mineralocorticoids regulate our blood pressure and electrolyte 
balance, glucocorticoids regulate our glucose metabolism and immune response, and 
adrenal androgens, leading to virilization of the female external genitalia. The 
production of these hormones is tightly regulated by the renin-angiotensin-aldosterone 
system and the hypothalamus-pituitary-adrenal (HPA) axis.  
Congenital adrenal hyperplasia (CAH) is a group of rare inherited disorders of the 
adrenal cortex, that have decreased cortisol production and consequently increased 
adrenocorticotropic hormone (ACTH) concentrations leading to hyperplasia of the 
adrenal cortex in common. CAH is predominantly caused by an enzymatic defect of 21-
hydroxylase (CYP21A2 mutations), but other enzymatic defects, such as 11-
hydroxylase, 17-hydroxylase, 3β-hydroxysteroid dehydrogenase type 2, steroidogenic 
acute regulatory protein, P450 cholesterol side-chain cleavage enzyme, and P450 
oxidoreductase, are also known to result in CAH. In addition to cortisol deficiency and 
increased ACTH concentrations, 21-hydroxylase and 11-hydroxylase deficiency lead to 
accumulation of the precursor steroids before the enzymatic defect, and increased 
production of adrenal androgens (1, 2).  
Patients with CAH due to 21-hydroxylase deficiency suffer from the hormonal 
imbalance caused by increased ACTH and androgens, and decreased cortisol and 
aldosterone concentrations, and are at risk to develop adrenal crises and long-term 
complications, such as impaired gonadal function. This thesis aimed to gain further 
insights into the disturbed adrenal steroidogenesis and its long-term consequences in 
patients with CAH.  
 
The role of adrenal steroid precursors in congenital adrenal hyperplasia 
Cortisol deficiency can lead to severe complaints, such as weakness, fatigue, and 
weight loss, and also life-threatening adrenal crises especially in situations of increased 
demands of cortisol (3, 4). To prevent adrenal crises in CAH patients, lifelong treatment 
with glucocorticoids is indicated. Patients receive instructions to increase 
glucocorticoid dosages in moments of severe stress, such as surgery or severe illness, 
as this increases the demand for cortisol and the risk of adrenal crises (1). However, 
CAH patients appear to have less clinical signs of cortisol deficiency than expected 
9 
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based on their enzyme deficiency (5-9). Donaldson et al. reported that only a minority 
of the CAH patients with the salt-wasting type (the most severely affected patients 
without residual cortisol production) develops hypoglycemia or jaundice, two typical 
signs of cortisol deficiency (5). Furthermore, our research group reported a salt-
wasting CAH patient that was only treated with salt during the first two years of his life. 
During this time, he did not develop an adrenal crisis, not even during severe stress-
situations, such as surgery (6). Without neonatal screening, which is nowadays 
implemented in many countries, patients with the simple virilizing type of CAH mostly 
present to the clinic with complaints related to androgen excess although their cortisol 
production is severely impaired. However, no history of adrenal crises has been 
reported in these patients (7). Some reports have also shown that the reported non-
classic untreated CAH patients (less severely affected) generally do not develop adrenal 
crises, not even in severe stress-situations despite suboptimal cortisol response after 
ACTH stimulation (8, 9). In chapter 3 we have described a cohort of long-time 
untreated CAH patients with severe CAH and biochemically confirmed cortisol 
deficiency. Although about half of these patients had experienced episodes of severe 
stress, none of them reported any signs of adrenal crisis. These studies indicate that in 
CAH patients the expected biochemical diagnosis of cortisol deficiency is not always 
accompanied by the expected clinical complaints.  
In chapter 2 and 3 of this thesis we proposed that the glucocorticoid activity of the 
increased concentrations of steroid precursors of cortisol and aldosterone in CAH 
patients might explain the lack of clinical signs of cortisol deficiency. Mineralocorticoids 
and glucocorticoids exert their function by binding to their receptor, the 
mineralocorticoid receptor (MR) and glucocorticoid receptor (GR), respectively. After 
binding of the steroid in the cytoplasm, the receptor-steroid complex translocates to 
the nucleus of the cell. The receptor-complex can then activate gene transcription by 
binding to a hormone response element in the promotor region of the specific gene, 
initiating transactivation (10). Steroid cross-reactivity is a well-known phenomenon and 
can be explained by the high degree of homology of the DNA binding domain of the GR 
and MR (11). In chapter 2 we have described that 21-deoxycortisol is able to bind to 
the GR, causing nuclear translocation and transactivation of the GR with similar 
potency to cortisol. 17-hydroxyprogesterone and progesterone also caused 
transactivation of the GR but with lower potency compared to cortisol, whereas 
androstenedione was not able to bind, translocate or transactivate the GR. In chapter 3 
we confirmed this potency of 21-deoxycortisol, 17-hydroxyprogesterone, and 
progesterone to activate the GR and studied the potency of other mineralocorticoid 
and glucocorticoid steroid precursors. These results are in line with few other studies 
that determined the potency of some steroids to activate the GR. Four studies report 
that the potency of aldosterone is lower than that of cortisol (12-15) and two of these 
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studies report that 11-deoxycorticosterone has similar potency to aldosterone (13, 14). 
Rupprecht et al. furthermore found that progesterone had similar potency to 
aldosterone and 11-deoxycorticosterone (13). One study only compared progesterone 
and 17-hydroxyprogesterone and found similar potency to activate the GR (16). 
Corticosterone and 11-deoxycortisol had somewhat lower potency to active the GR 
compared to cortisol but higher potency compared to aldosterone and 11-
deoxycorticosterone (14). The potency of pregnenolone, 17-hydroxypregnenolone, 21-
deoxycortisol, 11-hydroxyprogesterone, and 16-hydroxyprogesterone to activate the 
GR has never been studied before. In chapter 3 we compared the structure-activity 
relationship of the steroid precursors of cortisol and aldosterone (Fig. 9.1). This 
revealed that 3β-hydroxysteroid dehydrogenation is a prerequisite for a steroid to 
activate the GR. We also found that the most potent steroids are 11-hydroxylated, 
which was suggested earlier (14, 17).  
CAH patients are known to have a hormonal imbalance with low cortisol and 
aldosterone concentrations, high androgen concentrations and accumulation of 
precursor steroids before the enzymatic defect. 17-hydroxyprogesterone 
concentrations in a 21-hydroxylase deficient (21OHD) patient can be increased over 
100x the normal reference value and are therefore used in the diagnosis of CAH. In 
chapter 3 we indeed found that median concentrations, as measured by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS), of 21-deoxycortisol (only 
measurable in 21OHD patients), 17-hydroxyprogesterone (127x higher), and 
progesterone (29x higher) were higher in 21OHD patients compared to controls.  
 
 
Fig. 9.1: Glucocorticoid activity is determined by the presence and absence of several molecular bonds. The 
molecular structure of cortisol, the main glucocorticoid, is presented. 3β-hydroxysteroid dehydrogenation (in 
green) is a prerequisite to enable a steroid to activate the glucocorticoid receptor (GR). Dehydrogenation 
alone, or in combination with 21-hydroxylation or 17-hydroxylation results in relatively low potency to 
activate the GR. Combination of dehydrogenation and hydroxylation of position 17&21, 11&21, or 11&17 
increased the potency to activate the GR, whereas the latter two combinations had similar potency as 
cortisol to activate the GR. This indicates the importance of 11-hydroxylation (in blue). 
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In 11-hydroxylase deficient patients higher concentrations of 11-deoxycortisol (457x 
higher) and 11-deoxycorticosterone (55x higher) were found. These results show that 
steroid precursors before the enzymatic defect accumulate. All these steroids were 
able to transactivate the GR with similar or somewhat lower potency compared to 
cortisol. Therefore these steroid precursors might compensate for the cortisol 
deficiency. 
Currently, CAH patients are treated with glucocorticoids to substitute cortisol and 
consequently lowering ACTH, thereby lowering adrenal steroid precursor 
concentrations. Turcu et al. showed that concentrations of 17-hydroxyprogesterone, 
progesterone and 21-deoxycortisol in treated 21OHD patients were still higher 
compared to healthy controls (18). Comparison of these concentrations in treated 
21OHD patients with the concentrations in our cohort of untreated 21OHD patients 
(described in chapter 3), showed lower concentrations of 17-hydroxyprogesterone, 
progesterone, and 21-deoxycortisol in treated 21OHD patients. This indicates that 
therapy indeed lowers steroid precursor concentrations and suggests that the 
compensatory mechanism of adrenal steroid precursors will decrease due to 
glucocorticoid treatment, possibly making CAH patients more vulnerable to adrenal 
crisis as they become highly dependent on their medication. This is especially the case 
in severe stress-situations were normal glucocorticoid dosages are not sufficient and 
stress dosages are needed to prevent an adrenal crisis. For this reason it is very 
important that patients are extensively informed on the risk of adrenal crises and the 
importance of therapy compliance and stress dosages. However, in developing 
countries, medication is not always available and sudden discontinuation of treatment 
will increase the risk on adrenal crises, as the patient has no cortisol substitution 
anymore and cannot compensate for this deficiency due to low concentrations of the 
steroid precursors.  
The decision to start substitution therapy with glucocorticoids to treat cortisol 
deficiency is based on cortisol concentrations after an ACTH stimulation test to 
simulate a severe stress-situation. Originally, to establish a threshold of a normal stress 
response, cortisol concentrations of patients that underwent major surgery (a severe 
stress-situation) and survived were used. These concentrations were compared to 
cortisol concentrations after insulin-induced hypoglycemia (19). Although cortisol 
concentrations after insulin-induced hypoglycemia were lower compared to a major 
surgery, the insulin hypoglycemia test provided the most acceptable means of 
assessing cortisol concentrations in response to stress (19). However, as many 
clinicians were reluctant or unable to use the insulin-induced hypoglycemia test, 
implementation of the ACTH stimulation test was considered. To test the applicability 
of the ACTH stimulation test to diagnose cortisol deficiency, cortisol concentrations 
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obtained with the insulin-induced hypoglycemia test were compared to ACTH 
stimulated cortisol concentrations (20). A good correlation was found between both 
tests and since then ACTH stimulation tests are performed to determine cortisol 
deficiency. A threshold of > 500 nmol/L for adequate adrenal function (reviewed in 
(21)) based on a fluorimetrical technique, which measures cortisol and corticosterone, 
but also small amounts of unknown substances (19), is still used. Current cortisol 
detection methods (LC-MS/MS) have improved significantly and new assay-specific 
lower reference limits of cortisol response to ACTH in healthy volunteers have been 
established (22). However, a new diagnostic cut-off value to determine cortisol 
deficiency has not been set yet.  
Based on our findings, we believe that this cut-off value should include the 
glucocorticoid activity of adrenal steroid precursors. Especially when it concerns CAH 
patients as they have increased concentrations of these precursors. We propose that 
future studies establishing a new threshold will include cortisol, 11-deoxycortisol, 11-
deoxycorticosterone, 11-hydroxyprogesterone, 21-deoxycrotisol, 17-
hydroxyprogesterone, and progesterone concentrations. Until now, measurement of 
these steroids requires LC-MS/MS, a very specific and accurate, but costly 
measurement method, which is not available in every laboratory. As there are no 
alternatives yet to measure these steroids accurately, regional central facilities to 
measure these steroids are recommended.  
A decision aid using the newly established threshold for cortisol deficiency should be 
developed to offer the patient personalized care by establishing a patient-specific 
glucocorticoid status value. The patient's total glucocorticoid activity might be 
determined using the formula below.  
Total glucocorticoid activity within a patient = a   [cortisol] + b   [11-deoxycortisol] + c   
[11-deoxycorticosterone] + d   [11-hydroxyprogesterone] + e   [21-deoxycortisol] + f   
17-hydroxyprogesterone] + g   [progesterone] 
This formula illustrates that the total glucocorticoid activity within a patient is the sum 
of the concentration of each steroid multiplied by a certain factor. Further research is 
needed to establish the numerical value of these factors, which will be difficult as many 
processes are involved in receptor activation and its biological response. Researchers 
should at least take into account the efficacy and potency of each steroid precursor. 
The efficacy of a steroid is reflected by the maximum effect (receptor activation) that 
can be reached and depends on receptor occupancy and the ability of the receptor 
complex to initiate a molecular response. The potency of a steroid is determined by the 
amount of steroid that is needed to produce a given effect, for which the EC50, the 
concentration that causes 50% of the maximal effect, is often used. The potency of a 
9 
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steroid depends on the affinity of the steroid to the receptor and the number of 
receptors available. After the development of the patient-specific glucocorticoid status 
value tool, guidelines for glucocorticoid treatment in CAH patients should be adapted 
to the newly established threshold of cortisol deficiency. Treatment might then be 
provided only to the patients with insufficient total glucocorticoid activity instead of 
treating patients based on deficient cortisol concentrations. Possibly, non-classic CAH 
patients would benefit most from this newly adapted threshold including all steroids 
with glucocorticoid activity as they only have mildly impaired cortisol concentrations 
and increased concentrations of steroid precursors. Currently, not all non-classic 
patients are treated with stress dosing of glucocorticoids even when their cortisol 
response is impaired. These patients can therefore help to establish the clinical validity 
of the patient-specific glucocorticoid status value tool. 
 
Impaired gonadal function in male CAH patients 
Although some untreated patients apparently are protected from adrenal crisis by the 
accumulation of precursor steroids with glucocorticoid activity (see above), in the past 
CAH patients had a substantial mortality risk due to the lack of effective treatment 
options and the subsequent occurrence of adrenal or salt-wasting crises. Since 
glucocorticoid and -if necessary- mineralocorticoid supplementation became available, 
CAH patients have a prolonged lifespan and, thus, long-term consequences of CAH 
became of more importance. One of the most important long-term complication in 
male CAH patients is the impairment of fertility and gonadal function. Literature so far 
reported contradicting results as fertility and gonadal function in male CAH patients 
were reported ranging from normal to severely impaired (23-30). In chapter 7 we 
showed that gonadal dysfunction is a common complication in male CAH patients. 
Impaired fertility and gonadal function can have several causes: hypogonadotropic 
hypogonadism, testicular adrenal rest tumors, Sertoli cell dysfunction, impaired semen 
quality and psychosexual factors.  
Hypogonadotropic hypogonadism 
Testicular dysfunction caused by hypogonadotrophic hypogonadism is characterized by 
low testosterone concentrations combined with decreased gonadotropin 
concentrations in serum. However, in adult male CAH patients the use of testosterone 
concentrations in serum to diagnose gonadal dysfunction can be misleading, as 
measured testosterone in serum can be from adrenal and testicular origin. When the 
testosterone is derived from the testis, not much androstenedione is produced (31). In 
contrast, untreated or poorly controlled CAH patients have increased concentrations of 
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androstenedione (1). Therefore, it has been suggested by others (31) to use the ratio of 
androstenedione and testosterone concentrations (AD/T ratio) to determine the origin 
of measured total testosterone concentrations. A ratio higher than 0.5 indicates that a 
significant fraction of testosterone originates from adrenal steroidogenesis, and a ratio 
higher than 1 indicates that the majority of testosterone originates from adrenal 
steroidogenesis (31). In chapter 7 we found that endocrine disturbances of the 
hypothalamus-pituitary-gonadal (HPG) axis (low gonadotropins) were more often 
present in patients with decreased testosterone concentrations compared to patients 
with normal testosterone concentrations. We also showed that patients where the 
majority of testosterone originates from the adrenal gland (AD/T ratio>1) had more 
often low gonadotropins compared to patients with testosterone of testicular origin. 
This indicates that adrenal androgens contribute to the suppression of gonadotropin 
production. Probably, adrenal androgens are aromatized to estrogens (mainly in 
glandular tissues), leading to increased estrogens concentrations, which give negative 
feedback on the HPG axis. Although other precursor steroids, such as 11-oxygenated 
androgens, are also suggested to contribute to the suppression of the HPG axis (32, 
33), their exact role is not determined yet. We therefore recommend to include the 
AD/T ratio in combination with gonadotropin concentrations in the follow-up of adult 
male CAH patients to evaluate testicular function. 
Testicular adrenal rest tumors  
One of the most common complication in male CAH patients that can cause impaired 
gonadal function is the development of testicular adrenal rest tumor (TART)s. In 
chapter 4 we present a review on TART. The overall reported prevalence in classic 21-
hydroxylase deficient patients is 40% (range 14-89%), and the prevalence of TART in 
our European cohort described in chapter 7 was 49%. TART occurs both in pediatric 
and in adult CAH patients, and an increase in prevalence is seen during puberty (34-
38). TARTs are benign lesions of the testes that are typically located within the rete 
testis and can cause impaired gonadal function by obstruction of the seminiferous 
tubules or due to paracrine effects of hormones produced by TART.  
Until now the origin and cause of TART remain uncertain. As reviewed in chapter 4 
TARTs have adrenal and testicular characteristics, therefore a pluripotent steroidogenic 
cell type is hypothesized to be the origin of TART. As the gonads and adrenal glands 
have the same primordial origin, cells from the adrenogonadal primordium are a 
possible candidate. GATA transcription factors are involved in adrenogonadal 
development (39) and recently a possible relation of GATA transcriptions factors with 
TART development in mice was described (40-42). In chapter 5 we therefore 
determined GATA expression in human TART tissue and found gene expression of 
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GATA3, GATA4, and GATA6. We also found GATA3 and GATA6 expression in fetal and 
adult adrenal tissue, while GATA4 was expressed in fetal and adult testicular tissue. 
This confirmed adrenal and testicular characteristics of TART and suggested that 
dysregulation of GATA transcription factors might be involved in TART development.  
TARTs share morphological similarities with steroid-producing testicular Leydig cells. It 
is therefore difficult to histologically discriminate TART from Leydig cell tumors (LCTs) 
and several cases of LCTs in CAH patients have been described (43-48). Different 
treatment strategies are required as TARTs will only be surgically removed if severe 
pain complaints are present (49) whereas LCTs will be surgically removed with a testis-
sparing surgery or orchiectomy (50). Few characteristics, such as bilateralism, diagnosis 
of CAH, shrinkage of tumor after intensified glucocorticoid treatment, and/or presence 
of Reinke crystals, are used to discriminate between TART and LCT, but none of them is 
completely accurate, resulting in a chance of misdiagnosis and consequently incorrect 
treatment, which is reported in at least 2 cases (51, 52). In chapter 5 we describe the 
use of GATA transcription factors as discriminative markers. High gene expression of 
GATA3 and GATA6 in TARTs was discriminative from low gene expression in LCTs. 
However, protein expression was also determined to improve the usefulness of these 
markers in the clinic, but immunohistochemical quantification of these GATA factors 
could not discriminate between TART and LCT. In chapter 4 several other 
characteristics are discussed, but until now no single marker is able to discriminate 
TART from LCT. Future research is necessary to identify a single marker that is able to 
discriminate between both pathologies or might combine several individual markers 
that combined can discriminate TART from LCT accurately to prevent misdiagnosis and 
incorrect treatment. Further studies should also investigate the use of these markers in 
less-invasive material, such as blood or urine, to be of applicable use. For now, 
clinicians should at least consider the presence of CAH, bilateralism, and possibly try 
intensified glucocorticoid treatment to discriminate TART from LCT.  
Poor hormonal control, characterized by high ACTH, 17-hydroxyprogesterone, and 
androstenedione concentrations, seems to be associated with the development of 
TART (reviewed in chapter 4) as TART prevalence is higher in CAH patients that are 
more severely affected and thus have higher ACTH concentrations. In chapter 6 we 
describe a unique patient with recurrent Cushing disease after bilateral adrenalectomy, 
who developed testicular tumors. These tumors were similar to TART based on 
messenger RNA expression analysis and steroid metabolome profiling. This unique case 
also suggests the importance of chronic exposure to high concentrations of ACTH in 
TART development as this patient experienced high ACTH concentrations from 11 years 
old on. These ACTH concentrations ranged from 10 times to more than 200 times 
higher than normal. However, in chapter 7 and chapter 4 we describe TART in less 
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severely affected CAH patients, who have only mildly increased ACTH concentrations. 
This might imply that the duration and timing of increased ACTH concentrations is of 
more importance compared to the actual amount of ACTH present for the 
development of TART. Also other growth-promoting factors might be of importance, 
such as luteinizing hormone and angiotensin II, but this has yet to be studied in detail. 
ACTH binds to its receptor (MC2R), which signals via cyclic adenosine monophosphate 
(cAMP), a second messenger that can bind to cAMP response elements (CREB). One or 
several CREB sites are present in GATA genes and we showed in chapter 5 that 
incubation of a fetal testis cell line with cAMP led to increased expression of GATA3, 
GATA4, and GATA6. This is line with previous studies that published increased 
expression of GATA transcription factors in gonadal cell lines after stimulation with 
cAMP (53-55). However, we could not determine whether ACTH influences GATA 
expression in TART as currently no ACTH-sensitive animal or cell model is available.  
Currently no treatment exists yet to prevent the formation or treat TART. Intensified 
glucocorticoid treatment might cause shrinkage of TART in some, but definitely not in 
all CAH patients with TART (24, 56-61). Surgery is only recommended when severe pain 
complaints are present, as removal of the TART does not improve fertility outcomes 
(49). With no suitable therapy in place CAH patients should be informed about the risks 
of the development of TART and consequently the risk on infertility. We advise 
clinicians to monitor their CAH patients regularly with ultrasound, starting already in 
childhood, and offer CAH patients with TART to cryopreserve their semen for later 
fertility purposes. Furthermore, prevention of the development of TART should be 
pursued by optimizing treatment strategies already in childhood to pursue normal 
ACTH concentrations.  
 
Quality of life in male patients with CAH 
Several factors, such as having a chronic disease and experiencing long-term 
complications, can affect quality of life (QoL). Impaired QoL has been reported in CAH 
patients, although most studies focus on female patients as they experience genital 
virilization and masculinization and consequently often need corrective surgery 
(reviewed in Reisch et al. (62)). QoL studies in male CAH patients are scarce and the 
results contradicting showing either impaired (27, 63, 64), equal (65) or better (66) QoL 
in male CAH patients compared to reference populations. In chapter 8 we showed that 
QoL in European male CAH patients is good, reporting scores similar to healthy 
reference populations. Male CAH patients even rated their QoL higher compared to 
chronically ill reference populations and compared to patients with a 
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disorder/difference of sex development (DSD), including Turner Syndrome, Klinefelter 
syndrome, XY female DSD, and XY male DSD. One of the differences between CAH and 
DSD is the presence of increased adrenal steroid precursors. These steroid precursors 
are able to activate the GR as described in chapter 2 and 3 of this thesis, which might 
explain why these patients experience less complaints of their cortisol deficiency than 
expected. Fewer complications might lead to better QoL observed in male CAH 
patients. Furthermore, we found in chapter 8 that QoL was higher in CAH males 
compared to CAH females and that undertreatment based on subjective scoring or 
increased 17-hydroxyprogesterone concentrations in male CAH patients was 
associated with higher QoL scores. This suggests that undertreatment resulting in 
androgen excess in male CAH patients does not impair QoL, in contrast to female CAH 
patients that suffer from virilization and masculinization due to androgen excess and 
have lower QoL. QoL was significantly higher in undertreated male CAH patients 
compared to overtreated male CAH patients, which might imply that male CAH 
patients suffer more form glucocorticoid excess due to overtreatment. Only based on 
QoL, one might suggest to undertreat these patient. However, untreated CAH patients 
have increased ACTH concentrations, which may lead to an increased risk of TART 
development and consequently decrease QoL. Treatment in CAH patients remains 
difficult and all advantages and disadvantages should be evaluated per patient to 
provide optimal treatment reducing the risk on long-term complications in CAH 
patients and increasing QoL (Fig. 9.2).  
 
Concluding remarks 
In this thesis, I describe the disturbed adrenal steroidogenesis and long-term 
complications regarding male gonadal function in CAH patients. We show that elevated 
adrenal steroid precursors can activate the GR and therefore are able to compensate 
for the cortisol deficiency, thereby possibly preventing the development of adrenal 
crises in some (untreated) CAH patients. Future research should focus on establishing a 
new threshold to determine cortisol deficiency based on all GR-activating steroids. In 
this thesis, we also show that impairment of gonadal function and fertility is a common 
complication in male CAH patients, although they rate their QoL as good. TART is one 
of the commonest complication in male CAH patients with a prevalence of 40% and 
occurs in children and adults with an increase in prevalence during puberty. TARTs are 
hyperplastic steroidogenic cells with adrenal and testicular characteristics. 
Although the origin of TART is currently unknown, it is hypothesized that TART cells 
originate from a pluripotent cell, such as fetal Leydig cells or cells from the 
adrenogonadal primordium. Poor hormonal control, characterized by increased ACTH 
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concentrations, is associated with increased prevalence of TART, probably causing the 
hyperplasia of the pluripotent cells. Unfortunately, there are no treatment options yet 
to prevent TART development and no guidelines on how to treat TART are established. 
Future research should therefore focus on the development of TART to find druggable 
targets, possibly starting by developing more efficient therapies to lower ACTH 
concentrations. We recommend clinicians to increase male CAH patients' awareness of 
the risk of developing TART and consequently the risk on infertility. Patients should be 
screened regularly with ultrasound and semen preservation should be offered for 
future fertility purposes.  
 
Fig. 9.2: The balance of glucocorticoid treatment within male congenital adrenal hyperplasia patients. Accurate 
treatment of the congenital adrenal hyperplasia (CAH) patient defined as normalization of elevated adrenal 
androgens with substitution of deficient steroids results in normalization of growth and normal development. 
However, it is hard to achieve accurate treatment as there is delicate balance between under-, accurate, and 
overtreatment. It is known that undertreatment or no treatment can lead to weight loss (2), impaired insulin 
sensitivity (67), premature pubarche and rapid skeletal outgrow (2), advanced bone age (2) and fatigue (2). In 
this thesis, we showed that in undertreated/untreated gonadal function can be impaired due to 
hypogonadotropic hypogonadism (chapter 7) caused by the aromatization of elevated adrenal androgens. 
Gonadal dysfunction can also be caused by testicular adrenal rest tumors (TARTs) (chapter 4-7). 
Undertreated CAH patients have increased ACTH concentrations, which is an important stimulating factor in 
the development of TART. Furthermore, we showed that quality of life (QoL), rated on a 0-100 scale (higher 
scores reflect better QoL), was significantly higher in undertreated CAH patients (QoL=70.8-100) compared 
to overtreated CAH patients (QoL=58.3-87.5)(chapter 8). Overtreated patients might be more vulnerable to 
adrenal crises as adrenal steroid precursors are decreased. Adrenal steroid precursors have glucocorticoid 
activity and might compensate for the cortisol deficiency (chapter 2-3). It was already known that 
overtreatment can lead to weight gain (2, 67), hypertension (67), stunted growth in children (2, 67) and give 
a decline in bone mineral density (2, 67). Also glucocorticoid induced suppression of the hypothalamus-
pituitary-gonadal axis leading to hypogonadotropic hypogonadism was reported (26). All these advantages 
and disadvantages of over- or undertreatment should be evaluated per patient to provide optimal treatment. 
Abbreviations: CAH, congenital adrenal hyperplasia; QoL, quality of life.  
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De bijnieren hebben belangrijke endocriene functies in ons lichaam. Zij zijn 
verantwoordelijk voor de productie van steroïdhormonen en catecholamines en 
regelen hiermee levensnoodzakelijke functies zoals de stressrespons of zoutregulatie. 
De bijnierschors produceert drie soorten steroïdhormonen: mineralocorticoïden 
(zouthormoon), glucocorticoïden (stresshormoon) en androgenen (mannelijke 
hormonen). Mineralocorticoïden regelen onze bloeddruk en elektrolytenbalans, 
glucocorticoïden (o.a. cortisol) regelen ons glucose metabolisme en immuunrespons en 
de androgenen geproduceerd door de bijnierschors leiden vooral bij vrouwen tot de 
ontwikkeling van pubisbeharing. De productie van deze hormonen is streng 
gereguleerd door het renine-angiotensine-aldosteronsysteem (regulatie van de 
mineralocorticoïden) en het hypofysair geproduceerd adrenocorticotroop hormoon 
(ACTH, regulatie van cortisol). 
Het adrenogenitaal syndroom (AGS) is een groep zeldzame, overerfbare afwijkingen 
van de bijnierschors. AGS kenmerkt zich door verlaagde cortisol productie, met als 
gevolg verhoogde ACTH productie dat uiteindelijk leidt tot overstimulatie en 
hyperplasie van de bijnierschors. AGS wordt grotendeels veroorzaakt door een 
enzymatisch defect van 21-hydroxylase (CYP21A2 mutaties). In dit proefschrift 
concentreren wij ons met name op 21-hydroxylase deficiënte (21OHD) patiënten. Door 
de verhoogde ACTH productie accumuleren voorloperstoffen van de steroïdhormonen: 
de steroïd precursors. Deze worden voor een groot gedeelte omgezet in androgenen, 
aangezien deze productie niet-aangedaan is. AGS patiënten hebben dus een 
verstoorde hormoonbalans bestaande uit verhoogde androgeen en verlaagde cortisol 
en aldosteron concentraties. Ook lopen zij risico op het ontwikkelen van een 
bijniercrisis en het ontwikkelen van langetermijncomplicaties zoals verminderde 
gonadale functie. Dit proefschrift heeft als doel om meer inzicht te krijgen in de 
verstoorde bijnier steroïdogenese in AGS patiënten en de langetermijnconsequenties 
van AGS.  
 
De rol van bijnier steroïd precursors in adrenogenitaal syndroom 
Cortisoldeficiëntie kan leiden tot verschillende klachten, zoals zwakheid, vermoeidheid 
en gewichtsverlies, maar ook tot levensbedreigende bijniercrisissen met name in 
situaties van ziekte met grotere cortisolbehoefte. AGS patiënten maken te weinig 
cortisol en worden levenslang behandeld met glucocorticoïden. Ook ontvangen zij 
instructies om de dosering glucocorticoïden op te hogen bij ernstige stressmomenten 
zoals een operatie of ziekte. Sommige 21OHD patiënten rapporteren minder klinische 
tekenen van cortisoldeficiëntie dan verwacht wordt op basis van de mate van de 
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enzymdeficiëntie. In hoofdstuk 3 beschrijven we een cohort van langdurig 
onbehandelde AGS patiënten en biochemisch bevestigde cortisoldeficiëntie. Hoewel 
ongeveer de helft van de patiënten periodes van ernstige stress hebben doorgemaakt, 
heeft geen van hen tekenen van een bijniercrisis gerapporteerd. Dit toont aan dat in 
AGS patiënten de verwachte klinische klachten niet altijd overeenkomen met de 
biochemische diagnose van cortisoldeficiëntie in AGS patiënten 
In hoofdstuk 2 en 3 van dit proefschrift stellen we dat de glucocorticoïde activiteit van 
de verhoogde concentraties van steroïd precursors voor cortisol en aldosteron in AGS 
patiënten mogelijk het gebrek aan klinische symptomen van cortisoldeficiëntie kan 
verklaren. Mineralocorticoïden en glucocorticoïden voeren hun functie uit door te 
binden aan de bijbehorende receptoren: de mineralocorticoïden receptor (MR) en de 
glucocorticoïden receptor (GR). Het steroïdhormoon bindt zich aan de receptor in het 
cytoplasma van de cel, waarna het receptor-steroïd complex zich verplaatst naar de 
kern van de cel (translocatie). Daar kan het receptorcomplex gentranscriptie initiëren 
(transactivatie) door te binden aan het hormoon-respons-element in de promotor 
regio van het desbetreffende gen. Kruisreactiviteit van steroïden is een bekend 
fenomeen en kan verklaard worden door de grote overlap in de structuurformule van 
de steroïden en in het DNA-bindende deel van de GR en MR. In hoofdstuk 2 hebben we 
beschreven dat 21-deoxycortisol kan binden aan de GR en dat het zowel translocatie 
als ook transactivatie veroorzaakt met eenzelfde potentie als cortisol. 17-
hydroxyprogesteron en progesteron veroorzaken ook transactivatie via de GR, maar 
met een lagere potentie vergeleken met cortisol, terwijl androsteendion niet in staat is 
te binden en geen translocatie en transactivatie kan veroorzaken. In hoofdstuk 3 
hebben we de potentie van 21-deoxycortisol, 17-hydroxyprogesteron en progesteron 
om via de GR transactivatie te veroorzaken bevestigd en hebben we de potentie van 
andere mineralocorticoïde en glucocorticoïde precursors bepaald. Deze resultaten 
komen overeen met enkele andere studies die de potentie voor GR transactivatie van 
slechts een beperkt aantal steroïden hebben bepaald. Uit de structuur-activiteit-relatie 
van de steroïd precursors bleek dat 3β-hydroxysteroïd dehydrogenatie een vereiste is 
voor een steroïd om transactivatie via de GR te kunnen veroorzaken. Verder vonden 
we ook dat de meest potente steroïden 11-gehydroxyleerd waren.  
AGS patiënten hebben een hormonale disbalans met lage cortisol en aldosteron 
concentraties, hoge androgeen concentraties en accumulatie van de steroïd 
precursors. 17-hydroxyprogesteron concentraties in onbehandelde AGS patiënten 
kunnen tot wel meer dan 100x verhoogd zijn vergeleken met de normale 
referentiewaarden en worden daarom ook gebruikt voor de diagnose van AGS. In 
hoofdstuk 3 hebben we inderdaad verhoogde mediaan concentraties van diverse 
steroïden gemeten in serum van 21OHD patiënten vergeleken met controles: 21-
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deoxycortisol (alleen meetbaar in 21OHD patiënten), 17-hydroxyprogesteron (127x 
verhoogd) en progesteron (29x verhoogd). In 11-hydroxylase deficiënte patiënten 
vonden we hogere concentraties van 11-deoxycortisol (457x hoger) en 11-
deoxycorticosteron (55x hoger) in vergelijking met controles. Deze resultaten laten zien 
dat steroïd precursors accumuleren. Al deze steroïden zijn in staat transactivatie te 
veroorzaken via de GR met vergelijkbare of met lagere potentie in vergelijk met 
cortisol. Daarom zouden deze steroïden mogelijk kunnen compenseren voor de 
cortisoldeficiëntie.  
Momenteel worden AGS patiënten behandeld met glucocorticoïden als substitutie voor 
cortisol. Dit verlaagt ook de ACTH concentraties, wat weer het gehalte van androgenen 
afkomstig uit de bijnier verlaagt. Turcu et al. hebben laten zien dat 17-
hydroxyprogesteron, progesteron en 21-deoxycortisol concentraties in behandelde 
21OHD patiënten nog steeds hoger waren vergeleken met gezonde controles. Een 
vergelijking van deze concentraties in behandelde 21OHD patiënten met de 
concentraties van ons cohort van onbehandelde 21OHD patiënten (beschreven in 
hoofdstuk 3) laat zien dat de concentraties van 17-hydroxyprogesteron, progesteron en 
21-deoxycortisol lager waren in behandelde 21OHD patiënten. Dit geeft aan dat 
behandeling met glucocorticoïden inderdaad de concentraties van de steroïd 
precursors verlaagt en suggereert dat het compensatiemechanisme van deze steroïden 
verlaagd zal zijn door behandeling met glucocorticoïden. Daarom is het belangrijk dat 
patiënten uitvoerig geïnformeerd worden over het risico op bijniercrisissen en het 
belang van therapietrouw en stressdoseringen. Echter, in ontwikkelingslanden, waar 
medicatie niet altijd beschikbaar is en ook kennis en infrastructuur niet optimaal zijn, 
zal het plotseling stoppen van glucocorticoïden het risico op een bijniercrisis mogelijk 
vergroten, aangezien zowel cortisol als steroïd precursors concentraties laag zijn door 
behandeling.  
Het besluit om te starten met substitutietherapie met glucocorticoïden om 
cortisoldeficiëntie te behandelen is gebaseerd op cortisol concentraties na een ACTH 
stimulatietest. Een afkapwaarde van >500 nmol/L voor adequate bijnier functie wordt 
nog steeds gebruikt, terwijl deze waarde gebaseerd is op een fluorimetrische bepaling 
die cortisol en corticosteron meet maar ook kleine hoeveelheden onbekende stoffen. 
De huidige methoden om cortisol te detecteren (vloeistofchromotografie met tandem 
massaspectometer (LC-MS/MS)) zijn aanzienlijk beter en nieuwe lagere assayspecifieke 
referentiegrenzen voor de cortisolrespons op ACTH bij gezonde vrijwilligers zijn 
vastgesteld. Een nieuwe diagnostische afkapwaarde om cortisoldeficiëntie te 
diagnosticeren is echter nog niet vastgesteld. Op basis van onze bevindingen raden we 
aan alle steroïd precursors met glucocorticoïde activiteit in deze diagnostische 
afkapwaarde mee te nemen. Zeker in het geval van AGS patiënten, waar verhoogde 
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concentraties van deze precursors aanwezig zijn. We stellen voor dat toekomstige 
studies die een afkapwaarde gaan vaststellen rekening houden met cortisol, 11-
deoxycortisol, 11-deoxycorticosteron, 11-hydroxyprogesteron, 21-deoxycortisol, 17-
hydroxyprogesteron en progesteron concentraties. Tot nu toe vereist het meten van 
deze steroïden LC-MS/MS, een zeer specifieke en nauwkeurige, maar tevens kostbare 
meetmethode, die nog niet in elk laboratorium beschikbaar is. Vandaar dat wij 
adviseren om deze steroïden in regionale expertisecentra te meten.  
 
Verminderde gonadale functie bij mannelijke AGS patiënten 
Sinds de beschikbaarheid van substitutietherapie met glucocorticoïden en mineralo-
corticoïden en betere monitoring bereiken AGS patiënten de volwassen leeftijd zonder 
ernstige complicaties en worden de langetermijngevolgen van AGS duidelijker. In 
hoofdstuk 7 beschrijven wij dat verminderde gonadale disfunctie een van de 
belangrijkste langetermijncomplicaties is bij mannelijke AGS patiënten. Verminderde 
vruchtbaarheid door gonadale disfunctie kan verschillende oorzaken hebben: 
hypogonadotroop hypogonadisme, testiculaire bijnier resttumoren, Sertolicel 
disfunctie en verminderde zaadkwaliteit. 
Hypogonadotroop hypogonadisme 
Testiculaire disfunctie veroorzaakt door hypogonadotroop hypogonadisme wordt over 
het algemeen gedefinieerd als lage testosteron concentraties in combinatie met lage 
gonadotropine concentraties in serum. Slecht ingestelde AGS patiënten hebben vaak 
lage gonadotropines door het remmende effect van bijnierandrogenen, maar in 
tegenstelling tot andere condities wel normale testosteron concentraties. Dit 
testosteron is omgezet uit een verhoogde productie van bijnierandrogenen 
(androsteendion). Daarom is door anderen gesuggereerd om de verhouding tussen 
androsteendion en testosteron (AD/T ratio) te gebruiken om de oorspong van de 
gemeten totale testosteron concentraties te bepalen. Een ratio hoger dan 0,5 geeft 
aan dat een significante fractie van testosteron afkomstig is uit de bijnier en een ratio 
hoger dan 1 geeft aan dat de meerderheid van testosteron afkomstig is van de bijnier. 
In hoofdstuk 7 wordt beschreven dat patiënten met een AD/T ratio>1 vaker lage 
gonadotropines hadden in vergelijking met patiënten met een ratio <0,5. Dit 
suggereert dat bijnier androgenen bijdragen aan de onderdrukking van de productie 
van gonadotropines. Waarschijnlijk worden deze androgenen voornamelijk in 
klierweefsel gearomatiseerd tot oestrogenen, welke leiden tot negatieve feedback op 
de hypothalamus-hypofyse-gonade-as. We adviseren om bij slecht ingestelde AGS 
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patiënten de AD/T ratio in combinatie met gonadotropines te meten voor de evaluatie 
van de gonadale functie. 
Testiculaire bijnier resttumoren 
Een van de meest voorkomende complicaties bij mannelijke AGS patiënten is de 
ontwikkeling van testiculaire bijnier resttumoren (beter bekend onder de Engelstalige 
afkorting TARTs: "testicular adrenal rest tumors"). In hoofdstuk 4 presenteren we een 
overzichtsartikel over TART, waarin de totaal gerapporteerde prevalentie bij 21OHD 
patiënten 40% is (variërend van 14-89%). De prevalentie van TART in ons Europese 
cohort (hoofdstuk 7) was 49%. TART komt zowel voor bij AGS kinderen en volwassen, 
waarbij een toename in prevalentie wordt gezien gedurende de puberteit. TARTs zijn 
goedaardige gezwellen die zich binnen de rete testis bevinden en kunnen leiden tot 
gonadale disfunctie door obstructie van de zaadbuisjes of door paracriene effecten van 
hormonen geproduceerd door TART.  
Tot nu toe is de etiologie van TART niet duidelijk. Omdat TART zowel bijnier als 
testiculaire eigenschappen heeft (hoofdstuk 4) veronderstellen wij dat TART ontstaat 
uit pluripotente steroïdogene cellen. Aangezien de bijnier en gonaden embryologisch 
eenzelfde oorsprong hebben zijn cellen uit het adrenogonadaal primordium een 
mogelijke optie als oorsprong voor TART. GATA-transcriptiefactoren zijn betrokken bij 
de adrenogonadale ontwikkeling en onlangs werd een mogelijke relatie van GATA-
transcriptiefactoren met TART-ontwikkeling in muizen beschreven. In hoofdstuk 5 
hebben we daarom de GATA-expressie in menselijk TART-weefsel bepaald en 
genexpressie van GATA3, GATA4 en GATA6 gevonden. Ook vonden we GATA3 en 
GATA6 expressie in foetaal en volwassen bijnierweefsel en GATA4 expressie in foetaal 
en volwassen testisweefsel. Dit bevestigde de bijnier- en testiculaire eigenschappen 
van TART en suggereerde dat ontregeling van GATA-transcriptiefactoren mogelijk 
betrokken zouden kunnen zijn bij TART-ontwikkeling.  
TARTs delen morfologische gelijkenissen met steroïd-producerende testiculaire 
Leydigcellen. Het is daarom moeilijk om TART histologisch van Leydigcel tumoren 
(LCTs) te onderscheiden en er zijn verschillende casussen van LCTs bij AGS patiënten 
bekend. Voor de behandeling van TARTs en LCTs zijn verschillende strategieën nodig, 
aangezien TARTs alleen chirurgisch worden verwijderd als er ernstige pijnklachten 
optreden, terwijl LCTs chirurgisch worden verwijderd met een testissparende operatie 
of orchiëctomie. Slechts enkele kenmerken, waaronder bilateralisme, diagnose van 
AGS, krimp van de tumor na behandeling met glucocorticoïden en/of aanwezigheid van 
Reinke kristallen kunnen worden gebruikt om onderscheid te maken tussen TART en 
LCT, maar geen van alle is volledig onderscheidend. Dit kan leiden tot een verkeerde 
diagnose en onjuiste behandeling die in ten minste twee gevallen is gerapporteerd. In 
9 
170 | Hoofdstuk 9 
 
hoofdstuk 5 beschrijven we het gebruik van GATA-transcriptiefactoren als 
onderscheidende markers. GATA3 en GATA6 komen hoog tot expressie in TARTs, 
terwijl deze laag tot expressie komen in LCTs. Om de bruikbaarheid van deze markers 
in de kliniek te verbeteren is ook de eiwitexpressie bepaald, maar 
immunohistochemische kwantificering van deze GATA-transcriptiefactoren kon helaas 
geen onderscheid maken tussen TART en LCT. In hoofdstuk 4 worden verschillende 
andere kenmerken besproken, maar tot nu toe kan geen enkele marker het 
onderscheid maken tussen TART en LCT. Toekomstig onderzoek is nodig om een 
marker of combinatie van verschillende markers te identificeren die in staat is om 
onderscheid te maken tussen beide pathologieën wat tot een juiste diagnose en 
behandeling leidt. Verder onderzoek zou zich moeten richten op het identificeren van 
markers in minder invasief te verkrijgen materialen zoals bloed of urine.  
Slechte hormonale controle, gekenmerkt door hoge ACTH, 17-hydroxyprogesteron en 
androsteendion concentraties, wordt geassocieerd met de ontwikkeling van TART 
(beschreven in hoofdstuk 4), aangezien de prevalentie van TART hoger is in de meest 
aangedane AGS patiënten met hogere ACTH concentraties. In hoofdstuk 6 beschrijven 
we een unieke patiënt met terugkerende Cushing na bilaterale adrenalectomie die 
testiculaire tumoren ontwikkelde. Deze tumoren waren vergelijkbaar met TART op 
basis van mRNA en steroïd expressie analyse. Deze casus suggereert ook het belang 
van chronische blootstelling aan hoge concentraties ACTH in TART-ontwikkeling, 
aangezien deze 27-jarige patiënt al aantoonbare hoge ACTH concentraties ondervond 
vanaf zijn 11e levensjaar. Deze ACTH concentraties varieerden in de loop der tijd van 10 
tot 200 keer hoger dan normaal. In hoofdstuk 7 en hoofdstuk 4 beschrijven we echter 
de aanwezigheid van TART in minder aangedane AGS patiënten, die slechts licht 
verhoogde ACTH concentraties hebben. Dit kan impliceren dat de duur en het tijdstip 
van verhoogde ACTH concentraties van groter belang zijn voor TART-ontwikkeling in 
vergelijking met de aanwezige hoeveelheid ACTH. Ook kunnen andere 
groeibevorderende factoren van belang zijn, zoals LH en angiotensine II, maar dit moet 
nog in detail worden bestudeerd. ACTH bindt zich aan de receptor (MC2R), die signalen 
afgeeft via cyclisch adenosine monofosfaat (cAMP), een secundaire boodschapper die 
kan binden aan cAMP-responselementen (CREB). CREB-sites zijn aanwezig in GATA-
genen en in hoofdstuk 5 hebben we aangetoond dat incubatie van een foetale 
testiscellijn met cAMP leidde tot verhoogde expressie van GATA3, GATA4 en GATA6. 
Dit komt overeen met eerdere studies die verhoogde expressie van GATA in gonadale 
cellijnen na stimulatie met cAMP aantoonden. We konden echter niet bepalen of ACTH 
de GATA-expressie in TART beïnvloedt, omdat er momenteel geen ACTH-gevoelig dier- 
of celmodel beschikbaar is. 
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Kwaliteit van leven in mannelijke AGS patiënten 
Verschillende factoren, zoals het hebben van een chronische ziekte en het ervaren van 
langdurige complicaties, kunnen de kwaliteit van leven (KvL) beïnvloeden. Verminderde 
KvL is bekend bij AGS patiënten, waarbij de meeste onderzoeken zich richten op 
vrouwelijke patiënten omdat zij genitale virilisatie en masculinisatie ervaren en 
daarvoor vaak corrigerende chirurgie nodig hebben. KvL-onderzoeken bij mannelijke 
AGS patiënten zijn schaars en de gerapporteerde resultaten zijn in tegenspraak met 
elkaar aangezien zowel een verminderde, gelijke als betere KvL is gerapporteerd. In 
hoofdstuk 8 hebben we aangetoond dat de KvL bij Europese mannelijke 21OHD 
patiënten goed is, waarbij de gerapporteerde scores vergelijkbaar zijn met gezonde 
referentiepopulaties. Mannelijke AGS patiënten beoordeelden hun KvL zelfs hoger in 
vergelijking met chronisch zieke referentiepopulaties en vergeleken met patiënten met 
een stoornis/verschil in geslachtsontwikkeling (DSD), waaronder het syndroom van 
Turner, Klinefelter-syndroom, XY-vrouwelijke DSD en XY-mannelijke DSD. Een van de 
verschillen tussen AGS en DSD is de verhoogde aanwezigheid van bijnier steroïd 
precursors. Deze precursors kunnen de GR activeren zoals beschreven in hoofdstuk 2 
en 3 van dit proefschrift, wat zou kunnen verklaren waarom deze patiënten minder 
klachten van hun cortisoldeficiëntie ervaren dan verwacht. Minder complicaties 
kunnen leiden tot een betere KvL, wat is waargenomen bij mannelijke AGS patiënten. 
Verder vonden we in hoofdstuk 8 dat de KvL hoger was bij AGS mannen vergeleken met 
AGS vrouwen en dat onderbehandeling op basis van een subjectieve score of 
verhoogde 17-hydroxyprogesteron concentraties bij mannelijke AGS patiënten 
geassocieerd waren met hogere KvL-scores. Dit suggereert dat onderbehandeling 
resulterend in een androgeenoverschot bij mannelijke AGS patiënten de KvL niet 
nadelig beïnvloedt, in tegenstelling tot vrouwelijke AGS patiënten die lijden aan 
virilisatie en masculinisatie vanwege een overmaat aan androgeen (en een lagere KvL 
hebben). KvL was significant hoger bij onderbehandelde mannelijke AGS patiënten 
vergeleken met overbehandelde patiënten, wat zou kunnen inhouden dat deze 
mannen meer lijden van overmatige glucocorticoïden als gevolg van overbehandeling. 
On(der)behandelde AGS patiënten hebben daarentegen verhoogde ACTH 
concentraties, wat kan leiden tot een verhoogd risico op TART-ontwikkeling en 
daardoor een verminderde KvL. Behandeling bij AGS patiënten blijft moeilijk en alle 
voordelen en nadelen moeten per patiënt worden geëvalueerd om een optimale 
behandeling te bieden die het risico op langetermijncomplicaties vermindert en een 
goede KvL waarborgt. 
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Slotopmerkingen 
In dit proefschrift beschrijf ik de verstoorde bijniersteroïdogenese en enkele 
langetermijncomplicaties met betrekking tot de mannelijke gonadale functie bij AGS 
patiënten. Wij laten zien dat verhoogde steroïd precursors de GR kunnen activeren, 
waardoor mogelijk de ontwikkeling van bijniercrisissen bij sommige (onbehandelde) 
AGS patiënten wordt voorkomen. Toekomstig onderzoek moet zich richten op de 
klinische betekenis van deze steroïden. In dit proefschrift laten we ook zien dat een 
verminderde werking van de testes, met name veroorzaak door TART, een veel 
voorkomende complicatie is bij mannelijke AGS patiënten. Helaas zijn er nog geen 
behandelingsopties om TART-ontwikkeling te voorkomen en er zijn geen richtlijnen 
vastgesteld voor de behandeling van TART. Toekomstig onderzoek moet zich daarom 
richten op de etiologie van TART en het vinden van een gerichte behandeling. Zonder 
geschikte therapie zouden AGS patiënten moeten worden geïnformeerd over de 
risico's van de ontwikkeling van TART en het bijbehorende risico op onvruchtbaarheid. 
Patiënten moeten regelmatig worden gescreend met echografie en preservatie van 
sperma moet worden aangeboden voor toekomstige vruchtbaarheidsdoeleinden. 
Ondanks serieuze langetermijncomplicaties rapporteren mannelijke AGS patiënten een 
goede kwaliteit van leven.  
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List of abbreviations 
0-9 
11-hydroxylase cytochrome P450 11B1  
11β-HSD corticosteroid 11β-dehydrogenase 
11OHD  11-hydroxylase deficient  
17β-HSD testosterone or estradiol 17β-dehydrogenase 
17-hydroxylase 17α-hydroxylase/17,20lyase  
21OHD  21-hydroxylase deficient  
3β-HSD  3β-hydroxysteroid dehydrogenase/∆5-4isomerase 
5α-reductase 3-oxo-5α-steroid 4-dehydrogenase 1 
95%CI  95% confidence interval 
A 
ACTH  adrenocorticotropic hormone  
AD/T  androstenedione/testosterone 
AMH  anti-Müllerian hormone 
AUC  area under the curve 
C 
CAH  congenital adrenal hyperplasia  
cAMP  cyclic adenosine monophosphate 
COS-7  fibroblast-like cell line derived from monkey kidney tissue 
CREB  cAMP response elements  
CRH  corticotrophin-releasing hormone  
D 
DHEA(-S) dehydroepiandrosterone (sulfate) 
DSD  disorder/difference of sex development  
DHT  dihydrotestosterone 
E-F 
EC50  estimated concentration for 50% transactivation  
FSH  follicle stimulating hormone 
G 
GFP  green fluorescent protein 
GR  glucocorticoid receptor  
H 
H295RA  ACTH-sensitive adrenocortical cell line 
hCG  human chorionic gonadotropin 
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HDDST  high-dose dexamethasone suppression test 
HEK293  human embryonic kidney cells 
HeLa  cell line derived from cervical cancer from Henrietta Lacks 
HPA   hypothalamus-pituitary-adrenal  
HPG  hypothalamus-pituitary-gonadal  
hs181.tes human fetal testis cell line 
I 
IC50  concentration that reduces binding of the radioligand by half  
IQR  interquartile range 
L 
LC-MS/MS liquid chromatography-tandem mass spectrometry  
LCTs  Leydig cell tumors 
LH  luteinizing hormone 
LRL  lower reference limit 
M 
MMTV-luc firefly luciferase reporter construct 
MR  mineralocorticoid receptor  
mRNA  messenger RNA 
MWU  Mann-Whitney U 
O 
OR  odds ratio 
P 
pRL-TK  renilla luciferase construct 
Q 
QoL  quality of life  
qPCR  quantitative polymerase chain reaction 
R 
ROC  receiver operating characteristic 
S 
SHBG  sex hormone-binding globulin 
T 
TARTs  testicular adrenal rest tumors A 
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Research data management 
Research data presented in this thesis and obtained during this PhD at the department 
of Pediatrics and department of Laboratory Medicine at the Radboud university 
medical center (Radboudumc) were archived according to the Findable, Accessible, 
Interoperable, and Reusable (FAIR) principles. The data was stored digitally at a local 
server, supported by the Information and Communications Technology (ICT) of 
Radboudumc and on paper in the form of labjournals. Data stored on the local servers 
were replicated daily to a server of the university. 
Human studies in chapter 3, 5, 6, 7 and 8 were conducted according to the principles 
accepted in the declaration of Helsinki. All participants gave oral and/or written 
consent to participate in the study. Additional measurements in coded samples were in 
accordance with the Code of Conduct of the Federation of Medical Scientific Societies 
in the Netherlands (http://www.federa.org/codes‐conduct). The research was 
approved by the local ethical committee of the Diponegoro University (chapter 3), by 
the institutional review board: CMO Radboudumc (chapters 5 and 6), or by the medical 
ethics committee at the Charité Universitätsmedizin Berlin and the local ethics 
committees of the other study centers (chapters 7 and 8). All data generated or 
analyzed in this thesis are included in published articles and its additional files are 
available from the associated corresponding author on request.  
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Op 15 januari 2015 begon ik mijn promotieonderzoek en nu bijna 4 jaar later kan ik op  
18 december 2018 mijn proefschrift verdedigen. Twee bijzondere data om te 
onthouden. Het onderzoek dat in dit boekje beschreven staat is natuurlijk niet alleen 
door mij tot stand gekomen. Onderzoek staat voor mij per definitie gelijk aan 
samenwerken en van elkaars specialisme en kwaliteiten gebruik maken. Er hebben dan 
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bijdrage die ze geleverd hebben.  
Allereerst wil ik mijn begeleiders Fred, Kees, Hedi, Paul en Teun bedanken. Een unieke, 
kleine onderzoeksgroep verdeeld over drie afdelingen. Maar hetgeen dat elkaar samen 
gebracht heeft is de passie die jullie allemaal hebben voor het endocrinologische 
onderzoek. Ik vind het heel bijzonder om te zien dat jullie nog steeds tijd vrij maken 
voor dit belangrijke onderzoek. Dit heeft me van het begin af aan ook geïnspireerd. 
Dank voor al jullie hulp in mijn promotieonderzoek naar AGS.  
Paul, dank ook voor de grote rol die je hebt gehad in mijn carrière. Zonder het 
voorleggen van deze functie had ik Hedi nooit leren kennen. Tijdens mijn 
promotieonderzoek heb ik gemerkt hoe fijn het is met je samen te werken. Jij kon altijd 
tijd voor mij maken, waardoor ik me enorm gesteund voelde. Ook heb ik genoten van 
onze gesprekken: de Formule 1 race analyseren, maar ook de interessante discussies 
waarin werk en hobby met elkaar vergeleken werden. Nooit gedacht dat we diverse 
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Hedi, al tijdens mijn eerste gesprek met jou en Teun zag ik je enorme gedrevenheid en 
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trouwe supporter bij al mijn presentaties op alle congressen. Dank je wel voor je 
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je daarnaast ook bedanken dat je mij als onderzoeker mee de kliniek in hebt genomen. 
Jouw klinische input is zeer waardevol geweest voor dit onderzoek.  
Fred, ondanks je drukke agenda wist je toch de tijd vrij te maken voor ons wekelijks 
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verhelderend. Ik zal jouw "opa-raad" met me meenemen.  
Teun, ik wil je bedanken voor je frisse en kritische blik. Het zorgde er elke keer weer 
voor meer focus in onze manuscripten. 
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De manuscriptcommissie, bestaande uit Didi Braat, Jack Schalken en Leendert 
Looijenga, wil ik bedanken voor de tijd en moeite die ze hebben gestoken in het 
beoordelen van mijn proefschrift.  
Ook wil ik mijn medepromovendi Karijn en Christiaan bedanken, hoe bijzonder is het 
dat we nu allemaal ons promotieonderzoek naar AGS hebben afgerond/aan het 
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voor de nodige ontspanning en ook het TML-bowling-kampioenschap zal me bijblijven, 
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al heb ik helaas niet mijn titel kunnen behouden. Annelies en Frans, bedankt dat jullie 
me op weg hebben geholpen in het lab en op de kweek. Ook nog een speciaal bedankje 
voor de promovendi van TML en KG, in het bijzonder Kioa, Anne, Pippa, Anke, Walinka 
en Sanne, zonder jullie waren het RIMLS-retreat, symposia en cursussen toch echt een 
stuk saaier geweest. Daarnaast ook een bedankje voor mijn kinderendocrinologie-
collega's: de 'moord-tocht' in de binnenstad en het schilderuitje zal ik niet snel 
vergeten. 
Krissie, Marika, Anke, Ellen en Yvonne. Tijdens onze studie biomedische wetenschappen 
hebben we elkaar leren kennen en het 'achtung-die-kurve'-spelen tijdens de 
incubatiestappen van onze practica hebben heel wat te weeg gebracht. De laatste 
jaren zien we elkaar met name in de SQL, waarin we onder het genot van een speciaal 
biertje (of twee, of.... ) elkaar bijpraten over ons onderzoek, vakanties en eigenlijk alles 
wel. Bedankt voor de gezelligheid! Ik hoop dat we in de toekomst toch ook nog met 
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Iedereen die me geholpen heeft in de afgelopen 4 jaar, maar die ik hier vergeten ben 
te noemen wil ik ook heel graag bedanken. Zonder jullie was het niet gelukt. Everybody 
who helped me reach my goal in the last 4 years, but whom I forgot to mention here, 
thank you very much. Without your help I wouldn't have made it this far.  
Zoals iedereen wel gemerkt heeft komt een PhD niet vanzelf. Het is hard werken en je 
hebt er veel steun voor nodig. Niet alleen op het werk! Zeker de activiteiten en de 
mensen buiten het werk zijn van grote waarde geweest. 
Als ik denk aan de mensen die in de afgelopen tijd telkens weer vroegen hoe het ging, 
en steeds door bleven vragen naar mijn onderzoek, dan komen mijn lieve vrienden 
Gaby en Thijs, Floris en Renee, Lieke en Martijn en Sanne en Maarten naar boven. 
Enorm bedankt dat jullie tijd en aandacht vrijgemaakt hebben en geprobeerd hebben 
te snappen waar mijn onderzoek over gaat. Sanne, wat vind ik het fijn dat jij vandaag 
ook naast mij als paranimf staat. 
Naast mijn directe vrienden hebben ook de leden van het koor waar ik zing een 
enorme interesse getoond in mijn onderzoek, Pur Sang: Karin, Antoinette, Diny, Jeanine, 
Hanneke, Nancy, Caroline, Riet, Marieke, Karin, Louis, Philip, Thijs en Niels bedankt! 
Jullie, soms kritische, vragen waren een welkom gespreksonderwerp, en het zingen was 
een heerlijke afleiding. 
Mijn familie heeft me natuurlijk ook gesteund, maar toch wil ik Jeanny en Bert, Hans en 
Koosje, Sjef en Petra en Marga even extra bedanken voor de aandacht die ze mij 
gegeven hebben. 
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Marian, Jan, Iris en Rick. De eerste verdediging die jullie mee gaan maken en hoewel 
jullie dan niet bekend zijn met het promoveren hebben jullie wel altijd interesse 
getoond in mijn onderzoek. Dank daarvoor. De afgelopen tijd is zoals jullie weten 
behoorlijk druk geweest en het is dan ook lange tijd geleden, dat ik jullie heb 
opgezadeld met een spelletje. Ik beloof jullie dat hier snel verandering in zal komen.  
Ook mijn familie, Stefan, Christine, Karin, Roy, Lars, Jens, Suus, Nils, Remko, Paulien, 
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Tot slot, mijn lieve Gijs. Zonder jou was het me waarschijnlijk niet gelukt. Dank voor je 
geduld en alle hulp. Ook bedankt voor het ontwerpen van de kaft van het boekje. Ik 
ben trots op het resultaat! We hebben samen al veel mooie momenten meegemaakt, 
maar van de kleine gewone momentjes geniet ik misschien nog wel meer: ik vind het 
heerlijk om samen met jou op de tennisbaan te staan, samen te zingen, de Formule 1 
te kijken: lekker op de bank of live, en zo het blijkt zelfs om te gaan kamperen. Ik hoop 
dat we samen nog vele mooie momenten gaan beleven. Ik hou van jou! 
  
A 
188 | Appendices 
 
 
525750-L-os-Engels Processed on: 31-10-2018
Manon Engels
Congenital adrenal hyperplasia
about causes and consequences 
RIM
LS
2018-21
Congenital adrenal hyperplasia | M
anon Engels
Pr
om
oti
e 
M
an
on
 E
ng
el
s
18 Decem
ber 2018
Manon Engels
mengels91@hotmail.com
Maanstraat 12
6543 VT Nijmegen
Paranimfen
Remko Engels
Sanne van Raaij
Uitnodiging
voor het bijwonen van
de openbare verdediging
van mijn proefschrift
Congenital adrenal hyperplasia:
about causes and
consequences
op dinsdag 18 december 2018
om 16.30 uur precies
in de aula van de 
Radboud Universiteit Nijmegen,
Comeniuslaan 2 te Nijmegen.
Je bent van harte welkom
bij deze plechtigheid
en de aansluitende receptie.
